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Superparamagnetic iron oxide nanoparticles (SPIONs) are used in many biomedical 
applications such as drug delivery, as therapeutic agent for hyperthermia treatment and contrast 
agent for molecular magnetic resonance imaging (MRI). Apart from the synthesis of novel 
SPIONs there have been technical developments such as new MRI pulse sequences for positive 
contrast imaging. The most prominent are GRadient-echo Acquisition for Superparamagnetic 
particles with Positive contrast (GRASP), Inversion Recovery with ON-resonant water 
suppression (IRON) and Susceptibility Gradient Mapping (SGM). 
 
Four novel SPIONs of different sizes, coatings and surface charges were assessed in terms of 
their application as MR contrast agents. The !" and !"∗ relaxivities in water and breast cancer 
cells were investigated in vitro and the effects on the relaxivity when SPIONs move from a free 
to a bound state were described. The most promising SPION was also investigated in vivo with 
a multi echo gradient-echo sequence and a range of positive contrast imaging techniques. For 
the GRASP and IRON technique a dynamic preparation phase was devised to optimise the 
positive contrast imaging parameters. We developed a novel positive contrast imaging 
technique based on the Dixon multi echo sequence for improved SPION visualisation and 
quantification. The Dixon positive contrast technique was compared to already established 
techniques such as GRASP, IRON and SGM. Finally, it was determined that fat suppression 
with Dixon is superior to SPIR for positive contrast imaging with the IRON technique.  
 
Overall, this work makes a contribution to the development of novel SPIONs for 
nanotheranostic applications. In particular, new developments for positive contrast imaging with 
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1.1. Multimodal Nanotheranostic Approach 
The most essential factors in the battle against cancer are early detection and effective treatment 
options [1]. Currently, anti-cancer drugs have severe limitations such as poor biodistribution 
and pharmacokinetics [2]. Combination of diagnostic (e.g. contrast agent for medical imaging 
modality) and therapeutic (e.g. anti-cancer drug) agents in one multifunctional unit is referred to 
as nanotheranostics [2]–[4]. Ideally, theranostic nanoparticles should be able to selectively 
accumulate in the tumour, enable early tumour detection, deliver anti-cancer drugs of 
therapeutic doses, and be biodegradable and biocompatible [1]. Nanotheranostics can be used to 
assess biodistribution and accumulation at the target site, monitor release of the anti-cancer 
drug, enhance therapeutic efficacy, and predict the therapeutic response [2]. 
 
Superparamagnetic iron oxide nanoparticles (SPIONs) are well suited for theranostic purposes. 
They have large surface areas to form SPION-conjugates and are good MR and multi-modal 
imaging contrast agents [5], [6]. SPIONs are subject to opsonisation in vivo where salts, 
proteins, and cells bind to the SPION surface leading to recognition by the mononuclear 
phagocytic system (MPS) and eventually clearance from the blood stream. In particular 
macrophages in the liver, bone marrow, and spleen are responsible for removal of SPIONs from 
the circulation [7]. Surface modification by poly(ethyleneglycol) (PEG) coating provides stealth 
characteristics which limit phagocytosis. In order to deliver a drug, it can be loosely attached to 
the coating through physical interactions or covalently bound to the surface with a linker 
molecule [8]. Alternatively, SPIONs can be encapsulated into nanocarriers together with anti-
cancer drugs for a theranostic cancer strategy [9]. 
 
The accumulation of the theranostic particles in the tumour through the enhanced permeability 
and retention (EPR) effect (leaky neovasculature at the tumour site) [10] is referred to as passive 
targeted delivery [11]–[17]. The cellular uptake primarily happens via micropinocytosis [18], 
[19]. This target strategy depends heavily on the neovascularisation of the tumour. However, the 
vascularisation of a tumour is highly heterogeneous. It depends on the tumour type, location, 
and disease state, as well as the patient. This makes tumour targeting via the EPR effect an 
inconsistent phenomenon [20], [21].  
 
Through the attachment of ligands to the surface of the theranostic particle targeting can be 
improved (active targeting approach). Specific ligands bind to overexpressed receptors at 
angiogenic endothelial or cancer cells [22], [23]. These ligands promote cell internalisation of 
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the theranostic particle via receptor mediated endocytosis [3], [24] which leads to an increased 
cellular uptake [25], [26]. This improves anti-cancer efficacy by shifting the nanoparticle 
intratumour distribution from the extracellular to the intracellular compartment [27], [28]. 
Popular targeting ligands for cancer cells are the folate receptor [29]–[32] and the RGD peptide 
[33]–[35] that binds to +,-. integrin [36], [37]. 
 
An alternative to passive and active targeting is stimuli-mediated targeting where the drug 
carrier releases its content as a result to an external stimulus [38]–[40]. The tumour 
microenvironment has a pH that is lower than the normal physiological pH [41]. This 
phenomenon can be used for acid triggered drug release [42], [43]. SPIOs exposed to an 
alternating magnetic field (AMF) are able to absorb this energy and convert it into heat [6], [26]. 
Cancer tissue has a higher sensitivity to heat than healthy tissue. Therefore, SPIOs can be used 
for hyperthermia treatments to destroy cancerous tissue through the localised application of 
heat. Hyperthermia has been investigated in several pre-clinical studies [44], [45] and clinical 
trials [46], [47]. Ultrasound can be used for the disruption of the blood-brain barrier, 
permeabilisation of tissue membranes, extravasation of carriers, triggering of temperature-
depending drug release, and the ablation of tumour tissue [48]–[51]. Another strategy uses an 
external magnetic field to accumulate the superparamagnetic theranostic probes at the tumour 
[25], [52]–[57]. 
 
In addition to the above targeting strategies, it is also possible to combine these to create 
multifunctional platforms. Popular combinations are active and acid-triggered drug release [58] 
and magnetic targeting combined with hyperthermia using SPIOs [59]. Instead of hyperthermia, 
magnetic targeting has also been successfully combined with ultrasound to open the blood-brain 
barrier and deliver the therapeutic agent [60]. Photodynamic therapy (PDT) is the accumulation 
of a drug containing a photosensitiser at the tumour cells where the drug becomes activated 
upon radiation with light. Combining active targeting and PDT increases specificity thereby 
decreasing the damage to normal tissue from the latter [61], [62]. Further combinations reported 
in the literature are active and magnetic targeting [63], magnetic targeting and PDT [64], and 
photothermic therapy which is the local heating of cancer tissue caused by near infrared light 
resulting in hyperthermia-induced destruction of cancer cells [54], [65], [66]. 
 
Most in vivo data in the literature only focuses on diagnostic or therapeutic efficacy of 
theranostics [67]. Those studies that show efficacy for both, diagnostic and therapeutic 
purposes, are often using a combination of targeting strategies. Theranostic probes using SPIOs 
have limitations that result in challenges for in vivo applications and the translation into the 
clinic. These limitations are inappropriate biodistribution [68], [69], formulation challenges (i.e. 
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high manufacturing costs and complexity of production) [70], [71], and opposing concentrations 
and time lines for diagnostic and therapeutic probes [72]. The main challenge is certainly poor 
tumour accumulation in vivo that leads to difficulties for the imaging and anti-tumour efficacy. 
By combining different targeting strategies in a single nanoprobe, the limitations of each 
individual strategy can be overcome which is called a multimodal nanotheranostic approach. 
 
1.2. Aims 
§ To investigate and compare different novel SPIONs in terms of their suitability as MRI 
contrast agents (relaxivities) with respect to their chemical nature. /" and /"∗ can be 
used to differentiate between free and cell-bound SPIONs by MRI as demonstrated 
elsewhere. The aim of the present work was to extent this approach to five SPIONs by 
investigating the ability to differentiate whether a particular particle is cell-bound or 
free by MRI. 
§ Assess the most promising new SPION in vivo in tumour-bearing mice and compare it 
their imaging characteristics with quantitative 0"∗ mapping and susceptibility gradient 
mapping. 
§ Investigate different new SPIONs in terms of their ability to produce positive contrast 
with several well established positive contrast techniques (i.e. GRASP, IRON, SGM). 
§ Devise and develop dynamic preparation phase for GRASP and IRON to optimise the 
positive contrast imaging parameters. 
§ Implement and assess a novel positive contrast technique based on the Dixon method 
and compare it to established positive contrast techniques. 
§ Investigate an effective fat suppression technique that can be combined with an off-
resonance imaging technique to allow in vivo positive contrast imaging without 
interference from fat signal. 
 
1.3. Thesis Overview 
Chapter 2 is an overview of the MR physics starting with a description of the nuclear magnetic 
resonance phenomenon, its quantum-mechanical origin and a practical description using 
classical mechanics (i.e. Bloch equations) for the understanding of the signal generation. The 
radiofrequency excitation of spins and their relaxation properties are discussed in the laboratory 
and rotating frame of reference. This chapter furthermore describes signal acquisitions methods 
such as spin echo and gradient-echo acquisitions. Finally, signal encoding and a brief 




Chapter 3 reviews established methods for 01 and 0" mapping. For the former, basic inversion 
and saturation recovery techniques are described. The focus is on the inversion recovery 
techniques, specifically the Look-Locker sequence. Developments of the Look-Locker such as 
MOLLI, ShMOLLI, Look-Locker-EPI and FLASH are reviewed. This chapter also described 
important 0" mapping sequences such as multi echo spin-echo sequences, DESPOT2 and the 0"prep. 
 
Chapter 4 reviews established positive contrast imaging techniques. Popular sequences are the 
GRadient-echo Acquisition for Superparamagnetic particles with Positive contrast (GRASP or 
whiter marker imaging), Inversion Recovery with ON-resonant water suppression (IRON) and 
Susceptibility Gradient Mapping (SGM) which is a postprocessing technique. Another method 
described uses a balanced steady-state free precession (b-SSFP) sequence for positive contrast 
imaging which is called Fast Low Angle Positive contrast Steady-state free precession 
(FLAPS). 
 
Chapter 5 provides an overview of the background of superparamagnetic iron oxide 
nanoparticles (SPIONs). These inorganic particles have been intensely investigated in the past 
20 years as MRI contrast agents. This chapter will introduce the different types of magnetisation 
in the context of superparamagnetism and molecular structures of iron oxides, their synthesis 
and stabilisation strategies. The main part of this chapter will review the biomedical 
applications of SPIONs via passive and active targeting routes with an emphasis on cancer and 
cardiovascular application. 
 
Chapter 6 describes my own work on the implementation of two established positive contrast 
sequences (GRASP and IRON). The changes made to the Philips GOAL-C pulse programming 
environment are described in detail. The implemented sequences were tested and the scan 
parameter evaluation and optimisation is discussed. 
 
Chapter 7 describes my own work on the implementation of the Dixon technique as a positive 
contrast imaging technique. I describe the optimisation in a phantom study of different SPION 
concentrations. The Dixon positive contrast method was compared with other more established 
positive contrast techniques such SGM, GRASP and IRON. In addition to utilising Dixon as a 
positive contrast imaging technique, I have investigated its capability as a fat suppression 
technique on IRON images and compared those results to fat suppression using spectral pre-




Chapter 8 describes my own work on the characterisation (i.e. the 01, 0" and 0"∗ mapping for 
relaxivity determination) of 24 novel iron-oxide nanoparticles and a comparison in terms of 
their application as MRI contrast agents. These nanoparticles were developed by the MultiFun 
project and synthesised by collaborators. For comparison, four commercial samples were also 
evaluated. Furthermore, it has been reported in the literature that R2 and R2* mapping can be 
used to differentiate between free and cell-bound SPIONs by MRI. In this in vitro study I 
reproduce and extend these results with our novel iron-oxide nanoparticles. 
 
Chapter 9 describes my own on the investigation of two SPIONs, ferumoxytol (commercial 
sample) and MF66-PEG in vivo in a mouse model of cancer. Both SPIONs were compared for 
their abilities to produce negative contrast using a gradient echo sequence and positive contrast 
using SGM as a post-processing technique.  
 
Chapter 10 is a discussion chapter on the general role and novel aspects of the thesis within the 
field.  
 





2. Introduction to Magnetic Resonance Imaging 
2.1. History of Magnetic Resonance Imaging 
The history of magnetic resonance imaging (MRI) can be traced back to Wolfgang Pauli [73], 
one of the great physicists of the 20th century. Pauli helped in the discovery of the neutrino and 
discovered the quantum mechanical exclusion principle for which he was awarded the Nobel 
Prize for physics in 1945 [74]. In 1924 Pauli noticed irregularities in spectra on which basis he 
suggested that atomic nuclei must possess a magnetically related spin property [73]. Following 
Pauli’s assumption, Isidor Rabi used varying fields to influence magnetic resonance in gases 
which proved the existence of magnetic spin in 1938 [75]. He was honoured with the Nobel 
Prize for physics in 1944 [76]. Two years later in 1946, Edward Mills Purcell and Felix Bloch 
independently discovered that the nuclear magnetic resonance (NMR) effect [77], [78] 
described by Rabi could also be observed in solids for which they shared the 1952 Nobel Prize 
in physics [79]. The discovery of Purcell and Bloch was monumental as it allowed the study of 
NMR of different materials and biological samples. More than 20 years later in 1971, Raymond 
Damadian measured relaxation times on tumours and found that the spin-spin relaxation time 
was longer in tumours than in healthy tissue [80]. This made the scientific community aware of 
the fact that NMR could potentially have a use in medical diagnostics. In 1974, Paul Lauterbur 
thought of the concept of using magnetic field gradients in all three orthogonal directions in 
addition to the static magnetic field to have a slightly different magnetic field strength at each 
position in the sample under investigation [81]. One year later in 1975, Richard Ernst showed 
how data sets from various volume elements could be acquired at the same time which would 
lead to a complex mix of frequencies and how to use a Fourier transform to extract different 
frequency components [82]. The Fourier transform is central to the development of MRI. It is a 
mathematical approach invented by Jean Baptiste Joseph Fourier in the early 1880’s. The 
Fourier transform allows the dissection of a signal that is oscillating in the time domain into its 
frequency components [83]. It was finally Peter Mansfield who developed the right 
mathematical approaches to produce an image from NMR signals [84]. So it was really 
Lauterbur, Mansfield and Ernst who transformed the NMR phenomenon into the medical 
imaging device that is an essential part of today’s medical diagnostics. Lauterbur and Mansfield 
were honoured in 2003 with the Nobel Prize in medicine for their discoveries concerning 
magnetic resonance imaging [85]. 
 
2.2. Nuclear Magnetic Resonance 
“Nuclear magnetic resonance (NMR) is the study of magnetic properties and energies of nuclei” 
[86] which are the building blocks of matter. The structure of matter is described with quantum 
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mechanics. However, magnetic resonance imaging is concerned with human bodies that 
represent a huge number of nuclei that behave collectively [87]. Therefore, this work will 
wherever possible use classical vector mechanics to gain the required understanding of the 
processes involved.  
 
2.2.1. Nuclear Spin 
Matter is made up of molecules that are built from atoms. Every atom has a nucleus consisting 
of protons and neutrons. The nucleus is surrounded by electrons that sit in so-called orbitals. 
Electrons are pure primary particles that cannot be further subdivided whereas protons and 
neutrons are made up of even smaller particles called quarks. But for the description of the 
NMR phenomenon, it is sufficient to remain at the nuclear level. Every nucleus with an odd 
atomic number (number of protons) and/or an odd atomic mass (sum of protons and neutrons) 
possesses a spin. The concept of the spin property of nuclei which enables Magnetic Resonance 
Imaging is not only difficult but also highly abstract. Spin is a quantum mechanical property 
and it may well be that humans are incapable of understanding the full depth of quantum 
mechanics. However, nuclear spins can be thought about in a physical and geometrical way and 
such a classical viewpoint allows understanding the majority of MRI concepts. Classically, the 
nuclear spin can be imagined as a physical rotation of the nucleus which is why it is often 
referred to as spin angular momentum 2. Both names, nuclear spin and spin angular momentum, 
are interchangeable. In that sense it can be thought of as a sphere of electromagnetic charge that 
is spinning about its own axis as shown in figure  1. According to classical electromagnetism, 
this will create a current loop that gives rise to a magnetic dipole moment [87], [88]. 
 
Figure 1: Illustration of a nucleus as a sphere rotating about its own axis with nuclear angular 
momentum 3 (reproduced from Liang and Lauterbur [87], p. 59). 
 
2.2.2. Nuclear Magnetic Dipole Moment 
Every nucleus has a nuclear angular momentum 3 that is made up of two contributions. One 
stems from orbital motion 4 and one stems from the intrinsic spin or spin angular momentum 2. 
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 3 = 4 + 2 (1) 
The magnitude of the spin angular momentum is defined with a spin quantum number 7 that can 
be an integer or half-integer value. 
 2 = ℏ 7 7 + 1  (2) 
In equation (2) the constant ℏ is the Planck constant divided by 29, ℏ = :";. Every nucleus that 
has a spin can be seen as a particle with electric charge that rotates around its own axis (figure  
1). According to classical electromagnetism, a spinning charged object creates a magnetic field. 
Such a microscopic magnetic field has a direction (left-hand rule) which is represented by the 
nuclear magnetic dipole moment <. The magnetic moment is related to the spin angular 
momentum 2 according to equation (3). 
 < = =2 (3) 
The proportionality constant is the gyromagnetic ratio and it depends on the nucleus. It can be 
positive or negative. If the gyromagnetic ratio is positive so is the magnetic moment parallel to 
the spin angular momentum. A negative gyromagnetic ratio means that magnetic moment and 
spin angular momentum have an antiparallel position to each other. For hydrogen, the most 
important nucleus in MRI applications, the gyromagnetic ratio is >"; = 42.58	CDE/0. By 
combining equations (2) and (3), the magnitude of the magnetic moment is defined as  
 < = =ℏ 7 7 + 1  (4) 
The nuclear spin quantum number can take integer and half-integer values, = 0, 1" , 1, ." , 2, I" , … . 
Only nuclei with 7 ≠ 0 possess the NMR phenomenon. Hydrogen has a nuclear spin quantum 
number of 1". That is determined by a set of quantum mechanical rules where it is described that 
nuclei with an odd mass number have half-integer spins. Equation (4) determines the magnitude 
of the magnetic dipole moment but its orientation in space is completely random at thermal 
equilibrium as shown in figure 2 [87]. 
 
Figure 2: Random spatial orientation of dipole moments each associated with a spinning nucleus 




A spin system in MRI is the entity of all spins of the same type (e.g. spin of hydrogen atom) in a 
sample. Those spins with the same resonance frequency (i.e. spins in the same tissue that have 
the same chemical environment) are called an isochromat. All the magnetic dipole moments of a 
spin system cancel each other out macroscopically and no net magnetisation is observed. 
However, a net macroscopic magnetisation vector C can be defined that will take values other 
than zero when an external magnetic field of strength LM is applied. A spin system with NO spins 
where <P is the nth nuclear spin, C is the sum of the magnetic moments of all nuclei in the 
sample. 
 C = <PQRPS1  (5) 
In the presence of a static magnetic field of strength LM that has a direction, the individual spin 
vectors start to align with the magnetic field lines and macroscopic magnetism is observed. The 
three orthogonal directions in space are referred to as x-, y-, and z-direction. This is called the 
laboratory frame of reference with the unit directional vectors T,	U, and V. At thermal equilibrium 
the z-component of the spin angular momentum 2 is given by 2W = XOℏ. The z-component of 
the magnetic moment is then 
 <W = =XOℏ (6) 
In equation (6), XO is called the magnetic or azimuthal quantum number that can have 27 + 1 
values, XO = 	−7, −7 + 1, … , 7 − 1, 7. For a proton with ‘spin one-half’, which means 7 = 1" 
and XO = ± 1" there are two possible orientations for <W, pointing up (parallel to LM) or pointing 
down (antiparallel to LM). If no external magnetic field is present, then all 27 + 1 energy states 
with the same spin quantum number 7 but different magnetic quantum numbers XO have the 
same energy (degeneracy). However, with an external magnetic field present, the magnetic 
moment can only take discrete values which lead to discrete energy levels of the two different 
orientations given by 
 [ = −<	LM = 	−<WLM = −=ℏXOLM (7) 
Substituting the magnetic quantum number into equation (7) leads to 
  XO = 12	 7\]^	_\ ↑ : [↑ = 	− 12 =ℏLM (8) 
  XO = −12	 7\]^	bcd^ ↓ : [↓ = 	12 =ℏLM (9) 
The energy difference between the two orientations can be calculated to ∆[ = [↓ − [↑ = =ℏLM. 
The splitting of nuclear energy under the application of an external magnetic field is called the 
Zeeman splitting. In the case of a hydrogen nucleus, the degeneracy turns into two energy levels 
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in which the spin up (parallel) orientation is the lower energy state and therefore more likely 
(figure 3).  
 
Figure 3: Zeeman splitting of a system with spin 1" such as that of a hydrogen nucleus 
(reproduced from Liang and Lauterbur [87], p. 65). 
 
Thermal energy is responsible for some of the spins to overcome the energy separation and also 
occupy the spin down (antiparallel) position. The magnitude of the Zeeman splitting depends on 
the difference in spin population which is given by the Boltzmann relationship. 
 
N↑N↓ = g∆h ij (10) 
In equation (10), N is the number of spins in the up ↑  or down ↓  position, T is the absolute 
temperature in Kelvin and k is the Boltzmann constant 1.38	×10m".3/n . According to 
equation (10), there are >:opq;ij more spins in the lower and more stable energy state. This 
difference in population gives rise to the measurable net magnetisation C that points along the 
direction of LM. 
 
C = CrT + CsU + CWV = <r,PQRPS1 T + <s,P
QR
PS1 U + <W,P
QR
PS1 V




PS1 V= 12 N↑ − N↓ =ℏV = ="ℏ"LMNO4V0 = CWM 
(11) 
The transverse terms of <P are zero because of random phase distribution of the precessing 
magnetic dipole moments [87], [88]. 
 
2.2.4. Free Precession and Larmor Frequency 
According to classical mechanics, the nuclear magnetic dipole vector < will experience a torque 
when placed in a magnetic field which equals the rate of change of its angular momentum. 
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 b2bt = <×LMV (12) 
With equation (3), equation (12) can be written as 
 
b<bt = =<×LMV (13) 
Equation (13) is a first-order differential equation that has the following solutions.  
 <rs t = <rs 0 gmu>opv (14) 
 <W t = <W 0  (15) 
Equations (14) and (15) are the mathematical descriptions of a precessional motion in z-
direction of < about the LM field direction as shown in figure 4. The angular frequency of the 
nuclear precession is called the Larmor frequency wM and it is a central quantity in MRI. 
 wM = =LM (16) 
The Larmor frequency is important because the net magnetisation vector C precesses at that 
frequency. It depends on the gyromagnetic ratio γ, which is a constant unique to every nuclei, 
and the static magnetic field strength LM [87], [88].   
 
Figure 4: Illustration of the precessional motion of < about the LM which can be compared to the 
wobbling of a spinning top under the influence of the gravitational field of the earth (reproduced 
from Liang and Lauterbur [87], p. 62). 
 
2.2.5. Bloch Equation 
The net magnetisation vector C changes with time when in addition to the static magnetic field LM a second short-lived magnetic field L1 t  is applied. The next section will discuss L1 t  
fields in more detail. However, there is a central equation in MRI that describes the dynamics of 
nuclear magnetisation called the Bloch equation.  
 bCbt = =C×L − CrT + CsU0" − CW − CWM V01  (17) 
In equation (17), T, U, and V are unit vectors in x-, y-, and z-direction, respectively. The 
exponential terms in the Bloch equation are approximations to represent what is observed. The 
23 
 
time constants 01 and 0" will be discussed in more detail below. They demonstrate that the 
magnetisation changes as a function of time [87], [88]. 
 
2.2.6. Radiofrequency Excitation 
The resonance phenomenon is central to the description of MRI. Resonance is the achievement 
of phase coherence among the spins in a particular spin system that is precessing in a random 
fashion. In order to achieve phase coherence, an oscillating, time-dependent, magnetic field L1 t  is used. Such a magnetic field is referred to in the literature as a radiofrequency (rf) field. 
Other names include rf excitation, rf pulse, or L1 field. The radiofrequency field described by 
classical mechanics can be pictured as rotating equally to the precessing spins. According to 
quantum mechanics, an oscillating magnetic field of energy [xy = ℏwxy can transfer spins 
between energy states if [xy is equal to the difference in energy between the two spin states ℏwxy = ∆[ = =ℏLM. Such a transition can establish coherence. From that follows the resonance 
condition which simply says that the Larmor frequency wM is equal to the frequency of the 
radiofrequency field wxy.  
 
2.2.6.1. Rotating Frame of Reference 
So far a static orthogonal axes system was used for the description of the behaviour of various 
vector quantities in space. This was called the laboratory reference frame. Before starting the 
explanation of rf excitations, the rotating reference frame shall be introduced. It offers 
conceptual simplicity in describing rf excitations of a spin system. Spins align with a static 
magnetic field and a constant precession of the spins about that field results. Precession can also 
be understood as a rotation. Any magnetic moment that interacts with a magnetic field 
undergoes an instantaneous rotation. Of particular interest in MRI is the application of a short-
lived rf field perpendicular to the static magnetic field. Such an rf field is capable of tipping the 
aligned spins in the transverse plane or in fact by any angle with respect to the static magnetic 
field. The rotating reference frame consists of three orthogonal axes but in comparison to the 
laboratory frame is rotating about an axis at angular frequency w. In the easiest case the rotation 
is about one of the three orthogonal axes. In figure 5a, the laboratory and rotating reference 
frames are shown from the perspective of the positive z-axis. The rotating frame of reference is 




Figure 5: Laboratory and rotating reference frames. a: Perspective from and rotation about the z-
axis. b: Rotation about an arbitrary axis (reproduced from Brown et al. [89], p. 38f). 
 
The rotating reference frame can also rotate about any arbitrary axis as shown in figure 5b. A 
rotational angular velocity vector Ω can be defined where the rotation is about the vector 
direction of Ω. The magnitude of this vector is the angular speed of rotation. A vector { that is 
rotating in the laboratory reference frame with angular frequency w can be defined. Such a 
vector will be fixed in the rotating reference frame which will make the discussion of certain 
concepts to do with radiofrequency fields easier. The mathematical treatment of the rotating 
reference frame is given below for a rotation about the z-axis. The three orthogonal axes will be 
labeled analogous to the laboratory frame but primed | ′, } ′, and	E ′  to allow distinguishing 
them. The same will be done for the unit directional vectors T, U, and V. The mathematical 
definition of the transformation of the laboratory frame to the rotational frame and vice versa is 
given by equation (18). 
 
TÅ = Çc7 wt T − 7]^ wt UUÅ = 7]^ wt T + Çc7 wt UVÅ = V  (18) 
Two rotating reference frames are of particular interest, the Larmor-rotating frame where the 
transverse plane rotates at w = wM (Larmor frequency) and the rf rotating frame where the 
transverse plane rotates at the frequency of the L1 field w = wxy. The time derivatives of the 
unit vectors defined in equation (18) in the rotating reference frame are 
 
bTÅbt = w×TÅbUÅbt = w×UÅbVÅbt = w×VÅ
 (19) 
The net magnetisation vector in the laboratory C  and rotating reference frame CxÉv  are 
defined as 
 C = CrT + CsU + CWV (20) 
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 CxÉv = CrÅTÅ + CsÅUÅ + CWÅVÅ (21) 
The transformation in equation (18) can be used to set C = CxÉv. 
 
CrÅCsÅCWÅ = coswt − sinwt 0sin wt coswt 00 0 1 CrCsCW  (22) 
The same can be done for the L1 field. It is important to remember that the rf excitation is 
usually applied in the transverse plane and therefore no z-component is considered. 
 L1 = L1,rT + L1,sU (23) 
 L1,xÉv = L1,rÅTÅ + L1,sÅUÅ (24) 
 
L1,rÅL1,sÅ = coswt − sinwtsin wt coswt L1,rL1,s  (25) 
Equations (22) and (25) which are the conversions of the magnetisation and excitation vectors 
between the static and rotating reference frames can also be given in complex numbers. 
 CrÅsÅ = Crsguàv 					⇒ 					 Crs = Cr + ]CsCrÅsÅ = CrÅ + ]CsÅ (26) 
 L1,xÉv t = L1 t guàv 					⇒ 					 L1 = L1,r + ]L1,sL1,xÉv = 	L1,rÅ + ]L1,sÅ (27) 
The time derivatives of the net magnetisation in the laboratory and rotating reference frame are 
given as 
 bCbt = bCrbt T + bCsbt U + bCWbt V (28) 
 äCxÉvät = bCrÅbt TÅ + bCsÅbt UÅ + bCWÅbt VÅ (29) 
From that it can be concluded that 
  bCbt = äCxÉvät + w×CxÉv (30) 
The time derivative of the net magnetisation in the laboratory frame is ãåãv . The rate of change of 
the net magnetisation in the rotating frame is çåéèêçv , hence ãåãv = ãåéèêãv ≠ çåéèêçv . 
 
2.2.6.2. Description of the B1 Field 
The L1 field is only applied for a very short time in the microsecond or millisecond range. Its 
oscillating frequency is in the radiofrequency range. The L1 field is significantly weaker than 
the static magnetic field (around 50 mT) and applied perpendicular to LM. Mathematically, the L1 field is described as 
 L1 t = 2L1ë t Çc7 wxyt + í T (31) 
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In equation (31), L1ë t  is the pulse envelope function, wxy is the carrier frequency, and í is the 
phase angle. The linearly polarised field from equation (31) oscillates along the x-axis. It is also 
possible to describe L1 t  with two fields that are circularly polarised where the two terms 
rotate on opposite directions. 
 
L1 t = L1ë t Çc7 wxyt + í T − 7]^ wxyt + í U+ L1ë t Çc7 wxyt + í T + 7]^ wxyt + í U  (32) 
The second term rotates counter clockwise in a direction opposite to the precessing spins and 
therefore has very little effect when the carrier frequency wxy is approaching the Larmor 
frequency wM. As a result of that, the effective L1 field is only the first term of equation (31).  
 L1 t = L1ë t Çc7 wxyt + í T − 7]^ wxyt + í U  (33) 
The x-component is represented by the cosine term and the y-component by the sine term. 
 L1,r = L1ë t Çc7 wxy + í  (34) 
  L1,s = −L1ë t 7]^ wxy + í  (35) 
Equations (34) and (35) can also be represented in a complex notation. 
 L1 t = L1,r t + ]L1,s t = L1ë t gmu àéìvîï  (36) 
The carrier frequency wxy is determined by the Larmor frequency and constant for most of the 
popular rf pulses used in practice. Shape and duration of an rf pulse and therefore its excitation 
property is determined by the envelope function L1ë t . Two widely used rf pulses are the 
rectangular and the sinc pulse. 
 Rectangular pulse: L1ë t = L1 vmñó/"ñó = oò			M	ô	v	ô	ñóM			Év:ëxöuOë  (37) 
 Sinc pulse:  L1ë t = oò	OuPõ ;yú vmñó/" ,M, 	 M	ô	v	ô	ñóÉv:ëxöuOë (38) 
The quantity ùû in equations (37) and (38) is the pulse width. 
 
2.2.6.3. On-resonance Excitation 
For simplicity it is assumed that there is a spin system containing only one isochromat that is 
precessing at the Larmor frequency wM. The initial phase angle í in equation (33) is assumed to 
be zero. Equation (25) can be used to define an rf pulse in the rotating reference frame as 
 L1,xÉv = L1ë t T (39) 
The effective field seen by the isochromats is 
 Lëyy = LMVÅ + L1ë t TÅ + wxy= = LM − wxy= VÅ + L1ë t TÅ (40) 
Because excitation occurs on-resonance, the excitation frequency is wxy = wM which means Lëyy = L1ë t TÅ. The Bloch equation in the rotating reference frame has the form 	
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çåéèêçv = =CxÉv×Lëyy and Lëyy = LxÉv + à> .  The Bloch equation for the on-resonance 
excitation is then 
 äCxÉvät = =CxÉv×L1ë t TÅ (41) 
Equation (41) describes the motion of the net magnetisation C that can also be stated in scalar 
form. 
 
bCrÅbt = 0bCsÅbt = =L1ë t CWÅbCWÅbt = =L1ë t CsÅ
 (42) 
Before the excitation, there is no transverse magnetisation which means CrÅ 0 = CsÅ 0 =0 . The magnetisation in z-direction equals the initial net magnetisation CWÅ 0 = CWM . Under 
these conditions, a solution of equation (42) is 
 
CrÅ t = 0CsÅ t = CWM	7]^ =L1ë t btvMCWÅ t = CWM	Çc7 =L1ë t btvM      0 ≤ t ≤ ùû (43) 
This shows that the application of an on-resonance excitation results in a rotation of the net 
magnetisation vector about the x’-axis. This is expected because the effective field Lëyy extends 
along that direction. In order to illustrate the effect of an on-resonance excitation in the rotating 
reference frame, the solution of the Bloch equation of a rectangular pulse shall be found. The 
solution of the Bloch equation for a rectangular L1 field is 
 
CrÅ t = 0CsÅ t = CWM	7]^ w1tCWÅ t = CWM	Çc7 w1t           0 ≤ t ≤ ùû (44) 
The angular velocity with which the net magnetisation vector rotates about the x’-axis is w1 =−=L1. Figure 6 illustrates that the time dependent magnetisation in y’- and z’-direction can be 
calculated by using simple trigonometric relations. When the net magnetisation is rotated away 
from the z’-axis by a L1 field to create transverse magnetisation CrÅsÅ, an angle can be defined 
between the z’-axis and C. This flip angle + can be calculated by 
 + = w1 t bt†óM = =L1ë t bt
ñó
M  (45) 
If the applied pulse is of rectangular shape, then + is defined as 





Figure 6: Behaviour of the time dependent magnetisation C under the application of a L1 field 
in the rotating frame (a) and the laboratory frame (b) (reproduced from Liang and Lauterbur 
[87], p. 79). 
 
2.2.6.4. Off-resonance Excitation 
In the previous chapter, on-resonance excitations were discussed. However, in most situations 
static field inhomogeneities are present that result in imperfect excitations of some isochromats. 
In such an off-resonance excitation, the effective magnetic field takes the form 
 Lëyy = LM − wxy= VÅ + L1ë t TÅ = ΔwM= VÅ + L1ë t TÅ (47) 
In equation (47), ΔwM = wM − wxy is a measure of how off-resonance the excitation occurs. In 
comparison to the effective field of an on-resonance excitation there is an additional component 
along the z’-axis as shown in figure 7.  
 
Figure 7: Effective field Lëyy of an off-resonance excitation. a: Lëyy in the rotating frame. b: 
Rotating magnetisation vector precessing about Lëyy (reproduced from Liang and Lauterbur 
[87], p. 89). 
 
As before, equation (48) which is the Bloch equation of motion of the net magnetisation during 




bCrÅbt = ΔwMCsÅbCsÅbt = −ΔwMCrÅ + =L1ë t CWÅbCWÅbt = −=L1ë t CsÅ
 (48) 
The solution of equation (48) for the specific case of a rectangular envelope function L1ë t =L1Π vmñó/"ñó  can be given as  
 
CrÅ t = CWM sin £ cos £ 1 − Çc7 wëyytCsÅ t = CWM sin £ 7]^ wëyytCWÅ t = CWM	 Çc7"£ + 7]^"£	Çc7 wëyyt           0 ≤ t ≤ ùû (49) 
The effective frequency is given as wëyy = ∆wM" + w1" and the angle £ is defined as £ =§!Çt§^ w1 ∆wM . Immediately after the application of the rf pulse, the flip angle about Lëyy is + = wëyyùû. This changes the solution to 
 
CrÅ 0î = CrÅ ùû = CWM 	sin £ cos £ 	 1 − cos +CsÅ 0î = CsÅ ùû = CWM 	sin £ sin +CWÅ 0î = CWÅ ùû = CWM	 Çc7"£ + 7]^"£ cos +  (50) 
where t = 0î denotes the time immediately after the application of an rf pulse. The main 
difference to the on-resonance excitation is that the transverse magnetisation is not limited to the 
y’-axis. A phase shift íM has occurred that can be calculated as 
 
tan íM = Cr 0îCs 0î = sin £ cos £ 	 1 − cos +sin £ sin + = 1 − cos +sin + ∆wMwëyy= tan +2 	 ∆wMwëyy (51) 
The magnitude of the magnetisation in the transverse plane is 
 
CrÅsÅ 0î = CrÅ" 0î + CsÅ" 0î= CWM sin £ 7]^"	+ + 1 − cos + "	Çc7"	£ (52) 
From equations (51) it can be seen that an almost linear increase of the phase shift íM with the 
frequency shift ∆wM occurs. Equation (52) shows that a decrease of the magnitude of transverse 
magnetisation results when the frequency offset is increased. 
 
2.2.7. Relaxation 
The application of an rf pulse to a spin system causes the net magnetisation vector C to lose 
longitudinal magnetisation CW and gain transverse magnetisation Crs. Once the L1 field is no 
longer applied, C will return to its equilibrium state which is parallel to the static magnetic field 
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LM. When C returns to equilibrium it will precess about the static magnetic field. At the same 
time, two relaxation processes take place. One is the regrowth of longitudinal magnetisation that 
is governed by the longitudinal relaxation time constant 01. The other is the decay of transverse 
magnetisation that is described by the transversal relaxation time constant 0". Relaxation occurs 
because of microscopic magnetic fields in the surrounding of the nuclei. Longitudinal and 
transverse relaxation processes can be mathematically described using the Bloch equation. It is 
important to note that the following exponential expressions for longitudinal and transverse 
relaxation are only valid for weak spin-spin interactions as it is the case in biological tissues and 
liquids. This means they are correct for most applications in MRI. The relaxations time 
constants 01 and 0" are different for different spin systems and depend on the type of tissue and 
surroundings [87].  
 
2.2.7.1. Longitudinal Relaxation 
Longitudinal relaxation is the recovery of longitudinal magnetisation. In the Larmor-rotating 
frame it takes the form 
 
bCWÅbt = −CWÅ − CWM01  (53) 
The term of the Bloch equation can be neglected because Lëyy = LM − wM/= VÅ = 0. By 
solving the first order differential equation an expression is obtained that describes the 
behaviour of the longitudinal magnetisation over time. 
 CWÅ t = CWM 1 − gmv/jò + CWÅ 0î gmv/jò (54) 
The term CWM is the longitudinal magnetisation without the application of a L1 field. After an 
excitation that would rotate C by 90° in the transverse plane, CWÅ 0î = 0. 
 CWÅ t = CWM 1 − gmv/jò  (55) 
Simple arithmetical operations can provide a definition for the longitudinal relaxation time 
constant 01. 
 CWÅ 01 ≈ 63%	CWM (56) 
This means the longitudinal magnetisation will have recovered 63% of its equilibrium 
magnitude in the time 01 as shown in figure 8b. The longitudinal relaxation time constant is also 
referred to as the spin-lattice time constant as it describes the exchange of energy between the 
spins of a nuclei and the surrounding. The longitudinal relaxation is improved (shortening of 01) 




Figure 8: Time dependent relaxation of the transverse (a) and longitudinal (b) magnetisation 
(reproduced from Liang and Lauterbur [87], p. 93). 
 
2.2.7.2. Transverse Relaxation 
The decay of the transverse magnetisation established during application of an rf pulse is 
referred to as transverse relaxation and described by 
 
bCrÅsÅbt = −CrÅsÅ0"  (57) 
The solution of this first order differential equation gives an expression that describes the 
change of transverse magnetisation over time. 
 CrÅsÅ t = CrÅsÅ 0î gmv/j© (58) 
Contrary to the longitudinal magnetisation, the transverse magnetisation is immediately after a 
90° rotation equal to the full magnetisation at equilibrium, CrÅsÅ 0î = CWM. 
 CrÅsÅ t = CWM	gmv j© (59) 
This allows to determine the transverse relaxation time constant 0". 
 CrÅsÅ 0" ≈ 37%	CrÅsÅ 0î  (60) 
Transverse magnetisation will be reduced down to 37% of its initial value within the time 0" as 
shown in figure 8a. The transverse relaxation time constant is also called the spin-spin time 
constant. The name refers to the fact that at a microscopic level, the magnetic fields of various 
dipoles interact with each other which causes a broadening of the resonance frequencies of the 
spins. These spin-spin interactions contribute to the loss of phase coherence of the transverse 
magnetisation. This process is also called dephasing of the spins. 0" relaxation processes depend 





2.2.8. Chemical Shift 
The resonance frequency of nuclear spins is determined by the gyromagnetic ratio which is the 
same for all nuclei of the same element even in different molecules. However, the resonance 
frequency also depends on the chemical environment of the nucleus. This phenomenon, the 
change in the resonance frequency of a specific nucleus, is called the chemical shift. It occurs 
because nuclei are shielded from the external magnetic field by the electrons orbiting them. 
Once a nucleus is exposed to a static magnetic field, its electrons start to rotate about LM in the 
opposite direction to the nuclear spin precession. Because electrons are charged, moving 
particles, a magnetic moment < is created. The magnetic moment of the electrons opposes the 
static magnetic field LM as shown in figure 9. As a result, the effective magnetic field 
experienced by the nucleus is changed and smaller than LM. This also leads to a different Larmor 
frequency. 
 Lëyy = LM − LM´ = LM 1 − ¨  (61) 
 wëyy = wM − wM´ = wM 1 − ¨  (62) 
This phenomenon is also called electronic shielding. The shielding constant ¨ is dimensionless 
and depends on the chemical environment of the nucleus. In order to define the chemical shift 
numerically, a reference frequency w≠ is needed. The chemical shift Æ of a sample with 
frequency wØ can be calculated as follows. 
 Æ = wØ − w≠w≠ ×10∞ = ¨≠ − Ø¨1 − ¨≠ ×10∞ ≈ ¨≠ − Ø¨ ×10∞ (63) 
The chemical shift is commonly expressed in parts per million (ppm) in order to make it 
independent of the magnetic field strength. The most abundant molecule with hydrogen in 
humans is water. For that reason water protons are the reference in MRI. Of interest is often the 
chemical shift of fat (lipids) which was shown to be at a resonance frequency with respect to 
water of about 3.5 ppm [86], [88]. 
 
Figure 9: Illustration of the opposing nature of the static magnetic field LM and the magnetic 




2.3. Signal Acquisition Methods 
2.3.1. Free Induction Decay 
Free induction decay (FID) signals are the easiest signals produced by a spin system. They are 
generated by a single rf excitation pulse and the free precession of the net magnetisation vector C about the static magnetic field LM. The frequency of precession depends on the applied rf 
pulse according to the Larmor equation. As the magnetisation returns back to its equilibrium 
position while precessing about the z-axis, it has a longitudinal and transverse component. The 
transverse component can be detected with the same rf coil that produced the excitation pulse. 
As the name indicates, the signal is based on electromagnetic induction as described by Michael 
Faraday. An electromotive force ε is induced by a change in flux in the coil that is caused by the 
rotating magnetisation vector [88]. 
 ± = −äΦät  (64) 
The FID signal decreases over time and takes the following mathematical form: 
 2 t = sin + ≥ w gmv/j© à gmuàvbw¥m¥  (65) 
The characteristics of an FID signal is determined by the spectral density function ≥ w  which 
is the number of spins in the sample and described by its amplitude and the rate at which it 
decays. The maximum amplitude is always directly after the application of the +-pulse at t = 0.  
 µy = sin + ≥ w bw¥m¥ = CWM7]^+ (66) 
As can be seen, the maximum amplitude depends on the flip angle and the net magnetisation at 
thermal equilibrium. A typical FID signal is shown in figure 10. If the sample and the static 
magnetic field are both homogeneous, the FID signal decays with the time constant 0". This 
process which results in a decrease of the transverse magnetisation is also called dephasing of 
the spins. It is irreversible and stems from intrinsic magnetic fields of adjacent spins and is 
therefore also referred to as spin-spin relaxation [90]. In the case that inhomogeneities are 
present in the static magnetic field, the signal decays faster. The reason for that is that 
isochromats in the sample will have slightly different phases which means that their magnetic 
moments will cancel each other. This results in a smaller net magnetisation or a faster decay of 
the signal. In order to differentiate the signal loss due to field inhomogeneities from the 0" 
decay, a different time constant 0"∗ is used to characterise this faster decay. If a Lorentzian 





2 t = sin + CWM =∆LM "=∆LM " + w − wM " gm vj©gmuàvbw¥m¥= sin + CWM =∆LM "=∆LM " + w" gmuàvbw gmv/j©gmuàpv¥m¥= 9CWM=∆LM sin + gm>∆opvgmv/j©gmuàpv= 9CWM=∆LM sin + gmv/j©∗gmuàpv 
t ≥ 0 (67) 
From equation (67) we can see that 
 
10"∗ = 10" + =∆LM (68) 
From the derivation it is obvious that equation (68) only applies if the spectral density function 
takes a Lorentzian shape. However, due to its simplicity it is a very common and popular 
expression in the literature to express the relation between 0" and 0"∗. Other spectral density 
functions will not produce an exponential term for the FID envelope function and hence 0"∗ is 
the time constant of an approximating exponential. In practice, the time it takes for an FID 
signal to decay depends on the inhomogeneities present in the static magnetic field which is 
described by 0"∗ [87]. 
 
Figure 10: Decrease of amplitude with time of a typical FID signal (reproduced from Liang and 
Lauterbur [87], p. 113). 
 
2.3.2. Spin Echo 
In the previous chapter the free induction decay was introduced as a MR signal. Another MR 
signal is called an echo. There are two ways to generate an echo, by applying multiple rf pulses 
(spin echo signal) or by reversing a previously applied magnetic field gradient (gradient echo 
signal). This chapter will describe the spin echo (SE) signal which was discovered in 1950 by 
Erwin L. Hahn. The basic concept of it is to use refocusing rf pulses to realign dephasing 
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magnetisation vectors. The simplest spin echo sequence consists of two rf pulses (90° and 180°) 
with a time delay ù in between. 90° − 	ù − 180° 
MR sequences based on spin echo signals are very common and of particular importance. 
Figure 11 is a vector diagram that displays the behaviour of the magnetisation and the formation 
of a spin echo. The first 90° rf pulse and the second 180° rf pulse are applied along different 
axes which are the x’- and y’-axis, respectively. For simplicity a sample with two isochromats is 
assumed; one precessing at a slow (wO) and one precessing at a higher (faster) frequency (wy). 
The first 90° pulse rotates the magnetisation vectors of both isochromats onto the y’-axis as 
shown in figure 11a where they immediately start to precess about the z’-axis. Because the two 
isochromats precess at different frequencies, they will continuously go out of phase over time 
which is depicted in figure 11b. After the time delay ù, the phase angle between the two 
magnetisation vectors in the transverse plane will be wy − wO ù. At that point the second 180° 
rf pulse is applied which causes the vectors to flip-over in the transverse plane as shown in 
figure 11c. Both vectors will precess in the same direction (i.e. clockwise) as before the 180° rf 
pulse. The faster vector of frequency wy that was ahead of the slower vector is now lagging 
behind. However, due to the faster precessional frequency it will have caught up with the slower 
vector after a time ù. That means both vectors are again in phase at time t = 2ù as shown in 
figure 11d.  
 
Figure 11: Behaviour of the magnetisation vector during spin echo formation. a: 90° pulse 
rotates the magnetisation vectors two isochromats onto the y’-axis. b: Isochromats precess at 
different frequencies and will go out of phase. c: Application of 180° rf pulse causes the vectors 
to flip –over in the transverse plane. d: Vectors continue to precess in the same direction and 




In a real sample, the number of isochromats with many different precessional frequencies will 
be much higher. Therefore, at time t = ù the transverse magnetisation CrÅsÅ will have 
completely disappeared due to total dephasing. CrÅsÅ grows again after the 180° refocusing 
pulse until all isochromats achieve phase coherence at t = 2ù. Ignoring the 0" relaxation, the 
same physical effect is responsible for the dephasing of the spins before the refocusing pulse as 
for the regaining of phase coherence after the 180° rf pulse. This means the transverse 
magnetisation is symmetrical about ù.  
 CrÅsÅ ù − t = CrÅsÅ ù + t  for 0 ≤ t ≤ ù (69) 
The rephasing of the transverse magnetisation for ù < t < 2ù is responsible for one side of the 
echo signal that has its highest amplitude when all isochromats are in phase again at 2ù. After 
that a dephasing occurs again for t > 2ù which is responsible for the other side of the echo 
signal as shown in figure 12. 
 
Figure 12: Signal behaviour in a spin echo sequence also showing the difference between 0" and 0"∗ decay (reproduced from Liang and Lauterbur [87], p. 116). 
 
An extension to the described simple two-pulse spin echo sequence is the CPMG echo train 
sequence. The difference is that instead of using only one 180° refocusing pulse a sequence of 
180° rf pulses is employed. As a result a train of spin echoes will be produced. The timeline of 
this sequence can be described as follows. The initial 90° pulse is applied at t = 0. This means 
that the series of 180° pulses is applied at 2^ − 1 ù where ^ = 1,2, … , N corresponds to the 
first, second, up to the nth refocusing pulse. The corresponding echoes are generated at t = 2^ù. 
The amplitudes of each echo are weighted by 
 [P = gm"Pñ/j© (70) 
All the echoes formed after the first, the primary echo, are called secondary echoes because they 
are echoes of the preceding echo. The CPMG echo train sequence is often employed for 0" 
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mapping measurements as the amplitude of the echoes depends on 0" as can be seen from 
equation (70) and shown in figure 13. 
 
Figure 13: CPMG echo train sequence with three echoes where the amplitude of these depends 
on 0" making it a standard 0" mapping sequence (reproduced from Liang and Lauterbur [87], p. 
130). 
 
This sequence was initially invented by Carr and Purcell in 1954. However, cumulative phase 
errors occurred due to imperfections in the train of 180° pulses. The solution to this problem 
was given by Meiboom and Gill in 1958 who proposed to stop applying all pulses along the 
same axis. Instead the refocusing pulses should be applied orthogonal to the 90° excitation 
pulse. CPMG stands for Carr-Purcell-Meiboom-Gill, the surnames of the four scientists who 
invented it. 
 
2.3.3. Gradient Echo 
Gradient echo signals are produced by employing time-varying magnetic gradient fields. These 
gradient fields are used to dephase and rephase the magnetisation vectors of the different 
isochromats in a sample to generate one or a series of echoes.  
 
2.3.3.1. Gradient Fields 
The z-component of a gradient field Lª  changes in one direction linearly. That direction is 
called the gradient direction which can be in x-, y-, or z-direction. Lª  will then be called an x-, 
y-, or z-gradient field accordingly. The gradient coils in a MR scanner system also produce 
gradient fields in the x- and y-direction (Lª,r and Lª,s). Due to the strong static magnetic field 
along the z-direction, the gradient fields in the x- and y-direction are negligible and Lª,W is 
simply referred to as Lª . The total magnetic field is the summation of the static magnetic field 
and the gradient field. 
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 L = LM + Lª,W V (71) 
In the case that not only one gradient coil is producing a gradient field but all three in x-, y-, and 
z-direction, Lª,W takes the following form: 
 Lª,W = ºr| + ºs} + ºWE (72) 
It is quite common to combine the three gradients in x-, y-, and z-direction into a gradient vector º. 
 º = ºr, ºs, ºW = ºrT + ºsU + ºWV (73) 
The gradient direction of L or Lª  is defined as the direction of º. It is essential to understand 
that º can point along the x-, y-, z-direction, or any arbitrary direction which is a combination 
of the three orthogonal directions. However, this must not be the direction of Lª  which is 
typically unknown. This means one needs to differentiate between the direction of the gradient 
field and the gradient direction of Lª,W.  
 
2.3.3.2. Formation of Gradient Echoes 
An rf pulse is applied to excite the spin system followed by a negative gradient in x-direction. 
This will cause spins that have a different position along the x-axis to have a different phase. 
 Ω |, t = = −ºr|btvM = −=ºr|t																	0 ≤ t ≤ ù (74) 
Equation (74) shows that the phase difference of spins in different x-positions increases with 
time. Due to the negative gradient, the spins dephase and the signal decays to zero after a time ù 
three times larger than the time constant that describes the decay. However, this time constant is 
of negligible importance for most applications. After application of the negative gradient, a 
positive gradient is switched on which causes the signal to regrow as the transverse 
magnetisation components rephase again. The spin phase angle takes the form 
 Ω |, t = −=ºr|ù + = ºr|btvñ = −=ºr|ù + =ºr| t − ù 												ù ≤ t ≤ 2ù (75) 
The dispersion of the phase of different spins caused by the negative gradient is reversed by the 
positive gradient that is switched on at t = ù. After another delay time ù all spins have rephased 




Figure 14: Signal behaviour in a gradient echo sequence where the echo is formed by reversing 
the gradient switched on at the time of the excitation pulse (reproduced from Liang and 
Lauterbur [87], p. 134). 
 
At that point the spin phase Ω is zero for all spins at different x-positions. The dephase and 
rephase gradients do not necessarily have to be of the same strength. However, this would result 
in an echo time different to 2ù. It is important to note that in reality LM inhomogeneities are 
usually present. This means that the spins will not be perfectly rephased in the centre of the 
rephasing gradient and the amplitude of the formed echo is 0"∗-weighted. This is an important 
difference to a spin echo signal where 0"∗-weighting is prevented by the 180° refocusing pulses.  
 
Figure 15: Train of gradient echoes produced by switching between positive and negative 
gradient strength (reproduced from Liang and Lauterbur [87], p. 135). 
 
Similarly to the CPMG echo train it is also possible to create a train of gradient echo signals. 
This can be achieved by switching between positive and negative gradient strengths as 
illustrated in figure 15. Such a multi-echo gradient echo (ME-GRE) approach leads to a stack of 
images where each image corresponds to one gradient echo [91]. The time constant 0"∗ and the 
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speed of gradient switching determine how many echoes can be collected. The switching 
between positive and negative refocusing gradients will lead to differences in the amplitude of 
the echoes. For that reason, only even or odd echoes should be considered for 0"∗ calculation. 
The key difference in measuring 0"∗ compared to 0" is that only a single excitation is required 
and no refocusing pulses which makes 0"∗ mapping faster [89]. 
  
2.4. Signal Encoding 
In order to produce an MR image it is essential to be able to differentiate spins in the sample 
(e.g. different tissues). Three orthogonal magnetic field gradients are used in MRI to spatially 
localise the obtained signal. First, a slice in the sample is selected with a slice-select gradient. 
For simplicity it is assumed that a conventional slice is selected in the transverse orientation 
which means the slice-select gradient is applied along the z-direction. Once a slice is selected, 
spatial localisation within a slice is done with two gradients that produce a grid-like structure. 
These two gradients are a frequency-encoding gradient along the x-direction and a phase-
encoding gradient along the y-direction. The description of spatial localisation in this work will 
focus predominantly on 2D imaging to illustrate the basic principles. In comparison to the topics 
above, explanations in this chapter will be less mathematical to allow for a phenomenological 
understanding of the mechanisms of image formation in MRI. 
 
2.4.1. Slice-select Gradients 
The slice-select gradient is switched on during rf excitation to only generate signal in a well-
defined area of the sample. Signal will only originate from a single slice along the z-direction 
where the resonance condition is fulfilled while all other protons are oblivious to the excitation 
pulse. The slice-select gradient is a magnetic field gradient that causes the magnetic field 
strength to vary linearly along the z-direction which has a direct influence of the slice thickness 




Figure 16: Slice thickness changes with the strength of the slice-select gradient (a) or the 
transmit bandwidth of the rf excitation pulse (b) (reproduced from McRobbie et al. [92], p. 118). 
 
An rf excitation pulse will include a well-defined range of frequencies referred to as the 
transmitter bandwidth. This width is controlled by the operator and defines the slice thickness 
(figure 16b). The slice-select gradient strength is determined by the change in magnetic field 
strength ∆LM over a certain distance ∆b. The change in magnetic field strength can be expressed 
in terms of the transmitter frequency ∆æ by using the Larmor equation: 
 ºW = ∆LM∆b = ∆æ=∆b (76) 
From equation (76) it is obvious that in order to decrease the slice thickness, the transmitter 
frequency needs to be decreased and/or the gradient strength increased (figure 16b). 
 
2.4.1.1. Slice Profile 
When considering slice-selection, the slice profile is an important concept. It describes the 
excitation of spins in the selected slice as well as in the rest of the sample. Ideally, only spins 
within the selected slice are excited while all other spins experience no excitation. The 
excitation profile is determined by the Fourier transformed rf pulse. The Fourier transform 
contains the frequency components of an rf pulse. These frequencies define the slice borders as 
they correspond to different spatial locations along the slice-select gradient. The ideal slice 
profile would be a rectangular Fourier transform whereby the spins in the slice are uniformly 
excited with no excitation outside the selected slice. This can only be approximated as such a 
perfectly rectangular Fourier transform can only be achieved with a sinc function of infinitely 
length. In practice, truncated sinc functions are used for rf excitation pulses. The majority of the 
frequency information is located in the central peak and truncating such a function after a few 
side ripples provides a fairly good approximation to an ideal slice profile. The result of 
truncating an rf pulse is that the edges of the selected slice might be excited slightly less or more 
than desired. Furthermore, some excitation may also occur outside of the slice. These effects 
result in a decrease in image quality and contrast and can be minimised by including as many 
periods in the truncated pulse as possible. A stronger slice-select gradient can be used to shorten 
the rf pulse and allow for more periods to be included. This is because a stronger slice-select 
gradient increases the transmitter bandwidth as can be seen in equation (76). A higher 
transmitter frequency results in a more “compressed” rf pulse. It can be concluded that by 
increasing the strength of the slice-select gradient, the duration of the rf pulse is reduced and the 




2.4.1.2. Rephasing Lobe 
Slices are not infinitesimally thin to allow inclusion of only one spin (proton) along the slice-
select direction. Spins with different frequencies will be present within a slice which dephase 
and cancel each other out. It is therefore necessary to apply a gradient of opposite sign to the 
slice-select gradient to rephase the magnetic moments. This rephasing lobe is half the area of the 
slice-select gradient. A rephasing lobe is only necessary for gradient echo sequences where the 
slice-select gradient is applied during the rf excitation pulse. For spin-echo sequences on the 
other hand, the slice-select gradient is turned on during the 90° excitation as well as the 180° 
refocusing pulse. The reason that no rephasing gradient is needed for spin-echo sequences is 
that dephasing and rephasing occur during the application of the 180° pulse as described in 
more detail above.  
 
2.4.2. Frequency-encoding Gradients 
After a slice is selected, gradients along the x- and y-direction are applied to localise the signal 
within a given slice. For signal localisation along the x-direction, a process called frequency-
encoding is applied where the gradient is turned on while the echo is collected. This gradient 
encodes the location of a spin along the x-direction based on the frequency of the measured 
signal. The frequency-encoding gradient is also sometimes called a readout gradient because it 
is applied during echo sampling. This also means that the echo will contain a range of 
frequencies and resemble a sinc function. The characteristic of a sinc function is that the more 
frequency components it comprises the more compressed it will be. In order to extract spatial 
information along the x-axis out of an echo a Fourier transform needs to be applied. Due to the 
presence of the frequency-encoding gradient during echo sampling, frequencies are linearly 
distributed in the x-direction. A Fourier transform will then provide information on the total 
signal at each location which again depends on tissue properties such as 01 and 0" relaxation 
times as well as sequence parameters such as repetition time (TR) and echo time (TE). All 
gradients cause dephasing of spins and therefore, analogous to the slice-select gradient, a 
rephasing gradient lobe is required to compensate for that. However, unlike with the slice-select 
gradient, the reverse frequency-encoding lobe is applied first to cause the spins to dephase. 
After that the frequency-encoding gradient is applied where rephasing is greatest in the centre of 
the gradient because the dephasing lobe is chosen to be half of the area of the rephasing 
gradient. In the case of a gradient echo sequence, it is the frequency-encoding gradient that 
produces the echo. For spin echo sequences, the frequency-encoding gradient adds a gradient 
echo contribution to the sampled echo. For gradient echo imaging it can be concluded that by 
increasing the strength of the frequency-encoding gradient, the duration of the echo can be 
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shortened as well as TR and TE. This is contrary to spin echo sequences where the total imaging 
time is normally not affected by the time required to sample the echo.  
 
2.4.2.1. Receiver Bandwidth 
The range of frequencies collected while the frequency-encoding gradient is turned on is 
referred to as the receiver bandwidth. It widens as the strength of the frequency-encoding 
gradient is increased for a constant field of view. The difference to the earlier mentioned 
transmitter bandwidth is that the receiver bandwidth applies to the sampled echo and the range 
of frequencies it is comprised of whereas the transmitter bandwidth refers to the rf excitation 
pulse. The receiver bandwidth is constrained by the sampling frequency. When increasing the 
frequency-encoding gradient and consequently the receiver bandwidth, the signal-to-noise ratio 
(SNR) is decreased.  
 
2.4.2.2. Sampling Frequency 
The sampling frequency describes the rate of echo sampling and its digitalisation. An analogue-
to-digital converter (ADC) is used for digitalisation of the signal and the rate at which that 
conversion occurs is given by the sampling frequency. Because the sampling frequency cannot 
be increased infinitely, the measured echo might be different to the original echo and some 
information might get lost. The relationship between the highest-frequency component and the 
sampling frequency determines how accurate the original echo is digitised and called the 
Nyquist theorem of sampling. According to that sampling of a signal must be at least at twice 
the frequency of the signal in order to get an acceptable representation of the original signal. 
The time necessary to sample a full echo is determined by the sampling frequency. 
 
 
2.4.3. Phase-Encoding Gradient 
The final step to achieve spatial localisation of a voxel is the application of a phase-encoding 
gradient along the y-direction. At this stage the reader is reminded that the direction of each 
gradient is arbitrary but for this work the convention is that slice-select, frequency-encoding, 
and phase-encoding gradients are applied along z-, x-, and y-direction, respectively. While the 
first two gradients used for spatial localisation slightly change the frequency of spins, the phase-
encoding gradient changes the phase. All gradients cause dephasing of spins because different 
precession frequencies cause differences in phase accumulated over time. Dephasing occurs 
faster the stronger the gradient is and the phase dispersion is larger the longer the gradient is 
applied. If there is no gradient present, the spins precess at the Larmor frequency. However, any 
accumulated phase dispersion is maintained. The phase shift caused by the phase-encoding 
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gradient changes linearly along the y-direction and is a result of the strength and duration of the 
gradient. In contrast to the slice-select and frequency-encoding gradients, the phase encoding 
gradient is not applied during rf excitation or echo sampling but at some time point in between. 
The idea here is that the part of the MR sequence from rf excitation to echo sampling is repeated 
several times with a different phase-encoding gradient every time that results in different phase 
shifts for each run. The number of phase-encoding steps Nøh  (i.e. number of repetitions) 
depends on the number of voxels along the phase-encoding direction. The echo sampled at each 
phase-encoding step will be different. After the application of the frequency-encoding gradient 
and the Fourier transformation of the echo, there will be as many frequencies as columns along 
the x-direction. Each frequency belongs to one column that is an unknown combination of the 
signals from each voxel along the y-direction. Phase-encoding now allows to solve the unknown 
voxel values in each column along the x-direction by providing enough equations (i.e. different 
combinations of the unknown voxel values) so that each of them can be determined. Spatial 
localisation is always linked with the concept of k-space which will be discussed in more detail 
in the next chapter. But it shall be mentioned at this point that each line in k-space is filled by 
one echo which differ based on the phase-encoding gradient used. When zero phase-encoding is 
applied, the respective echo has the largest amplitude because all spins are in phase. Contrary to 
that, higher phase-encoding gradients have lower amplitudes because the introduced phase shift 
causes dephasing of the spins.  
 
2.4.4. k-Space 
The echoes that are sampled during the application of an MRI pulse sequence are stored in k-
space which is the Fourier transformation of the anatomical representation of the sample (i.e. the 
MR image). Mathematically, the Fourier transform of an image can be written as 
 
D Vr, Vs = ℎ |, } gmu i¡rîi¬s b|b}¥m¥= ℎ |, } Çc7 Vr| + Vs} − ]	7]^ Vr| + Vs} b|b}¥m¥  
(77) 
The function D Vr, Vs  is the Fourier transform or spatial frequency map and ℎ |, }  describes 
the image, specifically the spatial distribution of the voxel signal intensities. This so-called 
image space can be imagined as a 2D grid of numbers where at each location, which is defined 
by two coordinates, there is a value of the signal intensity. The centre of the image space is at |, } = 0,0  which means that for a grid or image matrix with 256 by 256 coordinate pairs, 




Figure 17: Comparison of image space and k-space for an image with a matrix of 256x256 
coordinate pairs (i.e. pixels or voxels) (reproduced from Lee [93], p. 105). 
 
The k-space represented by D Vr, Vs  also adopts a grid of numbers where position is defined 
by a pair of coordinates Vr, Vs . Those coordinates refer to spatial frequencies Çc7Vr| and Çc7Vs}. Because the same grid is used for ℎ |, }  and D Vr, Vs , the signal intensity at a point 
in the grid is directly linked to D Vr, Vs  and describes the amount of spatial frequency 
components in the image at that point. Analogous to the image space, k-space is centred at Vr, Vs = 0,0 . A value in k-space at a certain location Vr, Vs  refers to the amplitude of the 
sinusoidal function of the image. Because the cosine function is symmetric, there is always a 
second value in k-space at −Vr|, −Vs} . According to equation (77), a multiplication of the 
image with Çc7 Vr| + Vs} − ]	7]^ Vr| + Vs}  needs to be performed followed by a 
summation across the image for all values of x and y in order to get a k-space value at a certain 
frequency determined by Vr, Vs . 
 
As previously explained, linear gradients are used for spatial localisation. These gradients 
introduce phase shifts that can be understood as a sinusoidal modulation. The amplitudes of the 
magnetisation vectors are not affected by the gradients and only depend on the pulse sequence 
parameters and the properties of the sample. But the direction of the magnetisation vectors is 
modulated in a sinusoidal fashion. Sinusoidal motion in phase is always associated with a 
frequency which is called “V”. Phase dispersion is greater the longer the gradient remains 
switched on. A strong gradient causes the phase shifts to increase faster. In terms of the 
sinusoidal function of which V is the frequency, V is larger if the gradient is switched on for 
longer and increases faster the stronger the gradient is. A positive gradient causes V to 
progressively increase while a negative gradient has the opposite effect. Accumulated phase 
differences are preserved after the gradient is turned off because all the spins in the sample will 
then return to precessing at the Larmor frequency. In order to produce an image, echoes during 
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the readout period are collected with a receiver coil which sums the contributions from all the 
spins in the sample slice. These spatial frequencies are stored in a grid (k-space). Fourier 
transform of k-space produces the MR image. Values for all combinations of Vr and Vs must be 
collected in order to fill k-space. The coordinates Vr and Vs are proportional to the area under 
the curves described by ºr and ºs. For a k-space matrix of 256×256 the receiver coil must 
sample a signal when the frequencies Vr and Vs of the sinusoidal modulation caused by the area 
under ºr and ºs change from −127 to +128 and all possible combinations of the two 
frequencies.  
 
2.4.4.1. k-Space Trajectories 
There are different ways in which k-space can be filled which is described by the k-space 
trajectories. The three most common ways to fill k-space are with a linear, spiral, or radial 
trajectory (figure 18). For the linear (Cartesian) trajectory, each horizontal line in k-space is 
filled during the sampling of one echo with a given phase-encoding step while running through 
all possible frequency-encoding steps. This ensures an evenly distribution of k-space filling. As 
the name suggests, a spiral k-space trajectory runs through k-space in a spiral pattern. This 
results in an oversampling of the centre of k-space where the low spatial frequencies are 
contained that provide contrast information. If the centre of k-space has high amplitude 
frequencies then the Fourier transformed image will show high signal intensity. The periphery 
of k-space contains the high spatial frequencies that are associated with information regarding 
image resolution. The radial method of filling k-space uses diagonal lines that all go through the 
centre of k-space.  
 
Figure 18: The most common trajectories to fill k-space, linear, spiral, or radial (reproduced 
from Lee [93], p. 109). 
 
2.4.4.2. Magnitude and Phase Images 
As shown in equation (77), k-space is generated by sine and cosine functions which means that 
k-space contains two sets. One of the sets is for the spatial frequencies of the cosine function 
which is symmetrical and a second is for the spatial frequencies of the sine function which is 
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asymmetrical. The sine frequencies are the imaginary part of a complex number (i.e. imaginary 
component of k-space) and the cosine frequencies are the real part (i.e. real component of k-
space). However, real and imaginary components are stored separately. The sine function 
represents asymmetries in the image as well as contains information regarding orientation (i.e. 
left, right, superior, or inferior). The imaginary component of k-space produces an imaginary 
image and the real component of k-space produces a real image. Imaginary and real images can 
be combined to calculate magnitude (modulus) images and phase images. The magnitude image 
is the “normal” MR image that is used in most clinical settings. C§√^]t_bg	]X§√g = 	 /g§ƒ	]X§√g " + ≈X§√]^§!}	]X§√g " 
The phase of the phase image goes from −180° to +180° and is defined as: ∆ℎ§7g	]X§√g = §!Çt§^ ≈X§√]^§!}	]X§√g/g§ƒ	]X§√g  
k-space possess a symmetry called the Hermitian conjugate symmetry where two quadrants are 
identical. This applies to the first and third quadrants as well as the second and fourth quadrants. 
This has the advantage that by only acquiring parts of k-space the other missing parts can be 
inferred and therefore acquisition times can be reduced. Hermitian conjugate symmetry only 
applies in the case of a perfectly homogenous magnetic field and inhomogeneities will therefore 
introduce phase errors.  
 
2.4.4.3. Voxel Size and Field of View 
There are two important concepts that are related to k-space which are voxel size and field of 
view (FOV). Similar to the image, k-space is of finite length and made up of voxels with 
dimensions ∆V	 ∆Vr, ∆Vs, ∆VW  that when multiplied by the matrix size for a specific dimension 
give the overall k-space size VvÉv«» Vr,vÉv«», Vs,vÉv«», VW,vÉv«» . Normally, the image matrix and 
the matrix of k-space are the same size. The inverse of the overall image size is the voxel size in 
k-space: 
 ∆Vr = 1… Àr (78) 
The same inverse relationship also applies between spatial resolution of the image (voxel size) 
and the total k-space size: 
 Ãc|gƒ	7]Eg | = 1Vr,vÉv«» (79) 
The relationships shown in equations (78) and (79) say that if spatial resolution is kept constant, 
increasing the FOV by a factor of two will half the voxel size in k-space. But if FOV is kept 
constant, then doubling spatial resolution (i.e. halving the image voxel size) will double the 
overall size of k-space. It is important to note that the strength of the gradients only alter the 
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3. T1 and T2 Mapping 01 and 0" mapping is the quantitative estimation of the longitudinal and transverse relaxation 
time constant, respectively. MRI pulse sequences that are designed to measure 01 and 0" are 
becoming increasingly important.  Many diseased tissues show significant changes in their 
relaxation times that can be used for diagnosis by MRI. 
 
3.1. T1 Mapping 
The aim of 01 mapping is to calculate a parametric map from multiple MR images, typically 
acquired along the temporal evolution of the CW magnetisation where every pixel has a 
quantitative 01 value reflecting the average longitudinal relaxation time constant of the 
associated voxel of the tissue under investigation. 01 mapping sequences are commonly used for 
the characterisation of nanoparticle-based contrast agents for cancer imaging applications [94]. 
The reason for 01 changes can be due to changes in water content or in the molecular 
environment [95]. Another application is in cardiovascular MRI where various disease states of 
the myocardium cause a change in the longitudinal relaxation time constant [96]–[99]. 01 
mapping has also been successfully demonstrated in the human brain [100] where it can be used 
to better understand the effects of multiple sclerosis on white and grey brain matter [101].  
The two main techniques used for 01 mapping are the inversion recovery (IR) and saturation 
recovery (SR) methods. Within these two main categories, various modifications and 
specialised techniques have been developed such as the Modified Look-Locker Inversion 
Recovery (MOLLI) and the Saturation Recovery Single-Shot Acquisition (SASHA). In 
addition, the estimation of 01 from a series of spoiled gradient echo (SPGR) images 
(DESPOT1) will be described. 
 
3.1.1. Basic Inversion Recovery (IR) and Saturation Recovery (SR) Sequences 
A generic inversion recovery (IR) sequence (figure 19) starts with an inversion pulse £uP, that 
tips the bulk magnetisation vector from the positive z-axis to the negative z-axis. The inversion 
pulse does not necessarily be exactly 180°, as long as it is larger than 90° negative longitudinal 
magnetisation is created. The inversion pulse can be slice-selective or nonselective. The spin 
system is assumed to be at thermal equilibrium before the application of the inversion pulse, 
which means the magnetisation vector is defined as C = 0, 0,CM . The transverse 
magnetisation immediately after the inversion pulse is Crs = CM sin £uP, and the longitudinal 




Figure 19: Generic inversion recovery sequence with the initial inversion pulse followed by a 
time delay (inversion time, TI) during which the longitudinal magnetisation will undergo 
relaxation. At the end of the inversion time a excitation pulse is applied in order to acquire an 
image (reproduced from Bernstein et al. [91], p. 607). 
 
It is common practice to apply a spoiler gradient after the application of the inversion pulse to 
dephase the transverse magnetisation. Such a spoiler gradient does not affect the longitudinal 
magnetisation. The time delay after the inversion pulse is called the inversion time (TI). The 
longitudinal magnetisation will undergo relaxation in its attempt to return to equilibrium 
magnetization CM, and align with the positive z-axis parallel to the static magnetisation vector LM. The 01 relaxation is described by the Bloch equation (80). 
 
bCWbt = CM − CW01  (80) 
When using CW = CM cos £uP, as the initial condition of the Bloch equation, a solution for the 
longitudinal magnetisation is given by  
 CW t = CM 1 − 1 − cos £uP, gmv/jò  (81) 
The inversion recovery pulse sequence can be structured into two parts. The first part being an 
IR module consisting of the inversion pulse, with optional slice-select and spoiler gradients, and 
inversion time. The second part is the remainder of the pulse sequence referred to as the 
imaging sequence (figure 19). The imaging sequence is self-contained and produces the image 
while the IR module only prepares the magnetisation to achieve a certain contrast effect. It is 
possible to execute more than one IR module before the imaging sequence. Two and three IR 
modules lead to double and triple inversion recovery sequences, respectively. Equation (81) is 
only valid if the repetition time (TR) between successive inversion pulses is at least 5 times the 
longest 01 measured. In practice, TR is always finite and the definition of CW t  depends on the 
imaging sequence. In the case of a spin echo sequence it is given by equation (82). 
 CW t = CM 1 − 1 − cos £uP, gmv/jò + gmj≠/jò  (82) 
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For the specific case of a complete inversion i.e. £uP, = 180°, the time-dependent longitudinal 
magnetisation is 
 CW t = CM 1 − 2gmv/jò + gmj≠ jò  (83) 
When the inversion pulse has an angle of 90°, i.e. CW 0 = 0, the sequence is referred to as a 
saturation recovery (SR) sequence because the longitudinal magnetisation is tipped completely 
in the transverse plane and therefore ‘saturated’. 
 CW t = CM 1 − gmv/jò  (84) 
Figure 20 shows two graphs, one of an inversion recovery and one of a saturation recovery 
curve.  
 
Figure 20: Comparison of inversion recovery (solid line) and saturation recovery (dashed line) 
(reproduced from Bernstein et al. [91], p. 610). 
 
Longitudinal magnetisation recovers along the z-axis for as long as the time delay is chosen by 
the operator. Relaxation is interrupted by an excitation pulse of the imaging sequence that 
performs the actual imaging. In the case that the repetition time between inversion pulses is 
much larger than the longitudinal relaxation time of the sample, i.e. 0/	 ≫ 01, the magnetisation 
available for imaging at the start of the imaging sequence is given by 
 CW 0≈ = CM 1 − 2gmjŒ/jò  (85) 
Apart from 01 mapping, inversion recovery sequences are also used for the nulling of 
magnetisation of a particular tissue by carefully selecting TI such as for black blood imaging 
[102]. A major disadvantage in practical applications is the long TR that is required. For that 
reason, it is common to use fast imaging techniques and 2D sequences are preferred over 3D. 
 
Due to its importance to fully understand 01 and 0" mapping pulse sequences, the physics of an 
inversion pulse will be briefly discussed in the following paragraph. A radiofrequency pulse is 
referred to as an inversion pulse if its application results in a negative z-component in the 
magnetisation vector. At equilibrium, CM is completely aligned with the static magnetic field LM 
along the positive z-axis. The normal flip angle for an inversion pulse is 180° and ideally no 
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transverse magnetisation is produced (figure 21a). In reality, imperfections in the inversion of 
magnetisation are present that result in residual transverse magnetisation (figure 21 b).  
 
Figure 21: Behaviour of the magnetisation vector for the application of an on-resonance 
inversion pulse in the rotating frame of reference. a: Ideal behaviour with the magnetisation 
vector being aligned along the negative z-axis. b: Imperfections result in incorrect alignment of 
the magnetisation vector with the z-axis which leads to residual transverse magnetisation 
residual (reproduced from Bernstein et al. [91], p. 77). 
 
A spoiler gradient is often applied immediately after the inversion pulse to dephase any 
transverse magnetisation (figure 19). Inversion pulses can be selective or nonselective which 
depends on the pulse width and shape. Those pulses with constant rf amplitude are usually 
nonselective. Pulses that have been amplitude modulated are typically frequency selective. The 
application of a frequency selective inversion pulse in the presence of a slice-select gradient 
results in a spatially selective inversion pulse. In the case that the inversion pulse is applied 
along the x-axis and spins are on-resonance, a precession of the magnetisation about L1 in the 
transverse plane results. Mathematically, the magnetisation can be described as 
 C t = CM 1 0 00 cos £ t sin £ t0 −sin £ t cos £ t 001  (86) 
and 
 £ t = = L1 t′ bt′vM  (87) 





Figure 22: Magnetisation vector rotates about the effective field which creates a transverse 
component. This off resonance effect on an inversion pulse is caused by the off-resonance term Δw/=  (reproduced from Bernstein et al. [91], p. 80). 
 
This causes the effective magnetic field Lëyy to be no longer aligned with the x-axis and Cr has 
a nonzero value because the magnetisation vector rotates now about Lëyy. Even with a flip 
angle of 180°, this results in a transverse component of the magnetisation vector. Spins that are 
off-resonance can come from magnetic field inhomogeneities, changes in magnetic 
susceptibility, chemical shift, and application of a slice-select gradient. The usual solution to 
off-resonance effects in an inversion recovery pulse sequence is to use an adiabatic inversion 
pulse which is insensitive to L1 inhomogeneities. 
 
3.1.1.1. Adiabatic inversion pulse 
Adiabatic pulses are fundamentally different to normal, amplitude modulated rf pulses. They are 
frequency (or phase) and amplitude modulated. The type of frequency and amplitude 
modulation determines the flip angle. Through changing the two modulation functions (i.e. 
frequency and amplitude) it is possible to uniformly flip spins exposed to different L1 fields 
with the same flip angle. 
 
Adiabatic pulses must fulfil the adiabatic condition. According to that the bulk magnetisation 
vector follows the effective magnetic field Lëyy. As the bulk magnetisation also precesses about 
the effective field in a cone-shape, it is important that the direction of Lëyy only changes 
negligibly during one precession period. The adiabatic condition can be mathematically 
expressed as 
 




For an rf pulse of the form L1 t = µ(t)gmuàéì v v where the frequency is described by a cosine 
function wxy t = 	w − =LW cos ”t  and the amplitude is described by a sine function µ t =Lr sin ”t , the effective magnetic field, i.e. its direction œ and amplitude Lëyy , are as follows 
 œ = arctan Lr sin ”tLW cos ”t  (89) 
 Lëyy = Lr sin ”t " + 	 LW cos ”t " (90) 
The adiabatic condition is satisfied if the modulation frequency ” is slow and/or Lëyy is strong. 
Because the bulk magnetisation follows the effective field under the adiabatic condition, when œ has completed a 180° rotation t = 9 ”  the magnetisation vector has also completed a full 
inversion. However, the inversion trajectory is different compared to normal inversion pulses. 
 
For the application of a full inversion, the hyperbolic secant pulse is usually used. This adiabatic 
pulse is also sometimes referred to as the Silver-Jospeh-Hoult pulse after the scientists who first 
described it. Mathematically it is given as 
 L1 t = µM sech -t 1îu÷ (91) 
In that equation, µM is the amplitude, < is a parameter (dimensionless) and - is the angular 
frequency of the modulation function. The frequency and amplitude modulation functions are 
given as 
 µ t = µM sech(-t) (92) 
 Δw t = −<- tanh(-t) (93) 
From equations (92) and (93) it becomes apparent that as the time variable t goes from −∞ to ∞, the two modulation functions behave very differently. The frequency modulation function 
starts at its maximum (i.e. <-), crosses the ordinate line (i.e. zero line) at t = 0 and continues 
with negative polarity until its minimum (i.e. – <-). The amplitude modulation function starts 





Figure 23: Modulation functions for a adiabatic inversion pulse (hyperbolic secant pulse). a: 
Frequency modulation function. b: Amplitude modulation function (reproduced from McRobbie 
et al. [92], p. 235). 
 
Adiabatic inversion pulses are a popular choice when using surface coils as the transmission of L1 fields is very nonuniform. They have also been used with short TI inversion recover (STIR) 
sequences for the inversion of lipid signals and in fluid-attenuated inversion recovery (FLAIR) 
to attenuate the cerebrospinal fluid for neuroimaging. Tissue perfusion measurements using 
arterial spin tagging is another common application [91].  
 
 
3.1.2. Look Locker Sequence 
A problem of the classical IR sequence is its time inefficiency. This is because a very long 
longitudinal recovery period is employed to ensure full recovery of the CW  magnetisation which 
results in a long acquisition time. In order to increase efficiency, a set of rf pulses with small 
angles + are employed to sample the longitudinal magnetisation after application of the 
inversion pulse. These imaging pulses of angle + are separated by a time ù. A separate phase 
encoding gradient of constant gradient strength is employed for each rf pulse. For a longitudinal 
recovery time of Nù, a total of N data points on the longitudinal relaxation curve can be 
collected. If 0/ = Nù, the sequence is conducted in the most efficient way. The N data points 




Figure 24: Sequence diagram of a Look-Locker acquisition where an inversion pulse is followed 
by a train of small flip angle rf pulses between which an echo is formed (reproduced from 
Brown et al. [89], p. 653). 
 
A typical Look-Locker sequence diagram is illustrated in figure 24. The following mathematical 
description of the Look-Locker technique will mainly follow Brown et al. [89]. After an 
inversion pulse £ follows a train of N − 1  small angle + rf pulses each separated by a time 
delay ù. The Nv: pulse will be an inversion pulse again with which a new cycle starts. It shall be 
assumed that before each +-pulse no remnant transverse magnetisation will be present. The 
longitudinal magnetisation immediately prior to the ^v: rf pulse is symbolised as CPm with ^ ∈1,2, … , N  and given as 
 CPm = C1m [1 cos + Pm1 − C¥m [1 cos + Pm1 − 1  (94) 
In the specific case of C1m it takes the form 
 C1m = −[1CQm + CM 1 − [1  (95) 
In equation (94) and (95), C¥m  is the steady-state value and CM is the equilibrium magnetisation. 
The magnetisation prior to the next inversion pulse in the steady-state is given by 
 CQm = C¥m 1 − [1 cos + Qm1 + CM 1 − [1 [1 cos + Qm11 + cos + [1 cos + Qm1  (96) 
The signal after the ^v: rf pulse is mathematically described by 
 2 ùP = - 1 − ⁄/PÉx¤ ∙ gm Pm1 ñ/jò∗  (97) 
with ⁄/PÉx¤ being the dynamic ratio which is the difference in the limiting values of the signal 
and - ≡ C¥m sin +. 
 ⁄/PÉx¤ ≡ C1m − C¥mC¥m = cos £ 1 − [1 cos £ Qm11 + cos £ [1 cos £ Qm1 + 1 (98) 
This leads to the definition of the apparent 01∗. 
 
ù01∗ ≡ ù01 − ln cos +  (99) 
In the case that the flip angle + is made vanishingly small (+ → 0) 
 lim·→M ù01∗ → ù01 (100) 
 lim·→M - → +C¥m  (101) 
and for N ≫ 1 
 lim·→M ⁄/PÉx¤ → 1 − [1Qm11 + [1Qm1 + 1 = 21 + [1Qm1 ≃ 2 (102) 
The measured signal will then approximate the following for a small flip angle +. 
 lim·→M 2 ùP ≃C¥m+1 − 2gm Pm1 ñ/jò (103) 
57 
 
As long as the flip angle + is small, the relaxation of the longitudinal magnetisation back to 
equilibrium after an inversion pulse is not disrupted. Because of the exponential signal 
behaviour between +-pulses, it is possible to do a nonlinear least square fit using equation (97)  
with the three parameters -, ⁄/ and 01∗. Once the apparent longitudinal relaxation time is 
determined, 01 can be found using equation (99). 
 
3.1.2.1. Modified Look-Locker Inversion Recovery (MOLLI) 
MOLLI was developed by Messroghli et al. [97] to overcome the limitations of the conventional 
Look-Locker (LL) sequence that up to this point was the gold standard for 01 mapping. The 
main problem of the LL technique was its limitation for cardiac imaging. Because the data 
acquisition happens continuously irrespective of the cardiac motion, 01 mapping can only be 
done for manually defined regions of interest and not pixel-by-pixel. This leads irrevocably to 
errors from misregistration. MOLLI allows for accurate 01 mapping of the myocardium within a 
single breath hold. That is achieved with two modifications compared to the LL approach. 
MOLLI allows selective data acquisition at a specific point of time in the cardiac cycle over a 
series of successive heart beats. That means that only one image needs to be acquired per 
heartbeat. Second, the multiple LL data sets with different inversion times that make up the 
MOLLI sequence can be merged into one data set. Having multiple LL data sets with different 
TIs available is invaluable to sample the relaxation curve sufficiently to get an accurate 01 
value. The readout of MOLLI is usually done with a balanced steady-state free precession 
(bSSFP) sequence [103], [104] because of better SNR compared to conventional gradient echo 
readout. For a more detailed description of bSSFP please refer to chapter 4.5.1.  and appendix I. 
The steady-state that is reached through the readout is less than the initial magnetisation CM. 
The longitudinal recovery is described by an apparent relaxation time 01∗ that is less than 01. 01 






Figure 25: Illustration of the MOLLI sequence scheme. Three Look-Locker experiments are 
performed with three different TIs. In a postprocessing step the images are regrouped to reflect 
their effective inversion time (reproduced from Messroghli et al. [97], p. 142). 
 
In the original publication, it was described with three successive LL acquisitions  that are ECG 
triggered for application in cardiac imaging. The first and second LL acquisition 441, 44"  
acquired three frames each, one frame per heart beat. The third LL acquisition 44.  acquires 
five frames. Each frame is a single shot acquisition and a recovery time of at least 4 seconds 
was given for the magnetisation to recover fully after each LL experiment. This is important to 
ensure the same initial magnetisation is flipped and therefore the same sampling at different LL 
experiments is from the same recovery curve. All three LL acquisitions start with a non-
selective 180° adiabatic inversion pulse. The inversion time to the first single shot readout 
changes for each LL experiment 0≈1, 0≈", 0≈. . However, the trigger delay (TD) from the R-
wave to the first readout remains constant to ensure images are always acquired at the same 
point of the cardiac cycle. That means that the time of the inversion pulse changes in each of the 
three LL experiments. The time delay between two readouts is a heartbeat interval and therefore 
depends on the subjects heartbeat. In order to receive one data set at the end, images have to be 
sorted according to t = 0≈ + ^ − 1 //. In that equation, ^ is the number of images in a 
specific LL acquisition and RR is the heart beat interval. After sorting the images, the 
Levenberg-Marquardt algorithm for non-linear curve fitting problems with three parameters can 
be applied [97] 
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 2≈ = µ − Lgm v jò∗  (104) 
Once A, B, and 01∗ have been found, 01 can be determined with 
 01 = 01∗ Lµ − 1  (105) 
Precision of the MOLLI method depends on the number of frames sampled along the recovery 
curve. The factor o„ − 1  is called the Look-Locker correction factor and stems from the fact 
that several readouts are being used with low flip angles.  
 
3.1.2.2. Shortened Modified Look-Locker Inversion Recovery (ShMOLLI) 
ShMOLLI was developed for cardiac MRI to acquire high precision and high resolution 01 
maps of the heart in a short breath-hold of 9 heartbeats. The ShMOLLI sequence uses a 
5(1)1(1)1 sampling scheme (7 images) in 3 IR intervals that are separated by one RR interval 0≠≠  (figure 26) [95]. 
 
Figure 26: Comparison of simulated signal behaviour of the MOLLI (a) and ShMOLLI (b) 
sequences steady-state free precession readouts (reproduced from Piechnik et al. [105], p. 3). 
 
Because of the shortened recovery period, the longitudinal magnetisation cannot fully recover 
and will significantly be affected by the preceding IR interval. As a result, the data collected in 
the 2nd and 3rd IR interval cannot simply be combined with the 1st IR interval to produce one 
data set as it was done for MOLLI. Therefore, conditional data analysis is used to solve this 
problem. If 01 of the tissue is long, only acquisitions 1-5 are used for the fitting. Sample 6 is 
included in the fitting if 01 is shorter than 0≠≠ but larger than 0.40≠≠. For 01 shorter than 0.40≠≠, all 7 acquisitions are utilised. The thresholds 0≠≠ and 0.40≠≠ are adopted according to 
the errors of the fit as 01 is unknown [105]. When all 7 images are acquired and used for the 
fitting of the magnetisation recovery curve, approximately 30% in precision is sacrificed 




3.1.2.3. Look-Locker Echo Planar Imaging Sequence (LL-EPI) 
The LL-EPI sequence consists of a magnetisation preparatory Look-Locker module 
(nonselective inversion pulse followed by multiple small flip angle + acquisitions) and an echo 
planar imaging (EPI) module (figure 27) [91]. The description of EPI is beyond the scope of this 
work but detailed description can be found in Brown et al [89], Bernstein et al. [91], Schmitt et 
al. [106] and DeLaPaz [107] among others. 
 
Figure 27: Fast 01 measurement with a Look-Locker sequence that uses an EPI module for a 
one-shot acquisition (reproduced from Gowland and Mansfield [108], p. 352). 
 
For 0/ ≫ 01, the signal after the nth readout is given by 
 2P = CW,P sin + 	gmjh/j©∗bEî¥m¥  (106) 
 in which CW,P is given by 
 CW,P = 	CM 1 − L 1 − (µL Pm1)1 − µL + µLPm1 1 − { − { µL Pm1  (107) 
In equation (107), µ = cos +, L = gmj‰/jò, and { = gmjÂ/jò. The time constants 0« and 0Ê are 
defined in figure 27. The echo time is defined as the time from the application of the readout 
pulse + to the point in time when the signal from the centre of k-space is collected. A 01 map is 
obtained by fitting the data from each EPI image to equation (106) by using a nonlinear least 
squares method [108]–[110]. This technique is able to produce 01 maps with high temporal and 
spatial resolution in less than 3 seconds. The fast acquisition brings the disadvantage of low 
SNR which means finding the optimal sequence parameters is important to achieve the best 
possible 01 map. There are several applications that require such fast imaging techniques such 
as for the study of contrast agent uptake in the brain [111] or the MRI of fetal organs [112].  
 
3.1.3. Look-Locker with a Fast Low Angle Shot (FLASH) Readout 
The concept of this technique as with the other Look-Locker methods is to acquire a series of 
images (here: snapshot FLASH images) to sample the recovery curve of the magnetisation after 
an inversion pulse. Because rf pulses are applied during sampling the recovery curve, an 
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apparent relaxation time 01∗ and a saturation value for the equilibrium magnetisation CM∗ must be 
considered. After application of the inversion pulse to a spin system at equilibrium, the temporal 
recovery of the magnetisation is given by [113], [114] 
 C t = CM∗ − (CM + CM∗)gmv/jò∗ (108) 
and 
 
101∗ = 101 − 10/ ln cos +  (109) 
In equation (109), + is the flip angle and CM∗ is given by 
 CM∗ = CM 1 − gmj≠/jò1 − gmj≠/jò∗ (110) 
A condition of this method is that 0/ < 01∗ which means equation (110) can be written as 
 CM∗ = CM 01∗01  (111) 
A three-parameter fit can be performed with the signal intensities according to 
 2 t = µ − Lgmv/jò∗ (112) 
Equation (112) yields values for A, B, and 01∗ from which 01 can be found according to 
 01 = 01∗ Lµ − 1  (113) 
 
3.1.4. Saturation Recovery Single Shot Acquisition (SASHA) 
Saturation recovery methods have a lower dynamic range compared to inversion recovery 
techniques but they could potentially offer improved accuracy. The advantage SR methods have 
is that each acquisition is independent of the other. By saturating the magnetisation before each 
measurement, the history of what has happened before the current measurement to the 
magnetisation vector is erased. SASHA is using a bSSFP [103], [104] readout (see chapter 
4.5.1. ) that offers good SNR and blood-tissue contrast. The SASHA scheme for 01 mapping of 




Figure 28: 01 mapping of the heart with saturation recovery single shot acquisition (SASHA).  
The first image is acquired before the application of any saturation preparation which is 
followed by a series of images acquired with a 90° saturation pulse (reproduced from Kellman 
and Hansen [95], p. 5). 
 
In the original publication, ten images were acquired where the first image is acquired before 
the application of any saturation preparation. After that a 90° saturation pulse is applied and one 
image is acquired in every RR interval. The saturation recovery time (TS) which is the time 
from the end of the saturation pulse to the centre line of k-space changes for every heartbeat. 
That way, multiple points along the SR curve are sampled. In addition, a variable trigger delay 
is added before the saturation pulse to ensure a constant cardiac phase is achieved for all 
images. The magnetisation at the start of a SASHA acquisition is 
 C 0 = 1 − Á«õvË«»gm(jØm„)/jò (114) 
In equation (114), Á«õvË«» is the saturation pulse efficiency and Δ describes the time from the 
beginning of imaging to the centre of k-space [115]. The recovery of the magnetisation is not 
affected by the readout which means no apparent 01∗ < 01 has to be considered and therefore no 
correction is needed. Because no apparent 01∗ is produced, a higher flip angle can be utilised for 
the readout. The advantage of using a higher flip angle is that the signal-to-noise ratio (SNR) of 
the sequence can be increased. However, this might also slightly change the shape of the SR 
curve which means that instead of a two-parameter signal model 2 02 = µ 1 − gmjØ/jò  a 
three-parameter model must be used for the fitting procedure. 
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 2 02 = µ − LgmjØ/jò (115) 
An additional fitting parameter however leads to a decrease in precision [95]. 
 
3.1.5. Driven Equilibrium Single Pulse Observation of T1 (DESPOT1) 
DESPOT1 is based on a spoiled gradient echo (SPGR) sequence (see appendix I) which is a fast 
gradient echo sequence in which the longitudinal magnetisation reaches a nonzero steady state. 
It is also referred to as steady-state incoherent (SSI) sequence in the literature [89]. The 
repetition time is selected to be shorter than the transverse relaxation time of the tissue. Residual 
transverse magnetisation at the end of each TR interval is spoiled which means a steady state is 
only achieved in the longitudinal magnetisation [104]. In the DESPOT1 sequence, after an 
initial inversion pulse of 180° and the time delay TI, a series of small flip angle excitations +-
pulses are applied. The magnetisation will eventually reach a steady-state for which the 
effective time constant 01∗ can be defined as 
 01∗ = 0/0/ 01 − ln cos +  (116) 
The signal intensity of the spoiled gradient echo 2≈Øøª≠  depends on 01, 0/, +, and the 
equilibrium magnetisation CM. 
 2≈Øøª≠ = CM 1 − [1 sin +1 − [1 cos + 					§^b					[1 = gmj≠/jò (117) 
Equation (117) describes a curve that is highly 01 weighted when 0/ is kept constant and the 
flip angle + is incrementally increased (figure 29a). By rearranging equation (117), it can be 
represented in a linear form (figure 29b) where the ordinate intercept is given as CM 1 − [1  
and the gradient is defined as [1. 
 
2≈Øøª≠sin + = [1 2≈Øøª≠tan + +	CM 1 − [1  (118) 
Performing a linear regression allows to determine 01 and CM as follows 
 01 = − 0/lnX 			and			X ⇒ √!§b]g^t (119) 
 CM = È1 − X 			and			È ⇒ c!b]^§tg	]^tg!Çg\t (120) 
The advantage of this method is that the overall measurement time can be shortened by a lot 
while maintaining a good SNR. This becomes even more important when measuring tissues 
with long relaxation times. It is often employed for 3D imaging because the DESPOT1 
sequence can easily combined with fast imaging techniques and possess a high inherent 3D 




Figure 29: Driven equilibrium single pulse observation of 01 (DESPOT1). a: Curve of spoiled 
gradient echo for a range of different flip angles + which is highly 01 weighted. B: Rearranging 
the signal equation defining the spoiled gradient echo allows its representation in linear form 
(reproduced from Brown et al. [89], p. 655). 
 
The effectiveness of this method in providing an accurate 01 map depends on finding the 
optimum flip angle for the measurement. This can be done numerically or analytically [116]. 
 
3.1.5.1. Numerical Method 
It was shown that it is sufficient to just measure the signal with two flip angles optimised for a 
particular 0/ 01 combination [117]. The regression line described by equation (118) contains 
data points of the form ØŒÍ,ÎÏÌÓ·Î , ØŒÍ,ÎÔÓ ·Î . If only two measurements are needed with flip angles +1 
and +", then only two data points are available for the linear regression. If it is assumed that 
each point has the same intrinsic error, then the gradient of the linear regression becomes better 
to estimate the further apart the two data points are. The ordinate distance between two data 
points is called the normalised dynamic range (DR). 
 ⁄/ = 2≈·,"CM sin +" − 2≈·,1CM sin +1 (121) 
When the location of the data points determines the precession, a fractional signal of the points 
can be defined. 
 …2 = 2≈·,1 + 2≈·," /22≈·,h  (122) 
In equation (122), 2≈·,h  is the Ernst signal which is obtained with the Ernst angle. By 




3.1.5.2. Analytical Method 
The above defined product ⁄/×…2 has its maximum when  2≈·,1 = 2≈·," which means the 
following simplification can be made. 
 æ = 2≈·,12≈·,h = 2≈·,"2≈·,h  (123) 
Deoni et al. [116] have plotted the product ⁄/×æ  versus 0/ 01 and æ and used a polynomial 
to fit the data and find its maximum. It was shown that the best precision for determining 01 is 
achieved with flip angles that lead to 2≈·,1 = 2≈·," = 0.712≈·,h . By expanding the signal 
intensity from equation (117) to 2≈ = æ×2≈·,h  and after some algebraic rearrangements an 
analytic solution for the optimal angles is found [116]. 
 + = 	 cosm1 æ"[1 ± 1 − [1" 1 − æ"1 − [1" 1 − æ"  (124) 
 
3.2. T2 Mapping 
The aim of 0" mapping is to calculate an image from multiple MR images where every pixel has 
a quantitative 0" value reflecting the average transverse relaxation time constant of the 
associated voxel of the tissue under investigation. A major application of reliable 0" mapping 
techniques is molecular imaging such as the cell tracking with MRI contrast agents [118]. The 
active and passive targeting of tumour cells with iron-oxide nanoparticles is of particular 
interest. A decrease in the signal intensity of the tumour area on 0" maps has been shown to 
correlate with successful targeting in xenograft models [119]. Several authors have also reported 
the successful application of 0" mapping for the detection [120], [121] and characterisation 
[122], [123] of prostate cancer in patients. Another application is in cardiac MR where elevated 0" values have been reported for acute myocardial infarction [124], [125] and myocarditis 
[126]. Neurologic diseases such as multiple sclerosis [127], epilepsy [128] and schizophrenia 
[129] show differences in transverse relaxation times compared to healthy brains.  
This work will describe three techniques that have been shown to provide successful 0" 
mapping results. Traditionally, a multi-echo spin echo (ME-SE) sequence is used with 
incrementally increasing echo times. More recent methods include the estimation of 0" from 
multiple bSSFP (see chapter 4.5.1.  and appendix I) images (DESPOT2) and the use of a 0"-




3.2.1. Multi-echo Spin Echo (ME-SE) Sequence 
The basic spin echo sequence consists of an initial 90° excitation pulse which brings the 
magnetisation vector in the transverse plane. After a time delay a second 180° refocusing pulse 
is applied that flips the dephasing spins about the transverse plane and brings them back 
together to form an echo. After the formation of an echo, the spins start to dephase again which 
means that multiple refocusing pulses can be applied to produce a series of spin echoes that 
have alternating positive and negative amplitudes (figure 13, chapter 2). Such a series of echoes 
is referred to as an echo train. A typical echo train length for 0" mapping is about 16 echoes 
long although shorter trains can also be sufficient. The range of echo times should go up to 
roughly three times the estimated 0" value [91]. Nonideal slice profiles can cause problems in 
2D imaging techniques of the spatially varying flip angles of the slice-selective excitation and 
refocusing pulses. The echo amplitude of a spin echo for a 90° − ù − 180° pulse sequence is 
proportional to sin. £ where £ is the flip angle of the excitation pulse. All other echoes have a 
reduction in amplitude by sin" £. The amplitude of the spin echo after the nth 180°-pulse is 
therefore proportional to sin"Pî1 £. The signal of the nth echo can be calculated by integrating 
the slice profile 	\ £ . 
 2≈ 0[P = CMgmjhÒ/j© b£ \ £ sin"Pî1 £  (125) 
In equation (125) it is assumed that all echoes are separated by a time TE and that the slice 
profile is normalised b£ \ £ = 1. With increasing ^, the bracketed expression is decreasing 
which is the signal loss. The exponential gmPy with æ > 0 can approximate that signal loss 
because when plotting the bracketed expression of equation (125) for a time-truncated sinc 
pulse, it resembles an exponential decay. The signal expression of equation (125) can therefore 
be written as 
 2≈ 0[P = CM sin £ gmjhÒ/j©gmPy (126) 
When fitting 2≈ 0[P  to an exponential function, an incorrect 0" value is obtained that 
underestimates the “true” 0" value. It is therefore called ‘apparent’ 0" value or 0",«ûû. 
 
10",«ûû = 10" + æ0[ (127) 
The underestimation of the transverse relaxation time can be reduced by increasing the echo 
time to its maximum. However, making the echo time too large also decreases the SNR. To 
resolve this problem, nonselective ‘hard’ pulses can be used for the refocusing pulses [89]. 
Named after its inventors, this sequence is called the Carr-Purcell 0" mapping sequence. 
Compared with individual spin echo experiments, the Carr-Purcell sequence compensates for 
irreversible dephasing from the diffusion of spins through magnetic field inhomogeneities as 
well as considerably shortens acquisition times. 
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 2≈ 0[ = CM g mjhj© ∙ g m>©∆o©Úñ©jh.  (128) 
In equation (128), ⁄ is the diffusion coefficient, 2ù is the echo spacing and ΔL the magnetic 
field inhomogeneity. For a small echo spacing, the second term approaches 1 and the signal is 
described by the first exponential term that depends on 0". A well known problem is 
imperfections in the 180° refocusing pulses which over the duration of the echo train can start to 
accumulate and cause incorrect 0" estimates. The Carr-Purcell-Meiboom-Gill (CPMG) 
sequence which is a modification of the above sequence compensates for L1 field 
inhomogeneities by applying the excitation pulse 90r°  and the train of refocusing pulses 180s°  90° out of phase. All refocusing pulses are still equally spaced by a distance of 2ù but 
all echoes are positive in this case (figure 30).  
 
Figure 30: Sequence diagram of a Carr-Purcell-Meiboom-Gill (CPMG) sequence showing slice-
select, phase-encoding, and readout gradients used to fill k-space (reproduced from Bernstein et 
al. [91], p. 778). 
 
Imperfections in the refocusing pulses cause the first and every odd numbered 180° pulse to be 
too small. However, the even refocusing pulses will have the correct height and precise 0" 
measurements are possible by only considering the even echoes. It must be noted that 01-
weighting can potentially be introduced in the measured signal by the stimulated echoes which 
will interfere in the analysis when trying to fit the data to a monoexponential decay curve. 
Magnitude reconstruction causes the noise floor to be nonzero which leads to an overestimation 
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of the 0" values. This can be resolved by utilising a three parameter nonlinear fitting model of 
the form 2 0[ = N + µgmjh/j©. 
 
3.2.2. Driven Equilibrium Single Pulse Observation of T2 (DESPOT2) 
The driven equilibrium single pulse observation of 0" technique uses a preexcitation refocused 
SSFP sequence [104] (appendix I) that includes a series of small flip angle excitation pulses 
[130]. The echo is formed before the excitation pulse and originates from refocusing residual 
echo at the time of the next rf pulse. This sequence is strongly 0"-weighted [104]. The signal 
intensity 2≈ØØÛø  depends on the flip angle +, 0/, 01, 0", and CM. The signal equation can take 
several forms depending on the conditions under which the sequence is run. For this description, 
the signal equation is given in the same form as in the original publication of this technique 
[116]. 
 2≈ØØÛø = CM 1 − [1 sin +1 − [1[" − [1 − [" cos + (129) 
Equation (129) is particular useful for short repetition times that are less than 10 ms and 
excitation pulses with alternating phase with [1 = gm(j≠/jò)	and [" = gm j≠ j© . The TR is to 
be kept constant while increasing the flip angle + incrementally. The data generated will show 
dependency on both 01 and 0". Equation (129)  can be rearranged to take on a linear form. 
 
2≈ØØÛøsin + = [1 − ["1 − [1[" × 2≈ØØÛøtan + + CM 1 − [11 − [1["  (130) 
In equation (130), hòmh©1mhòh© is the gradient X of a linear function and åp 1mhò1mhòh©  is the ordinate 
intercept È. From gradient and intercept, a value for 0" and CM can be found given that 01 and 
hence [1 is known. 
 CM = È 1 − [1["1 − [1  (131) 
 0" = − 0/ln X − [1X[1 − 1  (132) 
The optimal flip angle + can be determined in a similar way as above for the DESPOT1 method 
which is finding those flip angles that lead to optimal precession of the 0" value for a specific 
set of 0/, 01, and 0". The vector product of ⁄/ (equation (121)) and …2 (equation (122)) can be 
evaluated and were found to be maximised for 2≈·,1 = 2≈·,". Note that for the case of 
DESPOT2, the signal intensity in equation (130) comes from the SSFP sequence. Similar to the 
description of DESPOT1, …2 can be subsidised with æ. Using a polynomial fitting method, 
Deoni et al. [116] concluded that the optimal 0" precession is achieved for flip angles 2≈·,1 =
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2≈·," = 0.712≈h . Identical to the SPGR case presented above, an analytical solution can also be 
found for the ideal preexcitation refocused SSFP flip angles as 
 + = cosm1 −L ± L" − 4µ{2µ  (133) 
with µ = 2[1[" + 2[1["Ψ − 2[1[" [1 − [" Ψ + [1"["" + [1 − [" "Ψ" − f" 1 − Ψ E1 − E" " L = 2æ" 1 − Ψ [1 − [" − 2æ" 1 − Ψ [1[" [1 − ["  { = 1 − 2[1[" − 2 [1 − [" Ψ + 2[1[" [1 − [" Ψ + [1"["" + [1 − [" "Ψ" − æ" 1 − Ψ+ 2æ" 1 − Ψ [1[" − æ" 1 − Ψ [1"["" 
and Ψ = hòmh©1mhòh©. 
  
3.2.3. T2-weighted Magnetisation Prepared (T2Prep) Sequence 
This technique uses a 0"-weighted magnetisation prepared sequence called the 0"prep to 
quantitatively measure the transverse relaxation time constant. 0"-weighted magnetisation 
prepared methods have been introduced to the scientific community in 1990 by Haase [131]. It 
was demonstrated in the past that this method can also be used for 0" measurements [132], 
[133]. The principle technique is that a 90r°  excitation pulse is followed by a train of equally 
separated 180s°  refocusing pulses. When the echo of the final refocusing pulse is established, a 
tipup pulse returns the 0"-weighted magnetisation back along the longitudinal direction. The 
number N of refocusing pulses applied can vary and depends on the specific conditions [134]. 90r° − ù − 180s° Q − ù − t]\_\mr 
Because the transverse magnetisation after the initial excitation pulse dephases according to 
spin-spin relaxation, the refocused and flipped back longitudinal magnetisation at the end of the 
train of refocusing pulses is strongly 0"-weighted [91]. The 0" Prep sequence is nonselective 
and designed so that it is independent of LM and L1 field inhomogeneities by weighing the 
refocusing pulses in an MLEV pattern [135], [136] or utilising composite 180r°  pulses [137]. 
After the 0" Prep sequence, spoiler gradients usually dephase any residual transverse 
magnetisation before the readout part of the sequence. The 0" Prep can be combined with any 




Figure 31: 0" Prep module preceding other elements (e.g. Spoiling) and the sequence 
acquisition (e.g. gradient echo sequence) (reproduced from Bernstein et al. [91], p. 889). 
 
Quantitative 0" mapping using the 0" Prep sequence was recently demonstrated by Ding et al. 
[138]. The authors performed a three-dimensional whole heart 0" mapping at 3T using a 0"prep 
rf spoiled gradient echo (SPGR) sequence together with a saturation prepulse and a navigator. 
The adiabatic 0"prep [139] was used to achieve different 0" weightings by selecting different 0"prep echo times (i.e. time between the initial 90r°  excitation pulse and the tipup pulse). The 
first image was acquired without a 0" Prep 0[j©	øxëû = 0	X7  and then at echo times of 25ms 
and 45 ms.  
 
3.2.4. T2* Mapping 
The presence of magnetic field inhomogeneities contribute to the dephasing of spins and cause 
the transverse magnetisation to decay faster which is described in chapter 2.3. Magnetic field 
inhomogeneities that change over the size of a voxel are referred to as microscopic and provide 
information about the microstructure of the tissue [140]. The magnetic field distortions 
introduced by superparamagnetic iron oxide nanoparticles (SPIONs) are an example of this kind 
of inhomogeneity that produces 0"∗ decay. The other form of inhomogeneities are macroscopic 
that are constant over the size of a voxel such as imperfections in the static magnetic field 
caused by air/tissue interfaces or gradient fields [141].  
 
Multi-echo GRE sequences use increasing echo times and therefore the 0"∗ decay curve can be 
obtained from pixel-wise fitting of the signal intensity along the time axis [91]. 0"∗ mapping 
sequences use small flip angles to reduce the 01 influence and large voxel sizes. Because 0"∗ 
mapping is usually done with a 2D sequence, the slice thickness is normally considerably larger 




A problem with quantitative 0"∗ mapping is that for many applications such as molecular 
imaging with SPIONs [143] and the investigation of the vascular morphology of tumours [144], 
macroscopic inhomogeneities are unwanted. Therefore, it is important to correct for 
macroscopic magnetic field inhomogeneities in order to generate 0"∗ maps that reflect the 
microscopic inhomogeneities present in the tissue of interest. Various correction methods have 
been proposed such as the manipulation of the slice-select gradient [145] or the application of a L1 field [140], [146]. Wild et al. [147] proposed the combination of three successive ME-GRE 
images where slice refocus gradients are incremented in succession after using a numerical 
simulation to determine optimal incrementation. Other authors have developed a postprocessing 
method such as the correction for the sinc modulation generated by the macroscopic 
inhomogeneities under the assumption that these inhomogeneities are linear across the slice 
thickness [148]. Dahnke and Schaeffter [143] later simplified this method which led to 




4. Positive Contrast Imaging 
Positive contrast methods for MR imaging take advantage of local differences in susceptibility 
[149]. Local magnetic field susceptibilities are e.g. introduced by superparamagnetic iron oxide 
nanoparticles (SPIONs) or at tissue interfaces. The water molecules affected by the dipole field 
of SPIONs is visualised as signal loss with conventional spin echo or gradient echo sequences 
(negative contrast). A problem with depicting SPION accumulating areas with negative contrast 
is its ambiguity with other sources of signal loss such as air cavities in the abdomen [150]. 
Furthermore, it is generally easier to identify a white or bright signal on a T1 weighted MR 
image than it is to identify a black or dark area on a T2 weighted or proton density weighted 
MR image.  
 
Several techniques have been developed to generate positive contrast with SPIONs. These 
techniques can be grouped into three categories. The first category treats the dipole field 
introduced by SPIONs as local magnetic field gradients that add to the imaging gradients and 
cause a shift in k-space [150]. Examples are GRadient-echo Acquisition for Superparamagnetic 
particles with Positive contrast (GRASP) [151] and Susceptibility Gradient Mapping (SGM) 
[152]. The second group of techniques utilise the fact that SPIONs change the local Larmor 
frequency [150]. Inversion Recovery with ON-resonant water suppression (IRON) [153] is an 
example of a method that utilises off-resonance imaging to depict SPIONs as positive contrast. 
The final group of techniques exploits the different phase accumulation, specifically the 
different phase rotation angle, of on- and off-resonant protons [150]. An example of this is the 
Fast Low Angle Positive contrast Steady-state free precession (FLAPS) [154] technique that is 
based on a balanced steady-state free precession sequence [103]. 
 
4.1. Background Physics 
Superparamagnetic iron oxide nanoparticles have a different magnetic susceptibility than the 
background tissue. This introduces local magnetic field inhomogeneities which causes magnetic 
field variations within adjacent voxels. A change of the magnetic field strength leads to a 
change of the Larmor frequency according to the Larmor equation introduced in chapter 2. 
Hence, spins in an adjacent voxel will be precessing at different frequencies which results in a 
signal decay within the voxel due to intravoxel dephasing. The signal within a voxel can be 
described as 
 S¯˘˙˚¸ = 1V ρ r emˇd.r! 				and					φ = γB#,Ó$ x, y, z TE (134) 
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In equation (134) the additional phase component in z-direction due to the distortion of the local 
magnetic field LW,uP: is represented by φ. The voxel volume in mm3 is represented by V, ρ r  is 
the spin density, TE is the echo time, and γ is the gyromagnetic ratio. The field distortion caused 
by SPIONs is a dipole field that can be mathematically described as 
 B#,Ó$ x, y, z = c x" + y" − 2z"x" + y" + z" I/" 					with					c = BM∆χV4π  (135) 
In equation (135) BM is the external magnetic field along the z-direction. The difference in 
magnetic susceptibility per volume between the environment and the SPION is given by ΔχV. 
When integrating equation (135) over the slice-selection direction, the normalized complex 
signal expression for a voxel (equation 136) is obtained as  
 S x, y = 1d ρ x, y, z em+,-,./0 ˙,1,# 23dz4/"m4/"  (136) 
where d is the slice thickness in millimetre and ρ x, y, z  is the spin density in all three 
directions. 
 
4.2. GRadient-echo Acquisition for Superparamagnetic particles with 
Positive contrast 
GRadient-echo Acquisition for Superparamagnetic particles with Positive contrast (GRASP) 
was first described by Seppenwoolde et al. [151]. This method treats the field distortion as a 
local time invariant magnetic field gradient that is overlaid onto the imaging gradients such as 
the slice-selection gradient. A change in gradient strength results in a shift of the signal in k-
space. In the original publication, GRASP was referred to as the “white marker phenomenon” or 
“white marker imaging”. Both names, GRASP and whiter marker (WW), are used nowadays. 
 
4.2.1. Technical description of GRASP 
The addition of a gradient in the z-direction will change the local magnetic field experienced by 
the spins. The phase accumulation during acquisition will also change as a result of that. 
Mathematically, having an additional phase contribution from an additional gradient will 
change equation (136) according to 
 S x, y = 1d ρ x, y, z emγ,-,./0 ˙,1,# 23î56τ6#dz4/"m4/"  (137) 
Equation (137) contains additional components such as the strength of the susceptibility 
gradient GÔ (mT/m) and the time τÔ (ms) during which the spins experience this gradient. The 
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spatial dependence of the phase φ can be shown by treating the slice thickness as a summation 
of subslices of infinitesimal small thickness dz. For each subslice the phase will be 
 φ = ∂B#,Ó$∂z x, y, z TE + GÔτÔ (138) 
Signal conservation occurs when the phase described by equation (138) is zero at the point 
where the echo is acquired (TE) because the dephasing will be zero. This is called gradient 
compensation and illustrated by figure 32. 
 
Figure 32: Gradient compensation in the slice-select direction where the field inhomogeneities 
interpreted as gradient C add to the rephasing gradient B which will therefore need to be 
reduced in strength to rephase area A (reproduced from Seppenwoolde et al. [151], p. 785). 
 
In order to rephase the spins after the application of a slice-select gradient, the rephasing lobe 
(B) must be equal to area (A) which is half of the applied slice-select gradient. For a gradient 
echo sequence, this will produce a conventional gradient-echo at the echo time. If the strength 
of the rephasing lobe is decreased, the signal available at the echo time to produce an image will 
also be decreased due to a gradient imbalance. The reason for that is that not all spins will be 
rephased at the echo time which results in less available signal. Areas where there is an 
additional local gradient (C) due to the presence of the SPIONs, the spins can get fully rephased 
because the local additional gradient is added to the rephasing lobe and together compensate for 
the applied slice-select gradient. Therefore, for spins that are affected by the local magnetic field 
distortion of the SPIONs represented as an additional gradient, a fully rephased gradient-echo 
will occur with maximum signal intensity. The gradients in z- and x-direction can be found by 
finding the derivatives of equation (135). 
 
äLW,uP:äE |, }, E = 3ÇE −3|" − 3}" + 2E"|" + }" + E" :/"  (139) 
 
äLW,uP:ä| |, }, E = −3Ç| |" + }" − 4E"|" + }" + E" :/" (140) 
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Different region in the vicinity of the SPIONs will cause the phase to be zero according to 
equation (138). The reason for that is the spatial variation of different derivatives which means 
that the signal conservation occurs at different regions around the SPIONs [151], [155], [156]. 
Because the dephasing of spins is of central importance for the GRASP technique, all 
acquisition parameters that influence dephasing have a significant influence on the image 
quality. This means that the echo time, slice thickness, and strength of background gradients are 
parameters of vital importance for this technique. As shown by Seppenwoolde et al. [151] the 
transition from normal gradient-echo contrast behaviour to a positive contrast image is sudden 
when varying the background gradient. If the gradient is higher, i.e. the SPIONs introduce 
stronger magnetic field inhomogeneity, the signal near the SPIONs decreases. However, signal 
intensity relative to the background signal increases which means better contrast.  
 
4.2.2. Applications of GRASP 
Mani et al. [155] conducted a comprehensive phantom study with Feridex® (Advanced 
Magnetics, Cambridge, MA) which is a dextran coated SPION with a core size of 4.8 ± 1.0 nm. 
The authors prepared membrane phantoms of 1% agarose gel with different SPION 
concentrations to eliminate effects of the glass/gel interface and compared these with glass 
phantoms. A good positive signal was observed between 0.05 – 0.8 mM on clinical scanners of 
1.5T and 3T. The authors demonstrated that the positive signal was directly related with the 
signal loss on conventional gradient-echo images. However, when comparing the results at 1.5T 
and 3T the sensitivity of GRASP was greatly reduced at the higher field strength for the 
detection of low SPION concentrations. This might have implications for in vivo imaging at 3T 
or higher field strengths when only small SPION concentrations are delivered to the target 
region. The susceptibility difference at the glass/gel interface was significant and plastic or glass 
tubes are therefore not recommended for phantom experiments. The authors furthermore 
concluded that GRASP provides best results when the SPIONs are highly compartmentalised 
with limited iron particle uptake. 
 
The same research group also conducted a study to determine if ferritin depositions in a 
thrombus model could be determined with GRASP in vitro and in vivo. Incubating blood with 
ferritin was used for the in vitro thrombi model in which the GRASP sequence successfully 
verified the deposition of ferritin. GRASP and conventional 0"∗-weighted gradient-echo 
sequences were performed in vivo on a crush injury model in rabbits. The authors showed that 
signal enhancement by GRASP correlated with signal loss in the gradient-echo images which 




Signal variations within voxels caused by partial volume effects also produce positive contrast 
using the GRASP sequence. The authors who first described the GRASP technique reported in 
2007 a strategy to eliminate partial volume effects during imaging with GRASP. The normal 
signal response curve as a function of the applied gradients is asymmetric. Symmetrical signal 
responses must stem from partial volume effects and can therefore be subtracted. This technique 
was probed in vitro and in vivo in brain regions affected by susceptibility and partial volume 
effects. Partial volume effects were successfully eliminated in vitro and became negligibly small 
in vivo [157]. 
 
Mani et al. [158] used GRASP in an in vivo mouse model of myocardial infarction to 
dynamically track implanted stem cells. A complex of Feridex® (Berlex Laboratories, Wayne, 
NJ) and protamine sulphate was bound to embryonic stem cell-derived cardiac-precursor-cells. 
Half a million magnetically labelled stem cells were injected in infarcted mice and gradient-
echo and GRASP images were acquired at 9.4T at three different time points (baseline, 24h and 
one-week post injection). The negative contrast images acquired with the gradient echo 
sequence were in good agreement with the GRASP images which was confirmed by positive 
staining for iron with histology. 
 
4.3. Inversion Recovery with ON-resonant water suppression 
The first group to use an Inversion Recovery with ON-resonant water suppression (IRON) to 
achieve positive contrast with SPIONs was Stuber et al. [153]. The difference to the above 
described GRASP method is that the field inhomogeneities introduced by the SPIONs are not 
treated as an additional gradient but as the cause of a frequency shift of spins in the vicinity of 
the SPIONs.  
 
4.3.1. Technical description of IRON 
If SPIONs can be assumed to be spherical, then the magnetic field distortion they introduce can 
be mathematically described by 
 ∆B r,Θ 3˙Ï˚<ÓÌ¸~ ΔK	a.3r. 3cos"Θ − 1 BM (141) 
In equation (141) ΔK is the susceptibility gradient coefficient of the spherical object (SPIONs). 
The radius of the sphere is represented by a and r describes the distance from the magnetic 
sphere to any given point in space where ! shall be larger than the radius of the sphere ! >§ . The angle between ! and the direction of the main magnetic field LM is represented by Θ. 




 ΔwhrvëxP«» = =ΔLhrvëxP«» (142) 
Equations (141) and (142) demonstrate that by introducing objects such as SPIONs with a 
susceptibility gradient coefficient ΔK into the main magnetic field of an MRI scanner adds 
frequency components different to the Larmor frequency wM (figure 33a). IRON utilises the 
shift in resonance frequency of spins affected by the magnetic field disturbance by applying a 
saturation rf pulse that is spectrally selective to spins resonating at the Larmor frequency wM 
(on-resonant protons) (figure 33b). This saturation pulse has a limited bandwidth BW@ÌÏ  and is 
applied prior to the actual imaging part in the magnetisation preparation phase of the sequence. 
This results in the signal normally coming from on-resonant protons to be suppressed while 
only minimally affecting the off-resonant protons influenced by the SPIONs. This means that 
positive contrast can be generated in areas close to susceptibility introducing particles.  
 
Figure 33: MR signals in the frequency domain where a narrow bandwidth IRON pulse is used 
to suppress on-resonant protons while preserving the off-resonant components and the fat signal 
(reproduced from Stuber et al. [153], p. 1073). 
 
The angle of the applied saturation pulse α@ÌÏ can be changed and used to control the level of 
background suppression. The bandwidth of the saturation pulse BW@ÌÏ controls the size of the 
area with positive contrast. Figure 34a shows the pulse sequence diagram. The temporal 
development of the longitudinal magnetisation of the off-resonant spins is displayed in figure 




Figure 34: Signal behaviour over time of the on- and off-resonant frequency components for an 
acquisition preceded by fat suppression (dual-inversion) and the IRON prepulse (reproduced 
from Stuber et al. [153], p. 1073). 
 
The saturation pulse nulls the on-resonant protons at the time of the imaging sequence. The 
signal of fat and off-resonant protons however remains unaffected. In order to also remove the 
fat signal from the image, a dual inversion saturation pulse can be applied prior to the on-
resonant saturation pulse that only affects protons of short longitudinal relaxation time such as 
fat [150], [153], [159]. 
 
4.3.2. Applications of IRON 
In the original IRON publication, Stuber et al. [153] demonstrated the feasibility of generating 
positive contrast with IRON in a gelatine phantom containing a 0.5 mm diameter stainless steel 
sphere as well as with SPION-labelled stem cells in vitro and in vivo. For the stem cell 
experiments the authors used an agarose gel phantom that contained wells with mineral oil (fat) 
and wells with two million labelled canine mesenchymal stem cells. The in vivo experiments 
were conducted with New Zealand White Rabbits intramuscularly injected with SPION-labelled 
canine mesenchymal stem cells. The authors successfully demonstrated in vitro and in vivo that 
positive contrast can be achieved with IRON in the surrounding of SPION-labelled cells.  
 
Advantages of IRON are that the imaging part of the sequence does not need to be modified 
such as with GRASP. The in vitro studies of Stuber et al. [153] demonstrated a high correlation 
of SPION-labelled cells to the amount (i.e. volume) of positive contrast and could potentially be 
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used for non-invasive cell quantification. Furthermore, 2D and 3D images can be easily 
acquired and fast imaging techniques can be employed. A limitation of IRON is the increased 
power deposition when using a fast spin echo sequence. Moreover, positive contrast may also 
result at tissue borders or air-tissue interfaces for which higher order volumetric shimming is 
required. Local over- or undertipping of the magnetisation can be caused by B1 inhomogeneities 
at higher field strengths. For fat suppression, a second spectrally selective prepulse is preferred 
over a dual inversion technique to avoid T1 dependence of the longitudinal magnetisation from 
the off-resonant protons. Finally, the positive contrast achieved depends not only on the amount 
of cells successfully labelled with SPIONs but also their local spatial distribution and 
concentration which are highly variable factors in vivo [153]. 
 
Korosogiou et al. [159] administered monocrystalline iron oxide nanoparticles (MIONS) via a 
single bolus injection into rabbits. IRON images displayed very strong positive contrast in the 
paraaortic lymph nodes. Three days post injection the CNR in the blood vessels had approached 
baseline while the CNR in the lymph nodes was still highly enhanced. This technique has 
therefore potential to be used for nodal staging in cancer screening. 
 
Gitsioudis et al. [160] investigated the ability of IRON for steady-state equilibrium phase MR 
angiography (MRA) of a SPION coated with an amino-alcohol derivative of glucose. IRON was 
compared to a conventional T1-weighted MRA sequence by imaging the abdominal and thoracic 
aorta of 12 rabbits. For a wide range of SPION dosages, the vessel sharpness and quantitative 
contrast-to-noise-ratio (CNR) was consistently higher for the IRON images. This demonstrates 
the potential of IRON to be used for vessel imaging in conjunction with a suitable iron-based 
MR contrast agent. 
 
4.4. Susceptibility Gradient Mapping 
The two approaches for positive contrast imaging discussed so far (GRASP and IRON) have 
been very successful in displaying SPIONs but also suffer from major disadvantages. GRASP 
only compensates for susceptibility gradients along the slice-select direction. Furthermore, 
knowledge about the strength of the susceptibility gradient is necessary to optimise the strength 
of the slice rephasing lobe. IRON also requires a priori knowledge about the expected shift of 
frequency and is easily affected by chemical shift artefacts and other field inhomogeneities. 
Susceptibility Gradient Mapping (SGM) similarly to GRASP perceives the field distortions 
introduced by SPIONs as local susceptibility gradients. However, SGM is a postprocessing 
method that can be applied to any gradient-echo data set that has been saved together with the 
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complex data. Furthermore, SGM does not suffer from the above mentioned disadvantages of 
GRASP and IRON [152], [161]. 
 
4.4.1. Technique 
Any object with a magnetic susceptibility different to its surrounding creates a local 
inhomogeneity in an external magnetic field. As described for the GRASP technique, 
inhomogeneities that are larger than the voxel size change the applied imaging gradients which 
lead to a shift in the associated echo of a gradient echo sequence in k-space. In the case of a 
first-order approximation only the susceptibility gradient ºrOËO is considered. This resembles the 
linear part of the main magnetic field inhomogeneity. The susceptibility gradient and the 
imaging gradient ºru¤«B are additive and result in a different timing of the echo at the echo time. 
Mathematically, the readout signal of a 1D gradient-echo sequence is given by 
 S t = ρ n ∙ ∆x em"C+5D.EFGÏÓ∆˙e"C+5D6H6 Ïî23 Ó∆˙Im1ÓSM  (143) 
In equation (143), ∆x is the dimension of the pixel and ρ n ∙ ∆x  is the spin density. The 
assumption for equation (143) is that there are no other sources of phase distortions. In order to 
better understand the influence the susceptibility gradient has on the signal, equation (143) can 
be rewritten as 
 S t = ρ n ∙ ∆x em"C+5D.EFGÏ 1î 5D6H65D.EFG Ó∆˙	×e"C+5D6H6	23	Ó	∆˙Im1ÓSM  (144) 
From equation (144) the modification of the k-space trajectory can be isolated. 
 kÅ t = 1 + GÔ˙KÔG˙LÌM ∙ γ ∙ G˙LÌM ∙ t = 1 + GÔ˙KÔG˙LÌM ∙ k t  (145) 
Equation (144) and (145) make it evident that a susceptibility gradient leads to scaling in k-
space and adds a position dependent phase term. This ultimately results in a shift of the echo. At 
the time t = mτ˙ the imaging gradient completely cancels the susceptibility gradient when the 
total phase from equation (143) becomes zero. 
 −29 ∙ = ∙ ºru¤«BX ∙ ùr ∙ ^∆| − 29 ∙ =×ºrOËO X ∙ ùr + 0[ ∙ ^∆| = 0 (146) 
From equation (146), m can be determined with 1ñ¡ being the sampling rate 
 X = − ºrOËO ∙ 0[ºru¤«B + ºrOËO ∙ ùr (147) 
By using a short-term Fourier transform (STFT), local susceptibility gradients GÔ˙KÔ n∆x  can be 
investigated. These gradients are usually much smaller in comparison to the imaging gradients. 
Therefore, the scaling of k-space can be disregarded. Furthermore, GÔ˙KÔ n∆x  is assumed to be 
constant within a specified region denoted by r. The prior assumptions mean that the complete 
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data set can be divided into R regions in the image domain. This is achieved by summing over a 
rectangular window function that scans through all regions of the data set. 
 S k = ρ n ∙ ∆x ∙ rectI∙∆˙O n − r ∙ NR ∆x ∙ em∙"C∙+∙5D6H6 < ∙23∙Ó∙∆˙Im1ÓSM
Om1
<SM  (148) 
and 
 rectI∙∆˙O n − r ∙ NR ∆x = 1; 					r ∙ NR ≤ n ≤ r + 1 NR0; 																										otherwise (149) 
Equation (148) resembles the summation of Fourier transforms of data that lies within the 
rectangular window function at a specific position ! ∙ Q≠ ∙ ∆|: 
 
S k = STFT ρ n ∙ ∆x ∙ em∙"C∙+∙5D6H6 + ∙23∙Ó∙∆˙Om1<SM ,	 with										kÔKÔ r = γ ∙ GÔ˙KÔ r ∙ TE (150) 
and 
 2 V − VOËO = 	20…0 ≥ ^ ∙ ∆| ∙ gmu∙";∙>∙ª¡RSR > ∙jh∙P∙∆r  (151) 
Equation (150) shows that the signal in k-space S k  is the sum over STFTs where each Fourier 
transform has been shifted by kÔKÔ which is given by GÔ˙KÔ n∆x . The rectangular window 
function is very short which results in a change of the shape of the STFT due to convolution. 
However, this does not change the position of the maximum. In each region r the susceptibility 
gradient can be determined by finding the position of the maximum in k-space. This is called an 
echo-shift approach which also works for 2D and 3D data sets. In that case, the shift of the echo 
simply occurs in more than one direction. In the case of a 3D data acquisition, the susceptibility 
gradient for a particular voxel will take the form 
 G˙,1,#ÔKÔ ≈ −m˙,1,# ∙ G˙,1,#LÌM ∙ τ˙,1,#mτ˙,1,# + TE  (152) 
The shift of the echo in k-space has been illustrated in figure 35. The shift in two different 
regions is shown where arrows symbolise in what way that particular voxel is affected by the 




Figure 35: Illustration of the echo shift in k-space caused by inhomogeneities that can be 
understood as susceptibility gradients. The maximum of the shift can be found by fitting 
Lorentzian curve to the data (reproduced from Dahnke et al. [152], p. 598). 
 
By determining the position of the maximum in the “short term” k-space of the different regions 
allows finding the vector components of the susceptibility gradient. By summing over all “short 
term” k-space data, a representation of the global k-space is obtained [152], [161]. 
 
The reason local “short term” k-space is repeatedly used in this description has to do with the 
fact that in an object almost free of BM inhomogeneities, a small susceptibility gradient in one 
region would be difficult to detect. This is because the small echo shift would be overlapped by 
the main echo in the global k-space. The “short term” k-space of a particular region only 
includes local information which allows detection of even small echo shifts of low resolution. 
The STFTs used to determine the local echo shifts are performed in the different parts of the 
image space separately [152]. 
 
4.4.2. Applications of SGM 
Dahnke et al. [152] who first described SGM also performed a phantom and in vivo study to 
demonstrate the ability of SGM to produce positive contrast. A gelatine phantom with holes 
filled with different SPION concentrations and one hole (i.e. control) filled with agarose was 
imaged with a gradient-echo sequence. Agarose and SPIONs could not be distinguished in the 
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gradient-echo image but all SPION holes produced bright positive signal on the calculated SGM 
image while the agarose hole remained dark. Furthermore, holes with a higher SPION 
concentration were displayed brighter on the SGM magnitude image. The authors also 
subcutaneously implanted SPION-labelled and unlabelled (i.e. control) glioma cells in the 
flanks of nude rats. On gradient-echo images two weeks post implantation, the tumour has 
visibly grown and the tumour cells have been diluted. The calculated SGM image selectively 
shows the labelled cells as bright signals whereas the unlabelled cells remain unenhanced. 
 
The same research group compared SGM as a positive contrast method with GRASP and IRON 
in phantom experiments and in vivo in a preclinical study. The authors used a water phantom 
containing three vials of different Fe concentrations with SPION-labelled C6 glioma cells 
suspended in agarose gel. Six female nude rats had SPION-labelled C6 glioma cells implanted 
in the flanks and imaged with GRASP, IRON, and a gradient-echo sequence from which SGM 
magnitude images were calculated. SGM images showed the highest amount of positive contrast 
for small tumours (~5mm) compared to GRASP and IRON as these only covered parts of the 
labelled tumour. For larger tumours (~20mm), IRON could not detect labelled cancer cells 
while GRASP and SGM generated similar amount of positive contrast. A major disadvantage 
the authors pointed out is the inability to differentiate haemorrhage within the tissue and 
SPION-labelled cells. When comparing SGM for 2D versus 3D imaging, the sensitivity might 
decrease for the detection of SPION-labelled cells [161]. 
 
Varma et al. [162] compared SGM to GRASP and IRON in a phantom containing prostate 
marker seeds. SGM images were generated from a gradient-echo data set of SPION uptake in a 
balloon-injured swine carotid model. These authors agree that the SGM technique provided the 
greatest positive contrast. However, gradient echo images provided greater sensitivity to regions 
in the subject where susceptibility effects were weaker. 
 
Makowski et al. [163] utilised the SGM technique together with very small iron oxide particles 
(VSOPs) to assess the progression of atherosclerotic plaques in ApoE-/- mice. The authors 
demonstrated the feasibility of SGM in visualising and quantifying the increasing uptake of 
VSOPs in atherosclerotic plaques during different stages of plaque development. 
 
4.4.3. SGM using the original resolution (SUMO) 
A disadvantage of the SGM technique is that during the generation of the positive contrast 
magnitude image, the spatial resolution of the image is reduced. This makes it difficult to 
visualise small structures effectively. To overcome this limitation, a development of SGM that 
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retains the original resolution called SUMO has been proposed [164]. In the technical 
description of the SGM technique, whenever the maximum occurs at the edge of the rectangular 
window function, the window size is increased (i.e. N = N + 1). The influence of the local 
susceptibility gradient becomes less relevant in the constructed parameter map when increasing 
the window size because of an increase of neighbouring pixels that are unaffected by it. In order 
to detect local susceptibility gradients high spatial resolution is required to avoid compensation 
of the gradient by adjacent pixels included in the STFT. As an alternative, Varma et al. [164] 
suggested a filter in k-space F k, sT  to null an entire line in k-space at position sT. The 
Lorentzian shaped filter function is given by 
 F k, sT = 1 − ∆k"∆k" + k − sT " (153) 
The filter is applied to k-space like a sliding window. The centre of the filter (sT) will separately 
move in all three orthogonal directions. At every position sT  in k-space the filter is applied, the 
value will be set to zero and an inverse Fourier transform is used to calculate the corresponding 
image. 
 S k˙ = M x ∙ emCTD˙dx (154) 
 MÔV x = S k˙ ∙ F k˙, sT ∙ eîC˙TDdk˙ ÔVSTE./TEFD  (155) 
From that, a plot can be generated of the signal amplitude of every pixel for all possible 
positions of the filter. The echo shift in k-space is then found on a pixel-by-pixel basis by 
finding the minimum along the  sT axis 
 kÔ = min MÔV x ÔVSTE./TEFD  (156) 
Finding kÔ for all pixels in each orthogonal direction permits the construction of a parameter 
map of the k-space echo shift. This will then provide information about the susceptibility 
gradient GÔ. It is possible to also set a threshold to only visualise pixels with kÔ values above 
that threshold.  
 
The authors showed that the SUMO technique is able to resolve small local susceptibility 
gradients that were acquired with a low resolution acquisition while the SGM technique was 
unable to depict these. Furthermore, SUMO was used on in vivo MR images of a nitinol stent 




4.5. Fast Low Angle Positive Contrast Steady-State Free Precession 
(FLAPS) 
Fast Low Angle Positive contrast Steady-state free precession (FLAPS) is based on the bSSFP 
sequence (see below chapter 4.5.1. ). The FLAPS method is a very fast positive contrast 
imaging technique that does not require any additional imaging pre-pulses or postprocessing 
efforts. Because it uses only small flip angles the power deposition is very low and the sequence 
can be used without concern at higher field strengths [150]. 
 
4.5.1. Balanced Steady-State Free Precession 
In a gradient-echo sequence each excitation pulse is separated by a time delay, the repetition 
time TR. During TR the dephasing of the spins due to imaging gradients or field 
inhomogeneities occurs as well as T1 and T" relaxation. The former causes the longitudinal 
magnetisation component to increase while T" relaxation results in a decrease of the transverse 
magnetisation. As described in chapter 1 these two processes, T1 and T" relaxation, occur at the 
same time. Because there is a train of excitation pulses, the next rf pulse will act on the changed 
magnetisation after which dephasing and relaxation occurs again. This process is repeated over 
and over which means that for a constant flip angle α, TR, and constant dephasing the 
magnetisation will reach a steady-state after a few repetition times. This is referred to as steady-
state free precession (SSFP). 
 
A special type of steady-state free precession sequences is where the dephasing caused by the 
imaging gradients is zero which is then called a balanced steady-state free precession (bSSFP). 
This means that each gradient applied will be fully compensated with another gradient of 
opposite polarity. The main difference between balanced and non-balanced SSFP (nbSSFP) is 
that the magnetisation in the latter is dephased after the echo formation by a spoiler gradient. 
The bSSFP sequence has an additional read gradient lobe that compensates for the dephasing at 
the end of the TR interval. This means that the net transverse magnetisation is zero at the end of 
TR in nbSSFP due to the complete dephasing of spins. In the case of bSSFP the spins are 
refocused at the end of the TR interval which means the magnetisation at the beginning and at 
the end of the TR period is very similar. Balanced SSFP sequences are usually run with a very 
short TR as it makes the sequence less sensitive to off-resonance effects (i.e. field 
inhomogeneities) [103], [104]. 
 
The contrast of bSSFP is composed of contributions from T1 and T". The signal intensity for on-
resonant spins depends on T1, T", TR, and α. 
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 MÔÔ = MM E" 1 − E1 sin α1 − E1 − E" cos α − E1E" (157) 
In equation (157), E1 = em2O/2ò and E" = em2O/2©. If TR is much smaller than either T1 or T", 
then equation (157) can be simplified to 
 MÔÔ = MM sin α1 + cos α + 1 − cos α T1T"  (158) 
The optimal flip angle α can be determined from the longitudinal and transverse relaxation 
times. 
 cos α = T1T" − 1T1T" + 1 (159) 
for which the signal amplitude is given by 
 MÔÔ = 12MM T"T1 (160) 
The highest signal is obtained when T1 and T" have similar values and for a flip angle between 
70-90°. Under these conditions a signal of 50% of MM can be achieved. No other sequence 
achieves such a high signal continuously. Compared to all other sequences bSSFP has the 
highest signal-to-noise ratio per unit time. It is important to note that despite it being a gradient-
echo sequence, bSSFP is not T"∗-weighted. Dephasing due to field inhomogeneities is almost 
completely refocused at TE = TR/2. This means a spin echo rather than a gradient-echo is 
formed. As can be seen in equation (157) the signal of a bSSFP sequence contains an additional 
weighing factor of em23/2© = E" for TE = TR/2 [103]. 
 
4.5.2. Technical description of FLAPS 
The transverse magnetisation in the steady-state at a point in space described by ! can be written 
as 
 M˙1 = MM sin α 2 1 + cos β r2 T1T" 1 − cos α + cos β r 1 + cos α + cos α + 1  (161) 
In equation (161), β r  is called the phase rotation angle. During the repetition time spins 
experience a phase rotation because of the magnetic field perturbation ∆B# along the 
longitudinal direction. 
 β ≡ β r = γ∆B# r TR (162) 
The difference in signal intensity of the off-resonant β  and on-resonant β = 0  spins (i.e. 




C β ≡ M˙1 β −M˙1 β = 0
= MM sin α 2 1 + cos β2 T1T" 1 − cos α + cos β 1 + cos α + cos α + 1
− 1T1T" 1 − cos α + cos α + 1  
(163) 
Positive contrast is generated when C β > 0. A peak contrast CY can be derived from equation 
(163) as 
 CY = 	MM 12 T"T1 − sin αT1T" 1 − cos α + cos α + 1  (164) 
Equations (163) and (164) are valid for a specific set of flip angles that satisfy equation (165) 
and a medium of given longitudinal and transversal relaxation times that is exposed to a 
repeated phase-cycle rf excitation of flip angle α. The maximal achievable positive contrast 
depends on the ratio of T1 and T" as well as the flip angle α. In the presence of field 
inhomogeneities, steady-state free precession signal behaviour is identical for specific β values. 
This means that no signal is detected from on-resonant spins while strong signal peaks are 
observed around the null points of β = ±nπ (	n → non-zero, odd integer). This is because 
across the null points the phase of the magnetisation changes at low flip angles but is relatively 
independent of any other β value. By increasing the flip angle the signal changes between on- 
and off-resonant spins decrease due to smoother phase transitions. The peak signal from a SSFP 
sequence for on-resonant spins (equation 160) is achieved for a flip angle according to equation 
(159). But as α approaches the ideal value, CY approaches zero which means no positive 
contrast is achieved at the optimal on-resonant SSFP signal conditions. In order to achieve 
positive contrast with SSFP, the following flip angle criterion must be met 
 0 < + < arccos T1T" − 1T1T" + 1  (165) 
From equation (165) it becomes evident that as the ratio of T1 and T" increases, the suitable 
range of flip angles that enable positive contrast imaging becomes smaller [154], [165]. 
 
4.5.3. Applications of FLAPS 
Dharmakumar et al. [154] proved the capability of FLAPS to produce positive contrast images 
on simple SPION phantoms. Cylindrical and spherical Perspex and rubber cases where filled 
with a Ferumoxide solution without any air inclusions. These were then immersed in a water 
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bath doped with gadolinium. The appropriate selection of the flip angle was essential to receive 
good positive contrast images. Moreover, the range of flip angles that allowed positive contrast 
imaging depends strongly on the ratio of T1 and T". The spatial distribution of the positive 
contrast varied as suspected with the geometry of the SPION-filled object as well as the ratio of T1 and T".  
 
In a follow up study, the same group showed in phantom studies that FLAPS can easily be 
combined with fat suppression in the form of a fat saturation prepulse which does not 
compromise quality of the positive contrast images. Furthermore, the positive contrast achieved 
with FLAPS is predominantly dependent on the imaging parameters [165]. 
 
Vonken et al. [150] compared several positive contrast techniques in a phantom study and 
concluded that the amount of positive contrast achievable with FLAPS and the background 
suppression are both lower compared to GRASP, IRON, and SGM. The authors also noticed 
that non-ideal shimming has a significant effect on positive contrast images acquired with 
FLAPS that manifests in artefacts in the form of dark bands in the image. 
 
4.6. Other relevant positive contrast techniques 
So far we have categorised positive contrast imaging techniques in three categories. Those that 
treat the dipole field of SPIONs as a local magnetic field gradient [151], a shift in the Larmor 
frequency [153] or the change in phase accumulation [166]. Positive contrast techniques can 
also be classified in those that use modified MRI pulse sequences and those that produce 
positive contrast images in a post-processing step from regular gradient and spin echo sequences 
[167]. 
 
4.6.1. Techniques with modified MRI pulse sequences 
Prominent examples of techniques that use modified pulse sequences are GRASP and IRON. 
The latter uses a spectrally selective inversion pulse to saturate on-resonant water at the time the 
image is acquired [153]. However, it is also possible to use a spectrally selective rf pulse to 
specifically excite those water protons affected by the dipole field of the SPIONs (off-resonant 
water) [168], [169]. The excitation of off-resonance water protons can also be achieved with a 
low-angle steady-state free precession sequence [154], [165], [166], [170], [171]. Apart from 
the techniques described in chapter 4, other positive contrast imaging techniques have been 
reported where the pulse sequence is modified. Kim et al. [172] reported the positive contrast 
imaging by acquiring a spin echo image and then subtracting an image acquired with a 
Susceptibility-Weighted Echo time Encoding Technique (SWEET). SPIONs are considered 0" 
89 
 
contrast agents that mainly affect the 0"∗ relaxation time. Girard et al. [173] have also explored 01 shortening properties by acquiring positive contrast images with an ultra-short echo time 
(UTE) sequence. Ultra-short spin echo sequences can be used for susceptibility mapping 
techniques [174]. There are many examples in the literature for UTE sequences for positive 
contrast [175], [176]. Seevinck et al. [177] described a frequency-encoded, 3D imaging 
technique using ultra-short TE (UTE) acquisition method [178] for a center-out RAdial 
Sampling with Off-Resonance reception (co-RASOR). The technique uses off-resonance 
reception and a large excitation bandwidth. An off-resonance frequency offset is introduced 
(∆æM) to the central reception frequency (æM) the radial signal can be shifted to the centre of the 
paramagnetic particle which therefore will be displayed with a hyperintense signal. The co-
RASOR method relies on knowledge of the susceptibility value of the paramagnetic particle as 
the shift of the off-resonance signal to the location of the particle depend on it. 
 
4.6.2. Post-processing technique 
Positive contrast imaging can also be based on phase recognition [179] and be implemented as 
part of a post-processing step. There are two main post-processing techniques, SGM and PGM 
[180], [181]. SGM measures the echo shift in k-space due to the susceptibility-induced gradients 
[182] which has been described in detail in chapter 4. Other techniques explored measuring the 
echo shift in the imaging space. PGM was shown to be likely to produce improved accuracy 
when acquiring images at higher resolution [180]. Two different methods to generate phase 
gradient maps have been described. One uses a standard forward difference operation on normal 
phase images in order to determine the phase gradient [183]. The phase gradient can also be 
calculated by implementing difference operation in the Fourier domain using a fast Fourier 
transform (FFT) without phase unwrapping [184]. Phase gradient maps can be used for the 
analysis of phase perturbations introduced by macroscopic objects [183], tissue differentiation 
of tissues with different susceptibilities through contrast enhancement [185] and for the 





5. Superparamagnetic Iron Oxide Nanoparticles (SPIONs) 
Superparamagnetic iron oxide nanoparticles and gadolinium chelates are two classes of MRI 
contrast agents that are in the focus of medical imaging research but also readily used in clinical 
practice. SPIONs are biocompatible and display no remnant magnetisation outside of the MR 
environment making them ideal for applications in MRI. In this chapter, the different types of 
magnetisms will be described and the physicochemical nature of iron oxides explained. The 
most popular synthesis strategies and common stabilisers will be discussed. The chapter finishes 
with a short literature review of current biomedical applications of SPIONs where the focus will 
be on MR imaging and treatment of cancer. 
 
5.1. Magnetism 
The nature of magnetic dipole moments and how they can be explained using quantum 
mechanical concepts was introduced in chapter 2. MR contrast agents based on iron (SPIONs) 
possess a specific type of magnetic characteristic called superparamagnetism. In the following 
the main types of magnetic behaviour that materials can display, dia-, para-, ferro-, and 




Atoms where each quantum mechanical sublevel contains an electron pair (one with spin up ↑ 
and one with spin down ↓) do not possess a net magnetic dipole moment. Each individual 
electron has a magnetic moment but due to the pairing of electrons, the overall atom will have 
no magnetic moment. Diamagnetism describes the existence of an induced magnetic dipole 
moment by an external magnetic field. The reason for that is a small alteration of the electrons 
orbital motion by the external magnetic field that leads to an extremely weak magnetic moment 
in the atom or molecule. The macroscopic induced magnetic moment is antiparallel to the 
applied magnetic field which means the induced magnetic field opposes the applied field. 
Diamagnetism is an omnipresent property of all materials but it might be obscured due to the 
presence of a stronger magnetic property such as para- or ferromagnetism. The strength of the 
induced diamagnetic field is directly proportional to the applied magnetic field and not 





Contrary to diamagnetism, when an atom has an unpaired electron in its outer shell, it possesses 
a permanent intrinsic magnetic dipole moment in the absence of an external magnetic field. This 
magnetic property is called paramagnetism. However, a sample of many paramagnetic atoms 
will not have a net magnetic moment because the individual magnetic dipole moments will be 
randomly distributed and cancel each other out. A bulk magnetisation can be achieved by 
applying an external magnetic field. The individual magnetic dipole moments preferentially 
align parallel to the external magnetic field and the strength of the bulk paramagnetic moment 
depends on the field strength of the applied field. The difference to diamagnetism is that the 
paramagnetic dipole moment is much stronger than the diamagnetic moment. Furthermore, the 
strength of the paramagnetic dipole moment heavily depends on the temperature. Similar to the 
nuclear magnetic dipole effect discussed in chapter 1, thermal energy accounts for the fact that 
not all individual spin moments will align parallel to the applied magnetic field. Some might 
align antiparallel to it. The proportion of spins that are aligned antiparallel to the applied field 
increases with temperature. Saturation magnetisation is therefore achieved in the region close to 
absolute zero (-273 °C) [89], [186], [187]. 
 
5.1.3. Ferromagnetism 
Ferromagnetism is fundamentally different to dia- and paramagnetism in the sense that the latter 
are properties of individual atoms or molecules while ferromagnetism can only be exhibited by 
a group of atoms or molecules that are combined in a crystal structure. When paramagnetic 
atoms are closely packed in a crystal structure, the magnetic dipole moments of neighbouring 
atoms will interact with each other and align in a parallel fashion. Such materials are 
magnetically ordered and within the material permanently magnetised domains are established. 
Each of these magnetic domains contains a vast number of spin dipole moments. A limiting 
factor in terms of their size is the range of the spin-spin forces. Normally, the magnetic domains 
are dispersed randomly and no net magnetisation is observed. However, upon the application of 
a magnetic field the magnetic domains will readily start to align parallel to the applied magnetic 
field and the material becomes magnetised. Ferromagnetic materials can be magnetised to the 
maximal potential (saturation magnetisation = almost all domains align parallel to applied field) 
with low external magnetic fields. Furthermore, a remnant magnetisation remains even when the 
applied magnetic field is completely removed. To remove the remnant magnetisation and 
demagnetise a ferromagnet, energy in the form of heat is required. That is because by aligning 
in a parallel fashion, the magnetic dipole moments of the individual magnetic domains have 
taken a low energy state which the system likes to retain. In order to demagnetise a 
ferromagnetic material it would need to be heated above a critical temperature (Curie 
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temperature) which depends on the ferromagnetic material. Above the Curie temperature, 
ferromagnetic materials show paramagnetic characteristics including the lack of remnant 
magnetisation. Examples of ferromagnetic elements are iron, cobalt, nickel, as well as several 
alloys and transition metal oxides [89], [186], [187]. 
 
5.1.4. Superparamagnetism 
Superparamagnetism [188] is a magnetic property obtained when decreasing a ferromagnetic 
particle until it only contains one magnetic domain. Particles that are superparamagnetic have 
unique characteristics that make them well suited for many applications especially as MRI 
contrast agents. Upon application of an external magnetic field, superparamagnetic particles will 
similarly to ferromagnetic materials exhibit a very strong magnetic field by achieving saturation 
magnetisation. However, once the external field is removed, no remnant magnetisation is 
observed because the magnetic dipole moments disperse in a random fashion due to thermal 
motion. That means, superparamagnetic particles show a similar magnetisation behaviour as 
paramagnetic materials with the difference that they are readily able to achieve saturation 
magnetisation and therefore can get much stronger magnetised [89], [186], [187], [189].  
 
5.2. Iron Oxides 
The most common forms of iron oxide in nature are magnetite (Fe3O4), maghemite (=-Fe2O3), 
hematite (+-Fe2O3) [190]. The former two exhibit superparamagnetism at room temperature if 
the particle size is smaller than ~20 nm [191], [192].  Iron oxide particles of that size are a 
single magnetic domain crystal which possesses superparamagnetism. SPIO exhibit a much 
stronger susceptibility effect than just paramagnetic materials such as gadolinium because the 
whole crystal aligns with the external field and saturation magnetisation is achieved [193]. This 
characteristic as well as the biocompatibility and biodegradability of magnetite and maghemite 
[194] makes them particularly well suited for biomedical applications. 
 
5.2.1. Magnetite (Fe3O4) 
From all transition metal oxides, the magnetism exhibited by magnetite is the strongest. It is 
ferromagnetic and has a lattice parameter of 8.396 Å. Because of its black-brown colour it is 
also referred to as black iron oxide [190], [195]. The crystal structure is an inverse spinel with 
planes of oxygen anions in a cubic arrangement. The Fe2+ ions occupy octahedral (Oh) 
interstitial sites and the Fe3+ ions are randomly distributed between tetrahedral (Td) and 
octahedral positions [196]. The spins of the ions occupying the tetrahedral and octahedral sites 
take antiparallel positions to each other when exposed to an external magnetic field [194]. 
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Because magnetite has Fe2+ and Fe3+ in its octahedral positions, electrons can move between the 
two at room temperature [197]. 
 
5.2.2. Maghemite (\-Fe2O3) 
Maghemite is formed from other iron oxides through heating or as a result of the weathering 
process of magnetite. In a laboratory setting, maghemite is the product of oxidising magnetite. It 
can easily be distinguished from magnetite because of its red-brown colour. Maghemite is 
ferrimagnetic and has a lattice parameter of 8.347 Å. Its crystal structure is similar to the one of 
magnetite but the spinel structure possesses vacancies in the cation sublattice (defect spinel). 
Fe3+ ions occupy two-third of the crystal sites which are arranged so that one vacant site follows 
two occupied sites [190]. The ordering of the vacancy decreases as the maghemite particle size 
becomes smaller [198]. Maghemite has a lower saturation magnetisation than magnetite [193]. 
 
5.3. Synthesis and Stabilisation of SPIONs 
In the last 20 years superparamagnetic iron oxide nanoparticles have been intensely investigated 
for their biomedical applications. New and improved synthetic routes have been proposed with 
the aim to produce monodisperse SPIONs while having good control over the particle size. 
Furthermore, SPIONs need to be stable in aqueous solution and be biocompatible.  
 
5.3.1. Synthesis strategies 
The simplest way to synthesise SPIONs that also offers the most control is via a wet chemical 
route. In the following the two main methods, coprecipitation and thermal decomposition, are 
described and further references are provided for the interested reader. 
 
5.3.1.1. Coprecipitation 
Superparamagnetic iron oxide nanoparticles such as magnetite and maghemite precipitate from 
an aqueous iron salt solution in an alkaline environment [199]–[203]. The size, shape, and 
composition of the SPIONs depend on the iron salt (e.g. nitrates, sulphates, chlorides, etc.) as 
well as the ratio of ferrous to ferric ions (i.e. Fe2+/Fe3+) and the pH [204], [205]. Isolation of the 
iron oxide precipitate is achieved by centrifugation or magnetic decantation. Usually the 
precipitate is washed with either nitric acid or perchloric acid and colloidally dispersed [193]. 
For a Fe2+/Fe3+ ratio of 2:1, the chemical reaction equation can be written as [190], [206] 
 …g"î + 2…g.î + 8 Dm → 	…g. q + 4D"  (166) 
It is important to ensure that the reaction environment is alkaline (i.e. pH 9 – 14) and free of 
oxygen by conducting the reaction in a nitrogen environment to avoid oxidation of Fe3O4 [187]. 
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In order to stabilise the SPIONs and prevent agglomeration, the iron oxide particles are often 
coated during the precipitation procedure through the presence of surface complexing agents 
[193]. There are several other methods that are based on the coprecipitation method that have 
been used successfully to synthesise SPIONs. Among those, the most common approaches are 
the microemulsion technique [207], the reduction precipitation [208]–[211] where an iron salt is 
reduced in the presence of an surfactant agent and the sol-gel approach [212]. 
 
According to Bagwe et al. [213] a microemulsion is a thermodynamically stable isotropic 
dispersion of two immiscible liquids. The microemulsion can either be oil-in-water or water-in-
oil. Iron oxides for biomedical applications are mostly synthesised with the water-in-oil 
approach [193]. The aqueous iron salt phase will form microdroplets by separating it with a 
surfactant coating from the organic phase (i.e. reverse micelle). Upon adding nanodroplets of a 
base, the two aqueous nanodroplets will collide, coalesce and break and iron oxide particles 
precipitate within the micelles [214]–[217]. SPION synthesis by microemulsion results in a 
uniform population [218] and offers good control over size and shape [219] of the nanoparticles. 
A disadvantage of this approach has been described where larger nanoparticles resulted because 
of poor crystallinity of the SPIONs [197]. 
 
5.3.1.2. Thermal Decomposition 
The decomposition of an organometallic precursor complex by applying heat or light is one of 
the simplest methods to synthesise SPIONs [192]. Thermal decomposition has also been 
popular because it is considered to produce monodisperse particles while allowing good control 
over the particle size. Common organometallic precursors are iron cupferron (Fe(Cup)3) [220], 
iron pentacarbonyl (Fe(OH)5) [221], [222], and iron triacetylacetonate (Fe(acac)3) [223]. The 
morphology and size of the resulting SPIONs is determined by the ratios and concentrations of 
the reactants, the temperature, reaction times, as well as the nature of solvents and precursors 
[224]. Rockenberger et al. [220] were able to receive monodisperse maghemite particles from a 
thermal decomposition reaction of Fe(Cup)3 in the presence of octylamine and trioctylamine. 
Hyeon et al. [225] described the synthesis of highly monodisperse maghemite particles of sizes 
between 4-16 nm from Fe(OH)5 in oleic acid at 100°C. Sun et al. [209] reported the synthesis of 
monodisperse magnetite particles (4-20 nm) from Fe(acac)3 that reacted with 1,2-
hexadecanediol in the presence of oleic acid and oleylamine. Li et al. [226] described the 
synthesis of magnetite from an iron salt (FeCl3) by thermal decomposition in an acidic or 




5.3.2. Stabilisation of SPIONs 
The surface of bare superparamagnetic iron oxide nanoparticles is hydrophobic. For biomedical 
applications these particles need to be in an aqueous solution. Uncoated SPIONs in an aqueous 
solution try to minimise contact with the solvent by exhibiting hydrophobic interactions that 
causes the particles to agglomerate and decrease their surface area to volume ratio. Larger 
SPION cluster exhibit dipole-dipole interactions and the magnetic behaviour changes from 
superparamagnetic to ferromagnetic. Nanoparticles with a remnant magnetisation agglomerate 
and can block blood vessels in biomedical applications [195], [227]. In addition, flocculation 
can occur because of the van der Waals force. Biomedical applications require monodisperse, 
stable, biocompatible particles which is why SPIONs are usually stabilised with a coating 
material [228]. The coating can be done in situ (during the synthesis of the SPION) or after the 
synthesis reaction in a separate step. Common coating materials are monomeric stabilisers such 
as carboxylates [229]–[232] and phosphates [190], [233]. Various long-chained polymers such 
as dextran [234] and polyethylene glycol (PEG) [235] have also been extensively studied as 
SPION stabilisers. Finally, inorganic materials such as silica [236], [237], gold [238], [239], or 
gadolinium [240], [241] have been utilised to coat bare iron oxide nanoparticles because they 
allow the binding of biological ligands to the surface of the SPION [224].  
 
5.3.2.1. Monomers 
Citric acid is a carboxylate that has been used to stabilise magnetite particles in an aqueous 
medium [229]. Citric acid possesses three carboxylic acid groups of which one or two are used 
for the coordination to the surface of magnetite. The uncoordinated carboxylic acid group(s) 
give the coated SPION surface a negative charge and therefore hydrophilic character [224]. One 
well described SPION that is coated with citric acid and has undergone clinical investigation is 
VSOP C184. It is synthesised by coprecipitation in the presence of citrate ions. The particle is 
very small with a hydrodynamic diameter of 8.6 nm [242], [243]. It was reported by Bee et al. 
[199] that the size of maghemite particles depend on the concentration of citrate ions. 
Krishnamurti and Huang [244] describe that the citrate has an effect on the Fe2+ kinetics. 
Moreover, the higher the concentration of citric acid during synthesis of the SPION the lower its 
crystallinity [245]. Changes in the surface geometry of the iron oxide nanoparticles have been 
reported because of citrate and other carboxylate coatings [246], [247]. Other carboxylates that 
have been used for coating SPIONs are dimercaptosuccinic acid (DMSA) [231], 
phosphorylcholine [232], [248], and gluconic acid [230]. The effectiveness of these coating 





Dextran is one of the most popular coating materials for iron oxide nanoparticles because of its 
biocompatibility [234], [249]. It is made up of +-D-glucopyranosyl units making it a 
polysaccharide polymer [224]. The first publication that described the coating of magnetite with 
dextran was by Molday and Mackenzie [250] in 1982. Ferumoxtran-10 [251] that has a 
hydrodynamic diameter between 15-20 nm was synthesised according to the method described 
by Molday and Mackenzie [250] and coated with dextran. Closely related to dextran are 
carboxydextran and carboxymethyl dextran that have been used to coat Resovist® [252] and 
ferumoxytol [253], respectively. The dextran chains have been reported to lead to ideal polar 
interactions with the surface of iron oxide nanoparticles. This is because of the relatively high 
bonding energy of all the hydrogen bonds formed by the hydroxyl groups over the length of a 
dextran molecule [254]. Polyethylene glycol (PEG) is hydrophobic and water-soluble. It 
increases blood circulation time and biocompatibility [255], [256]. PEG-coated SPIONs with 
hydrodynamic diameters between 60-100 nm (small) and 20-35 nm (ultra small) have been 
synthesised [257]. Polyethylenimine (PEI) [258], [259] can form cationic complexes when used 
to stabilise SPIONs. Negatively charged biomolecules such as DNA therefore interact with PEI 
electrostatically and allow PEI to enter cells via endocytosis [190]. Polyvinyl Alcohol (PVA) is 
hydrophilic and biocompatible and aids in the production of monodisperse nanoparticles by 
hindering agglomeration [260], [261]. Lee et al. [262] synthesised stable SPIONs in situ by 
precipitating an iron salt in an aqueous solution of PVA. It has been suggested that the binding 
of PVA to magnetite is irreversible. 
 
5.4. Biomedical applications 
Superparamagnetic iron oxide nanoparticles can be used for diagnostic and therapeutic 
applications as magnetite and maghemite are both biocompatible with a low cytotoxicity [195], 
[227]. It is common for biomedical applications with SPIONs to differentiate between passive 
and active targeting. This section will describe these two targeting approaches and provide 
examples with an emphasis on cancer applications in imaging and treatment.  
 
5.4.1. Passive targeting 
Superparamagnetic iron oxide nanoparticles that have been coated with a stabiliser but have not 
undergone any further functionalisation reach their target sites via distinct anatomic or 
physiological processes. The hydrodynamic diameter and surface charge of the SPION 
determine its targeting route. The blood circulation time, tissue uptake, opsonisation, as well as 




5.4.1.1. Clearance pathways 
The reticuloendothelial system (RES) is comprised of macrophages, monocytes, and their 
precursor cells. It is also referred to as the mononuclear phagocyte system (MPS). Monocytes 
are produced by progenitor cells and are released into the circulatory system. This allows 
monocytes to migrate to different tissues. Once they have diffused into a particular tissue, they 
can differentiate into macrophages that will have functional and morphologic qualities 
according to a particular function. This means that macrophages in different tissue have 
different functions. One common task all reticuloendothelial cells share is the clearance of 
damaged cells and external particles [263]. 
 
Plasma proteins such as albumin or immunoglobulins are adsorbed by SPIONs because of their 
large surface area to volume ratio. The adsorption of plasma proteins lead to a recognition of the 
SPIONs by Kuppfer cells of the liver and macrophages which are part of the RES. Coating with 
polyethylene glycol (PEG) [264] minimises protein adsorption and increases blood circulation 
time [265]. SPIONs with hydrodynamic diameters larger than 200 nm are taken up by the 
spleen due to mechanical filtration where cells of the RES remove the SPIONs. Nanoparticles 
with hydrodynamic diameters smaller than 10 nm are removed from the system by the kidneys. 
The ideal size for SPIONs in order to have a long blood circulation time is a hydrodynamic 
diameter between 10 and 100 nm. This size allows the SPIONs to reach small capillaries while 
avoiding the RES [187]. 
 
5.4.1.2. Cancer applications 
Fast tumour growth is accompanied by rapid angiogenesis [266] to ensure sufficient blood 
supply to the tumour. As a result, the neovasculature of tumours is damaged and leaky [267], 
[268] which results in an increased permeability for SPIONs. The nanoparticles are retained 
inside the tumour because of an underdeveloped lymphatic drainage system. This phenomenon 
is called the enhanced permeability and retention (EPR) effect which was first described by 
Maeda et al. [269]. The EPR effect will only lead to increased SPION accumulation in tumours 
if the nanoparticles are adequately coated to allow for a prolonged blood circulation times [270]. 
 
Moore et al. [270] have reported that SPIONs coated with dextran injected in a rat gliosarcoma 
model were taken up 10-fold more by cancerous tissue compared to healthy tissue. The 
maximum accumulation of SPIONs in the tumour occurs 24 hours post injection [271]. The 
internalisation of SPIONs by tumour cells most likely happens via pinocytosis rather than 
receptor-mediated endocytosis [270], [272]. Nanoparticles with smaller hydrodynamic 
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diameters are better suited to move into the tumour interstitium [273]. SPIONs also tend to 
accumulate in sites of inflammation where no cancer cells are present which decreases the 
cancer specificity of this approach [267]. Bone marrow lesions have been detected with SPIONs 
with high sensitivity [274]. Jordan et al. [275] showed in vitro the selective uptake of 
aminosilane nanoparticles by glioblastoma cells while healthy glial cells did not internalise the 
nanoparticles. However, these results do not directly translate in vivo as described by van 
Landeghem et al. [276]. SPIONs have also been used for the detection of focal splenic tumours 
[277] and the differentiation of metastatic and inflammatory tumours [278]. A general problem 
of molecular imaging with MRI remains its lower sensitivity compared to nuclear or optical 
imaging modalities [273]. 
 
Hyperthermia is based on magnetic induction where tumours with an accumulation of magnetic 
particles are exposed to an alternating magnetic field [279]. Magnetic nanoparticles such as 
SPIONs generate heat when brought into an alternating magnetic field because of the magnetic 
hysteresis loss. The temperature of the generated heat depends on various factors such as the 
magnetic field strength, the magnetic nature of the particles, the oscillation frequency and 
biological factors such as the blood flow rate in the target area. Most cancer cells die at 
temperatures above 43°C while healthy cells can withstand these temperatures [280]. Tumours 
exhibit a high interstitial pressure which can hinder the diffusion into the tumour interstitium for 
SPIONs larger than 50 nm. Therefore, MR imaging applications commonly use smaller 
SPIONs. However, these cannot generate enough heat to kill tumour cells for hyperthermia 
applications [273]. Preclinical experiments reported side effects such as oedema, cerebral 
necrosis, infarction, and focal haemorrhage [281]. For hyperthermia applications, SPIONs can 
be directly injected into the tumour. The aim of passive targeting in this case is to maximise the 
uptake of nanoparticles by cancer cells [273]. Dextran-coated magnetite particles have 
successfully been used for hyperthermia treatment of oral cancer. The particles where directly 
injected in the tumour on the tongue and temperatures between 43-45°C were reached [282]. 
The only hyperthermia application so far that was applied in a clinical trials study is for the 
treatment of the brain and prostate [46], [283], [284]. 
 
5.4.1.3. Other applications 
SPIONs with hydrodynamic diameters of more than 100 nm are taken up by the Kupffer cells of 
the liver which enables SPION-enhanced hepatic MRI [285]. Reimer et al. [286] demonstrated 
the improved detection of hepatic lesions with this approach. SPIONs with hydrodynamic 
diameters of around 30 nm can get from the vasculature to the interstitial space and move on 
from there via the lymphatic vessels to the lymph nodes where they accumulate [270], [287]. 
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The absence of SPIONs in the lymph nodes after intravenous injection could indicate metastases 
of a primary tumour that are blocking the lymphatic vessels [288]. 
Stem cells have the unique ability to divide in different cell types. They can therefore be used 
for tissue repair by replacing necrotic or damaged cells. By labelling stem cells with SPIONs, 
the migration of the stem cells can be monitored in vivo by MRI [289]. The labelling must not 
affect the functionality, vitality and mobility of the stem cell. Approaches for stem cell labelling 
mainly focus on SPION uptake by endocytosis [290]. Successful labelling depends on shape, 
size, surface charge and chemistry of the SPION as well as type of cell. SPIONs can be 
functionalised with peptides that are able to translocate the cell membrane or other surface 
ligands that aid in interactions with the cell membrane [291]. Specific examples of where this 
technique has been applied are for the treatment of brain trauma [292], Type 1 diabetes [293], 
chronic spinal cord injury [294], multiple sclerosis [295] and to monitor cell therapy in 
melanoma patients [296]. A current problem is the inability of MRI to quantify iron oxide 
nanoparticles. Furthermore, the differentiation between stem cells labelled with SPIONs and 
other sources of hypointense MRI signals is difficult. SPION-labelled stem cells might also 
undergo asymmetric cell division [297].  
Apart from magnetite and maghemite, chemically more sophisticated iron oxides have also been 
explored for their passive targeting ability. Examples are shape modified iron oxides such as 
nanocubes [298] and polyhedral nanoparticles [299]. Another option are iron oxides that have 
another transition metal incorporated in their crystal structure such as quantum dot-capped 
magnetite nanorings [300], cobalt nanoparticles [301], and manganese nanoparticles [302]. 
 
5.4.2. Active targeting 
Active targeting describes the conjugation of ligands with a particular affinity or functional 
groups to the surface coating of SPIONs to make their agglomeration in biological tissue highly 
specific [273]. Polymer coatings are popular because they provide many reactive parts such as 
carboxyl and amine groups useful in a variety of conjugation strategies [193]. Ligands that 
possess a particular affinity are aptamers, peptides, and antibodies. Antibodies are relatively 
large biomolecules which significantly increases the hydrodynamic diameter of the 
functionalised SPION. This decreases the chances of extravasation from the circulation and 
diffusion in the interstitium. However, antibodies possess a very high affinity which makes 
them interesting targeting agents. Antibodies that originated from a different organism than the 
one they are applied to might cause an immune response [273]. Active targeting provides 




5.4.2.1. Cancer applications 
SPIONs usually target the surface antigen in tumours because they are easily accessible. There 
are many early markers of cancer that can be targeted with functionalised iron oxide 
nanoparticles. These markers need to be specifically overexpressed on a particular cancer cell 
type and also accumulate the SPIONs intracellularly [193]. Examples are HER-2/neu receptor, 
mucin-1 antigen, carcinoembryonic antigen, folate receptor, transferrin receptor, CD-20 antigen, 
and integrins. The transferrin receptor has been described as a target for breast cancer [303]–
[305]. Several authors have described the targeting of the folate receptor overexpressed in 
several cancer cells [306]–[308]. Common in epithelial cell adenocarcinomas (i.e., pancreatic, 
breast, lung, colorectal, prostate, and gastric) is the underglycosylated mucin-1 antigen that can 
be targeted with the EPPTI peptide [309]. Gliomas upregulate matrix metalloproteinase-2 that 
can be targeted with the chlorotoxin peptide [310]. Breast cancer metastases overexpress the 
HER-2/neu tyrosine kinase receptor that attracts Herceptin [311], [312]. Hepatic carcinomas are 
in the focus of current targeting strategies because metastases from primary tumour sites in the 
lungs, breasts, colon, and rectum often form in the liver. Reimer et al. [313] have reported that 
the asialoglycoprotein (ASG) receptors are present in a healthy liver but absent in hepatocytes 
of metastatic or primary malignant tumours. SPIONs functionalised with annexin V have been 
described to successfully detect apoptotic cancer cells after therapy [314]. 
Active targeting of tumours after intravenous injection for hyperthermia applications remains a 
problem because the amounts of SPIONs accumulated in the tumour are considerably lower 
compared to intratumoral injection. The dosages of SPIONs required for a sensible 
hyperthermia effect have to be much higher than for MRI because of limited heating capacities 
of current iron oxide nanoparticles formulations. A reason for insufficient SPION accumulation 
in the tumour could be opsonisation processes. These might mask the ligand used for active 
targeting conjugated to the SPION surface. The functionalisation generally increases the uptake 
of SPIONs by cells but does not increase its overall accumulation (permeability) at the tumour 
site [273]. Ito et al. [315] combined the gene therapy for cancer treatment with hyperthermia. 
The therapeutic gene expression is induced by the heat generated from the hyperthermia effect. 
The authors described the positive effect the combined therapeutic approach had on hindering 
tumour growth in a preclinical mouse model.  
 
5.4.2.2. Cardiovascular applications 
Molecular imaging with SPIONs has also been applied to major cardiovascular diseases such as 
thrombosis, myocardial infarction, and atherosclerosis. Cyclic arginine-glycine-aspartic acid 
(RGD) peptides [316] can be conjugated to SPIONs to target the +ŒŒÊ-. integrin that is 
expressed on activated thrombosis platelets [317]. Another marker, the activated coagulation 
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factor XIII(FXIIIa), can be detected with an alpha2AP peptide conjugated to iron oxide 
nanoparticles. FXIIIa is a transglutaminase that plays a vital role in the formation of stable 
thrombi by crosslinking plasmin and fibrin inhibitors [318], [319]. Weissleder et al. [320] 
attached R11D10 to SPIONs and successfully targeted an infracted area with this monoclonal 
antibody specific to necrotising cardiac myocites. Kelly et al. [321] described the detection of 
atherosclerosis targeting the vascular adhesion molecule-1 (VCAM-1) which is an early marker 
for endothelial inflammation. Another proinflammatory marker of endothelial cells is E-selectin 
that is also associated with angiogenesis and tumour vascular endothelial proliferation [322], 
[323]. 
 
5.4.2.3. Other applications 
Apoptosis is of vital importance in acute myocardial infarction, cancer, and chronic 
inflammation. Zhao et al. [324] targeted apoptotic cells in vivo with SPIONs which offers real-
time monitoring via MRI of drug effects. SPIONs have also been successfully employed to aid 
with tissue repair. SPIONs coated with proteins or synthetic polymers can be directed between 
two tissue surfaces where tissue soldering is taking place at temperatures higher than 50°C 
[325]. Furthermore, SPIONs coated with inorganic materials such as gold or silica have been 
described as strongly light absorbing. When placed at the surfaces of tissue sites that need to be 
joined, these particles can aid the soldering upon application of laser light [326]. SPIONs can 
also transport and direct stem cells to a specific target site as well as proteins and growth factors 
that can help with tissue development [327]. Another application is the use of iron oxide 
nanoparticles as drug carriers for a targeted delivery. The pharmaceutical drug is conjugated on 
the surface of the coating and should be released at the target site. Of particular importance are 
charge, size and the nature of the coating material of the SPION for this application [328]. 
Magnetite antrapped in albumin was described as an approach to release anti-cancer drugs 
(adriamicin, mitomicin) at a tumour site [329]. Another author has reported that magnetite 
particles coated with poly(DL-lactide) can be used as polymeric spheres that are loaded with a 
pharmaceutical drug [330]. The overall advantage of developing and employing a targeted drug 




6. Implementation and optimisation of existing positive-
contrast MRI methods 
6.1. Introduction 
This chapter describes the implementation and optimisation of GRASP and IRON. The changes 
made to the code in the pulse programming environment are detailed and scan parameter 
optimisations are evaluated and discussed. 
 
A theoretical description of GRASP, IRON, SGM and FLAPS has been provided in chapter 4. 
To avoid repetitions, these techniques will not be described in detail again and the reader is 
referred to chapter 4 for further information. Chapter 4 also contains a brief literature overview 
about other relevant positive contrast imaging techniques for SPIONs. These techniques were 
not implemented or used as part of this thesis. However, these techniques should be mentioned 
within the thesis to put the experimentally utilised techniques in context and give the reader an 
overview of alternative methods. 
 
6.2. GOAL-C and the Philips pulse programming environment 
All MR experiments presented in this work were conducted on a clinical 3T Philips Achieva 
System. Philips provides a pulse programming environment to associated research institutions 
that allows to make changes to the built-in MRI sequences. The Philips pulse programming 
environment is called PARADISE that can be run in a virtual machine (e.g. VMware 
Workstation). PARADISE encompasses a file directory that includes the code for the built-in 
sequences, a simulation tool and a tool that graphically displays sequence (timing of gradients, 
radiofrequency pulses etc) that were run in a simulator. Files containing code were opened and 
edited in Microsoft Visual Studio C++ .NET version 2003. 
 
The MR pulse sequences are written in GOAL-C (Gyroscan Object-oriented Acquisition 
Language) which is similar of C++. Code files are categorised in three broad folders, MPF files, 
PDF files and global files. The latter is able to communicate across MPF and PDF. 
 
Code files are clearly labelled to indicate their function. As an example, the file ‘mmiffe’ is in 
the MPF (because of ‘mm’, a file in the PDF would start with ‘mp’), the content is related to 
imaging (because of the ‘i’) and describes a gradient echo sequence (because of ‘ffe’ which 
stands for ‘fast field echo’ and means gradient echo in Philips terminology). There are three 




6.3. Implementation of GRASP and IRON 
We first describe the implementation of GRASP and IRON in the pulse programming 
environment with examples of changes that were made to the code. The optimisation of the 
implementation will be discussed following on from that. 
 
6.3.1. Parameter definition and initialisation 
As a first step, the parameters for GRASP and IRON had to be defined. For GRASP, three 
parameters were required: 
• GRASP (Yes/No parameter, i.e. ON or OFF) 
• Gradient step (float, shows a default value that the user can change) 
• Gradient strength (float, shows a default value that the user can change) 
 
For IRON seven parameters were defined: 
• IRON (Yes/No parameter) 
• Frequency offset (float) 
• Bandwidth (float) 
• Frequency loop (Yes/No parameter) 
• Frequency step (float) 
• Bandwidth loop (Yes/No parameter) 
• Bandwidth step (float) 
All parameters that will be enabled for display and visible to the user must be included in a text 
file. Parameters are assigned a unique ID (e.g. MDXNIACQ125). The name of the parameter as 
displayed on the user interface is specified (e.g. gradient step [mT]). By using an indent, 
parameters can be shown as subordinate to other parameters. 
mpiacqtxt.txt (GRASP) mpispirtxt.txt (IRON) 
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All parameters were set up in relevant include files (“.h”). There are different types of 
parameters, MP parameters (available globally), UGN1 and EX parameters. An overview of 
parameter definitions for GRASP are shown below. 





The EX parameter for GRASP and IRON were specified in mpuexrcd.h. The other GRASP 
parameters were defined in include files labelled ‘acq’ (acquisition). To ensure parameters are 
globally available, i.e. in the PDF as well as MPF, they must also be defined in a global include 
file (mguacqrcd.h). 
 
In the file mpuacqrcd.h, the EX parameters were defined for the user interface by providing 
specific characteristics. EX_ACQ_GRASP is a YES/NO parameter which means the user can 
either have it on (Yes) or off (No). The other two parameters, EX_ACQ_GRASP_gradient_step 
and EX_ACQ_GRASP_gradient_strength were defined as float parameters. For both, 
characteristics such as the allowed range, default value and increment step were specified. The 
name tag is taken from the text files. After defining GRASP parameters for the user interface, 
they also had to be added to the IEX_ACQ parameter group. The three GRASP variables also 
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Because IRON was implemented using SPIR (see below for more information), the relevant 
include files (PDF and global) to define the IRON parameters were those labelled ‘spir’. The 
executables (EX parameters) were defined in the same include file as the GRASP parameters 
(mpuexrcd.h). Global MP parameters for the three Yes/No parameter (IRON, frequency loop, 
bandwidth loop) were defined in mgspirrcd.h. 





Definitions for the user interface (parameter characteristics) were done in mpuspirrcd.h for EX 
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6.3.2. Implementation in PDF and MPF 
In all source files where we made changes to the code, a trace was added so that parameters 
could be logged during scanning. Include files where relevant parameters had been defined were 
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For GRASP, changes were made in two PDF source files, mpiffe_sq_g.c and mpirfe_sq_g.c. 
The former refers to gradient echo sequences (FFE = Fast Field Echo) and the latter to spin echo 
sequences (RFE = Refocused Field Echo). We set the gradient strength and gradient step of the 










In the MPF, the gradient strength factor was assigned to the dynamic scan variable which will 
start at zero and increase by 1 with every iteration (the dynamic scan functionality must be 
selected by the user). This was implemented for gradient (mmiffe_mxg.c) and spin echo 
(mmirfe_mxg.c) and also enabled for fast imaging (turbo field echo). 
 
IRON uses an rf pulse to suppress the signal from on-resonant protons during the image 
acquisition. We decided to use the SPIR pulse for that purpose which was already implemented 
in the code. Specifically, the code contained three SPIR function, spir1, spir2 and spir3. Spir1 is 
used for fat and water suppression. Spir2 is used for the respiratory navigator. The spir3 
function was not enabled and had no functionality yet which is why we made some changes to 
the global source file mpuspir_g.c to be able to use spir3 for IRON. Furthermore, we wanted to 
be able to use SPIR fat suppression in combination with IRON and for that reason did not want 
to use spir1. 
 
As spir3 was not used by the code for any other functionality, it first had to be initialised 
including definition of the shot ID. The IRON offset was set to be equal to the standard SPIR 
offset as a default value. After that, all relevant IRON parameter were enabled for display. We 
added the function ‘uspir_calc_sq_spir3’ that defines the SQ’spir3 and adds it to the SOR’cycle. 
Within the validation function MPUSPIR_val13, we defined when the system should provide 
the user with a conflict. SPIR water and fat suppression must not be used at the same time. The 
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frequency and bandwidth loops can only be used when the dynamic study was selected and 
frequency and bandwidth looping cannot happen at the same time either. The IRON bandwidth 
was defined using the set_min_dur function. The frequency and frequency step were defined 
together with the bandwidth. 




Default IRON offeset 
 
Enabling parameters for display 
 
 








In the MPF (mmiffe_mxg.c), we enabled SQ’spir3 to ensure the function was available during 
scanning. To ensure the general SPIR functionality was available even when SPIR was not 
directly selected, we added (‘MP_SPIR_IRON == YES) throughout the mmiffe_mxg.c to all 
‘iffe_enable_spir’ functions. This is important because IRON was implemented based on SPIR 
but we wanted to ensure IRON and SPIR can be used separate from each other, i.e. IRON works 
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even when no SPIR fat suppression was selected. For the IRON implementation, it was 
important for us to be able to loop through different frequencies. We defined a frequency factor 
and frequency step from which the actual frequency could be calculated. At the beginning, the 
frequency factor (‘RFspir3:freq_factor3) is equal to the dynamic variable (iffe_dynamic_scan) 
which starts at zero and increases by one for each loop. For spir3, we defined three frequency 
factors. When the dynamic is zero, hence the frequency factor3 is zero, the frequency equals the 
frequency defined on the user interface and frequency factor1 is set to zero (only needed for the 
next loop). When the frequency factor3 (dynamic) is larger than frequency factor 1, then the 
frequency is increased by the amount defined by the frequency step (determined by the operator 
on the user interface). The frequency does no longer increase when the dynamic has reached its 
final value as defined by the operator.  
Enabling SQ’spir3 
 





6.4. Optimisation of positive contrast imaging techniques 
6.4.1. Test phantoms 
We used four different phantom setups for the sequence optimisation. Phantoms A, B and C 
consisted of a 140 mm crystallising dish (Technische Glasswerke Ilmenau GmbH, Ilmenau, 
Germany) with 5 mm thick custom-made Perspex holder capable of holding up to six 1.5 ml 
PCR tubes. Phantoms A, B and C had different vial setups and utilised different SPIONs (see 
below). Phantom D used the same crystallising dish filled with Gelatine that contained a ball 2.5 
mm steel ball bearing in the centre. 
 
Phantom A was loaded with five PCR tubes of very small superparamagnetic iron oxide 
particles vials (VSOP-200, Ferropharm, Teltow, Germany) of different concentrations (1.2 mM, 
0.6 mM, 0.3 mM, 0.15 mM and 0.075 mM) prepared by two-fold serial dilution. Phantom B 
was similar to phantom A but we added a vial of olive oil in the centre of the water phantom. 
Phantom C contained a centre vial filled with superparamagnetic iron oxide nanoparticle 
F1566 (Liquid Research Ltd., Bangor, UK). The iron concentration was selected to be very 
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high, 7.56 mg/ml which is equal to 135.37 mM. The centre SPION vial was surrounded by five 
water vials. The water vials were added to be able to investigate the effects of the presence of 
the PCR tubes on the centre vial, compare water within the PCR tube to the water in the 
phantom and to compare the different vial positions with each other in case of local magnetic 
field differences. Phantom D contained a steel sphere of 2.5 mm diameter which was embedded 
in 600 ml gelatine (6%) which was contained by a 1000 ml glass beaker (Schott). The gelatine 
was allowed to fully harden before the measurement. The steel ball bearing was completely 
encompassed in gelatine without any air pockets. 
 
6.4.2. GRASP 
The first gradient echo sequence we tested with GRASP was a turbo field echo (TFE) sequence 
in phantom A (figure 36) with the following scan parameters: echo train length = 15, flip angle 
= 5, echo time = 3.08 ms, repetition time = 6.8 ms. The slice refocusing gradient was varied 
between 0 mT and 2.5 mT in steps of 0.5 mT. 
 
Figure 36: First attempt to receive GRASP images with a TFE sequence with varying slice 
refocusing gradient strength (0 mT to 2.5 mT). 
 
The general quality of the images is poor and the water phantom is insufficiently suppressed. 
Hyperintensity is seen around the edges of all PCR tubes on all images, displaying non-
specificity regarding Fe concentration and strength of refocusing gradient strength applied. 
Hyperintensity is most likely the result of the phase change from water to the PCR tube. The 
vial with the highest Fe concentration shows increased hyperintensity on all images. The vials 
with the two highest VSOP concentrations showed increased hyperintensity in the 2.0 mT and 




The same sequence was tested in phantom C that contained a centre vial filled with F1566 from 
Liquid research of a high iron concentration (7.56 mg/ml or 135.37 mM). The images obtained 
from this experiment are shown in figure 37 and several interesting effects can be observed. At 
a refocusing gradient strength of -3.5 mT, the inhomogeneity introduced through the highly 
concentrated SPION solution is visible on the gradient echo image. At -2.0 mT, the signal from 
the on-resonant water protons in the phantom body starts to decrease (i.e. onset of background 
darkening). At a refocusing gradient strength of 1.0 mT, the majority of on-resonant protons in 
the water phantom have darkened (i.e. low signal intensity) while the inhomogeneity introduced 
by the SPION vial is displayed hyperintense. The SPION vial itself does not display any 
hyperintensity. Instead, the dipole field introduced by the SPION particles becomes 
hyperintense. We can eliminate an effect of the PCR tubes as 5 other PCR tubes filled with 
water are present that do not display the same hyperintensity effect. 
 
Figure 37: GRASP TFE sequence tested on phantom C. Good background suppression is 
achieved at a refocusing gradient strength of 1.0 mT. Inhomogeneity introduced by SPION is 
hyperintense. 
 
As the refocusing gradient is further increased, the on-resonant water signal remains dark but 
the image quality decreases (e.g. 10.0 mT). As this is the same sequence as before (figure 36), it 
appears GRASP works better with a higher inhomogeneity. 
 
We optimised the above described sequence by increasing the flip angle to 19 degrees and 




Figure 38: GRASP TFE sequence tested on phantom D. Complete background suppression is 
achieved at a refocusing gradient strength of -1.0 mT while displaying the dipole field of the 
steel ball bearing hyperintense. 
 
In figure 38, signal darkening of the on-resonant protons (gelatine phantom) starts at -2.0 mT. 
Before that, the dipole field introduced by the steel bearing is visible in the gradient echo image. 
At a refocusing gradient strength of -1.0 mT or higher, a positive contrast image is visible, 
displaying the dipole field hyperintense while darkening all on-resonant protons. As the 
refocusing gradient increases, hyperintensity of the dipole field decreases. At -1.0 mT, 
hyperintensity is at a maximum. A disadvantage at that refocusing gradient strength is that the 
phantom edges are slightly visible in head/toe-direction. 
 
In another optimisation step, we used the VSOP phantom B (vial of olive oil in the centre). We 
used the same sequence as before but increased the TFE factor from 15 to 20, selected a water-
fat shift of 2, the flip angle was changed back to 5 degrees, echo time was set to shortest (3.1 
ms) and the repetition time was kept at 6.8 ms. In addition, we switched on the SPIR fat 




Figure 39: GRASP TFE sequence tested on phantom B. Little hyperintensity is visible from the 
VSOP vials while background suppression onsets at -2.0 mT. 
 
Similar to previous results, on-resonant water darkening starts at -2.0 mT. In this sequence, the 
darkening is a lot more consistent. However, we obtained very little hyperintensity from the 
VSOP vials. 
 
So far we have focused GRASP testing on a TFE sequence. However, the implementation 
should also allow to test GRASP with a spin echo sequence (figure 40). We used a 2D turbo 
spin echo sequence (TSE factor 20) with the following scan parameter: echo time = 11 ms, 
repetition time = 855 ms, water-fat shift = 1.5, SPIR fat suppression switched on. 
 
Figure 40: GRASP spin echo sequence (TSE) tested on phantom B. Images show artefacts and 




Artefacts for positive and negative refocusing gradients are visible. These only appear along the 
frequency encoding direction. The MR frequency of the water phantom and the SPIO tubes will 
be considerably different and impact spatial encoding. The shift in the TSE readout was likely 
caused because the receive bandwidth was set too low. The hyperintensity also appeared 
inconsistent. The visible artefacts could have been optimised, but the inconsistent positive 
contrast behaviour let us to focus our optimisation efforts on the TFE sequences. 
 
In the previously tested TFE sequence we increased the repetition time to 12.8 ms and scanned 
phantom B again (figure 41) in which SPIR fat suppression was switched on. 
 
Figure 41: GRASP TFE sequence with TR = 12.8 ms and SPIR fat suppression. 
 
As before, background suppression onsets at -2.0 mT refocusing gradient strength. The increase 
in repetition time to 12.8 ms led to hyperintensity in the vial with lowest VSOP concentration. 
Surprisingly, not the vials with the highest Fe concentration produced the strongest hyperintense 
signal. Fat suppression worked for the vial content but small lobes of hyperintense signal are 
visible on all vials which predominantly results from the PCR vials themselves. As VSOP 5 
shows the strongest hyperintensity, it can be assumed that GRASP will need to be optimised for 
a specific iron concentration to achieve the desired contrast effects. 
 
All attempts to produce positive contrast images so far using GRASP have not led to images 
that showed good background suppression while displaying the VSOP vials hyperintense with 
hyperintensity being concentration dependent. We therefore tested phantom B with a TFE 
sequence based on the work by Vonken et al. [150]. The scan parameters were as follows: flip 
angle = 10, echo time = 1.64 ms (shortest), repetition time = 3.1 ms (shortest), water-fat = 





Figure 42: GRASP TFE sequence (based on [150]). Background suppression for refocusing 
gradient strengths greater than around 0 mT. 
 
Background suppression is inconsistent and not as good as with the steel sphere phantom 
(phantom D). The hyperintense signal from the VSOP vials do not allow a concentration 
differentiation. Plotting the signal intensity for different refocusing gradient strengths for the 
different VSOP concentrations, oil vial, water vial and phantom water is shown in figure 43. 
 
Figure 43: Analysis of GRASP images. a: Overview of ROI measurements. The phantom water 
was measured to estimate the effect the PCR tube has on the water vial. b: Diagram of the 
different signal intensities for different refocusing gradient strengths. 
 
Higher hyperintensity is achieved than at previous experiments but the highest is recorded for 
the vial containing only water. This suggests that the hyperintense signal is due to the PCR tube 
and not the SPION particles. 
According to figure 43, background suppression occurs for refocusing gradient strengths of 
greater than zero. However, the steps by which the refocusing gradient was changed were larger 
than 1 mT. We therefore repeated the above experiment and set the step to 0.1 mT. We obtained 




Figure 44: a: GRASP positive contrast images obtained with a TFE sequence at a refocusing 
gradient strength of -4.4 and -4.5 mT. b: Diagram of signal intensity over gradient strength for 
different phantom vials. c: Diagram of signal-to-noise ratio (SNR) over gradient strength. d: 
Diagram of signal intensity over Fe concentration for the images at -4.4 and -4.5 mT. e: 
Diagram of noise over gradient strength. 
 
From figure 44b and c it is obvious that the greatest difference in signal intensity and SNR 
between the VSOP vials and the water ROIs is at -4.4 and -4.5 mT. Figure 44d shows that if 
ignoring the lowest VSOP concentration, the signal intensity almost linearly increases with Fe 
concentration. 
 
For the next experiment, we used a gradient echo sequence with the following scan parameters: 
Flip angle = 25, echo time = 4.6 ms, repetition time = 100 ms, water-fat shift = minimum, SPIR 
fat suppression on.  In that experiment, the best image is the one at a refocusing gradient 
strength of -0.48 mT. The background suppression is not as strong as on some other scans but 
the VSOP vials are hyperintense (figure 45). After this experiment, we implemented a change to 
the user interface which allowed the user to select the refocusing gradient strength and the step 
by which it is increased (dynamic scans) to be a percentage of the original gradient strength. We 
repeated the experiment with the above described gradient echo sequence and acquired more 
image around the -0.48 mT (equal to around 50% of original refocusing gradient strength). The 
best images were obtained at 55.5%, 54% and 52.5% of the original refocusing gradient strength 




Figure 45: GRASP images obtained with a gradient echo sequence (TE = 4.6 ms, TR = 100 ms, 
FA = 25). The best image was obtained at a refocusing gradient strength of -0.48 mT. 
 
In figure 46c the signal intensity is plotted over the Fe concentration.  
 
Figure 46: GRASP images and analysis of a gradient echo sequence (TE = 4.6 ms, TR = 100 
ms, FA = 25). a: Best positive contrast images obtained at 55.5%, 54% and 52.5% of the 
original refocusing gradient strength. b: Signal intensity over rephrasing gradient strength. c: 




The relationship appears linear for lower Fe concentrations up to 0.6 mM. After that a saturation 
of signal intensity is observed. Because the solutions were prepared by two-fold dilution, the 
biggest concentration difference is between the highest and second highest concentration (i.e. 
difference of 0.6 mM). For that reason we cannot determine the exact Fe concentration at which 
saturation occurs. Saturation of signal intensity at higher Fe concentrations could result from 
nanoparticles agglomerating and as a result sedimenting within the timeframe of the experiment 
leaving less SPIO nanoparticles in solution to be captured by the imaging slice.  
 
After we obtained the GRASP images from figure 46, we went back to a TFE sequence. We 
used the sequence described above which was based on Vonken et al. [150] but made some 
changes to the echo and repetition times: Flip angle = 10, echo time = 3.1 ms (shortest), 
repetition time = 6.4 ms (shortest), water-fat = 2, TFE factor = 10, shot interval = 100 ms, 
profile order low-high. The best image was obtained at 50% refocusing gradient strength (figure 
47). 
 
Figure 47: GRASP images obtained with a TFE sequence (TE = 3.1 ms, TR = 6.4 ms, FA = 10). 
a: The best image was obtained at 50% of the original rephrasing gradient strength. b: Signal 
intensity over rephrasing gradient strength [percentage of original gradient strength]. c: SNR 
over rephrasing gradient strength. d: Signal intensity over Fe concentration for the 50% image. 
e: Noise over rephrasing gradient strength. 
 
From figure 47a, the background suppression and hyperintensity of VSOP vials is much 
improved to previous experiments. The best background suppression is achieved at a refocusing 
gradient strength of 50% (figure 47b). The hyperintensity of the VSOP vials appears to correlate 




We tested another FFE sequence with the following scan parameters: Flip angle = 25, repetition 
time = 100 ms, echo time = 1.36 ms, water-fat shift = minimum and SPIR fat suppression on. 
The best images were obtained at a refocusing gradient between 50 and 60% (figure 48). 
 
Figure 48: GRASP images obtained with a FFE sequence (TE = 1.36 ms, TR = 100 ms, FA = 
25). a: The best image was obtained between 50% and 60% of the original rephrasing gradient 
strength. b: Signal intensity over rephrasing gradient strength [percentage of original gradient 
strength]. c: Signal intensity over Fe concentration (51% and 53% images). 
 
The positive contrast images of figure 48a are promising. No signal can be seen from either the 
water or fat tube. All four VSOP vials are hyperintense and higher signal intensity corresponds 
to a higher Fe concentration (figure 48c). We also tested the exact same sequence but with half 
the repetition time, TR = 50 ms (figure 49). According to figure 49c, the relationship between 
the signal intensity of the VSOP vials and the Fe concentration is more linear, particularly 





Figure 49: GRASP images obtained with a FFE sequence (TE = 1.36 ms, TR = 50 ms, FA = 
25). a: The best image was obtained between 50% and 60% of the original rephrasing gradient 
strength. b: Signal intensity over rephrasing gradient strength [percentage of original gradient 
strength]. c: Signal intensity over Fe concentration (52% and 54% images). 
 
Finally, we wanted to try a TFE sequence with a higher flip angle and a very short repetition 
time: Flip angle = 30, echo time = 23 ms, repetition time = 1.36 ms, water-fat shift = minimum, 
and SPIR fat suppression on (figure 50). This particular sequence showed a very strong linear 
correlation between the hyperintense signal within the VSOP vials and the Fe concentration of 




Figure 50: GRASP images obtained with a TFE sequence (TE = 23 ms, TR = 1.36 ms, FA = 
30). a: The best image was obtained between 50% and 65% of the original rephrasing gradient 
strength. b: Signal intensity over rephrasing gradient strength [percentage of original gradient 
strength]. c: Signal intensity over Fe concentration (52% and 54% images). 
 
6.4.3. IRON 
The first optimisation scan was performed on phantom C. We used a turbo spin echo sequence 
with an echo train length of 9, echo time = 11 ms and repetition time = 855 ms. The IRON 
bandwidth was set to 100 Hz and the dynamic loop was started at an offset of -100 Hz and 




Figure 51: IRON images obtained with a TSE sequence (TE = 11 ms, TR = 855 ms). The strong 
inhomogeneity which originates from the centre vial does not allow for a complete background 
suppression. 
 
A satisfactory background suppression could not be achieved. The strong dipole filed of the 
F1566 vial is visible as a dark shadow in the centre which has a strong influence on the IRON 
implementation as the sequence loops through different IRON offsets. 
 
We tested a fast gradient echo sequence on the same phantom with an echo train length of 15, 
flip angle = 10 degrees, echo time = 3.3 ms and repetition time = 6.8 ms. In order to assess the 
effect of the bandwidth of the IRON pulse, we ran this experiment twice, the first time with 
IRON bandwidth of 120 Hz and after that with 200 Hz (figure 52 and 53). 
 
Figure 52: IRON images obtained with a TFE sequence (FA = 10, TE = 3.3 ms, TR = 6.8 ms). 





Figure 53: IRON images obtained with a TFE sequence (FA = 10, TE = 3.3 ms, TR = 6.8 ms). 
The bandwidth of the IRON pulse was set to 200 Hz. 
 
The background suppression has improved compared to the TSE experiment. Comparing the 
two TFE experiments, a broader IRON bandwidth increases the area of the phantom that can be 
suppressed. 
 
The TSE sequence described above was also tested on phantom D (steel bearing embedded in 
gelatine). The IRON bandwidth was increased to 200 Hz. The frequency offset was varied from 
-130 Hz to +20 Hz in steps of 10 Hz. Figure 54 shows a complete cycle, from the onset of 
background suppression, positive contrast image of the off-resonant protons and back to a 
negative contrast image. At an offset frequency of -50 Hz, background is fully suppressed and 
the dipole field of the steel bearing is shown hyperintense. 
 
Figure 54: IRON images obtained with a TSE sequence (TE = 11 ms, TR = 855 ms). The 
bandwidth of the IRON pulse was set to 200 Hz. The figure shows how the on-resonant protons 
are being suppressed at the right frequency offset and how their signal intensity increases again 




The same steel bearing phantom was used to test a TFE sequence with an echo train length of 
55, flip angle = 55 degrees, echo time = 1.36 ms and repetition time = 2.69 ms (figure 55). The 
bandwidth of the IRON pulse was 200 Hz. 
 
Figure 55: IRON images obtained with a TFE sequence (FA = 55, TE = 1.36 ms, TR = 2.69 
ms). The bandwidth of the IRON pulse was 200 Hz. The best positive contrast image is 
obtained at a frequency offset of -80 Hz. 
 
As seen in figure 54 for a TSE sequence, the whole cycle from zero background suppression via 
a positive contrast image at -80 Hz frequency offset and back to a negative contrast image can 
be seen. Compared to the spin echo sequence, the hyperintensity is brighter and the background 
suppression more convincing. 
 
All further sequence optimisation experiments where conducted on a SPION water phantom 
with four VSOP vials of different concentrations and a water vial (phantom A and B). Using the 
exact same TSE sequence as before (TE = 11 ms. TR = 855 ms, IRON bandwidth = 100 Hz) the 




Figure 56: IRON images obtained with a TSE sequence (TE = 11 ms, TR = 855 ms) on phantom 
A. The bandwidth of the IRON pulse was 100 Hz. 
 
This experiments confirms the weak background suppression as only parts of the water phantom 
are covered. Furthermore, the background suppression allows to still see the underlying 
phantom structures. The regions of hyperiontensity are small and mainly present at the vial with 
the highest and second highest concentration. Hyperintensity is only shown in the dipole field 
lobes in head/toe and left/right direction, the VSOP solutions do not show any hyperintensity. 
 
In another experiment we attempted to overcome the above described shortcoming by 
decreasing the repetition time to 517 ms and the IRON bandwidth was increased to 200 Hz. In 
addition, the water/fat shift was set to 1.5 and SPIR fat suppression was switched on. 
 
Figure 57: IRON images obtained with a TSE sequence (TE = 11 ms, TR = 517 ms) that used 




Figure 57 shows that almost the whole phantom could be suppressed at an offset of 180 Hz with 
the two highest VSOP vials being brightly visible. Compared to previous experiments, not only 
the lobes of the dipole field but the vials themselves are hyperintense. The background 
suppression is inconsistent in the centre of the phantom (patches). 
 
In an optimisation step we increased the TSE factor from 9 to 16 and also increased the echo 
time to 53 ms. Water fat shift was set to minimum while we kept the SPIR fat suppression 
activated. At an IRON bandwidth of 200 Hz we obtained the images shown in figure 58. 
 
Figure 58: IRON images obtained with a TSE sequence (TE = 53 ms, TR = 517 ms) that used 
SPIR fat suppression and a minimal water/fat shift. The IRON bandwidth was 200 Hz. 
 
Compared to the previous experiment, the image quality has significantly improved. While most 
of the phantom could be covered with ON-resonant suppression IRON pulse at 170 Hz (apart 
from the edges in the head-toe direction), the quality of suppression still lacked intensity and 
allowed to see underlying structures. Two PCR tubes stand out, the vial with the highest VSOP 
concentration displays hyperintense lobes in the left/right direction at a lower frequency offset. 
The vial with the second lowest VSOP concentration appears brighter throughout the 
experiment. 
 
The above mentioned TFE sequence (echo train length = 15, flip angle = 10, echo time = 3.3 
ms, repetition time = 6.8 ms) was tested phantom B (VSOP phantom). The IRON bandwidth 




Figure 59: IRON images obtained with a TFE sequence (FA = 15, TE = 3.3 ms, TR = 6.8 ms) 
on phantom B. The IRON bandwidth was 100 Hz. 
 
The selected IRON bandwidth was not enough to achieve a full background cover of the 
phantom. However, the background suppression was convincing and at an offset of -30 Hz the 
dipole lobes of the highest VSOP vial were clearly visible while the signal from the VSOP 
solution within the vial remained suppressed. 
 
In order to improve the coverage of the background suppression, IRON bandwidth was 
increased to 200 Hz while also increasing the echo train length to 30. Figure 60 shows the result 
where the majority of water phantom has successfully been suppressed apart from the edges in 
head/toe direction. The VSOP vials with two highest Fe concentrations are displayed 
hyperintense. A positive result from this experiment is that the hyperintensity indicates a 
possible Fe concentration dependence with the vial with the higher Fe concentration being 




Figure 60: IRON images obtained with a TFE sequence (FA = 15, TE = 3.3 ms, TR = 6.8 ms) 
on phantom B. The IRON bandwidth was 200 Hz. 
 
In order to further test the influence of the IRON bandwidth on the background suppression, we 
scanned the phantom with the same sequence but increased the IRON bandwidth to 300 Hz 
(figure 61). 
 
Figure 61: IRON images obtained with a TFE sequence (FA = 15, TE = 3.3 ms, TR = 6.8 ms) 
on phantom B. The IRON bandwidth was 300 Hz. 
 
At a lower frequency offset, the larger IRON bandwidth pulse is able to achieve background 
suppression where the narrower pulse fails. The sequence with the 300 Hz bandwidth also 
resulted in increased hyperintensity of the SPION vials. We plotted the signal intensity over the 
offset for all VSOP vials, oil vial, water vial and a position within the water phantom (figure 
62). 
 
Figure 62: Analysis of IRON TFE sequence. a: Illustration of where ROIs were drawn for the 
measurement of the signal intensity. As a comparison to the water-filed PCR tube, a ROI was 
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also drawn in the phantom water. b: Signal intensities of different ROIs (vials) for a range of 
IRON frequency offsets (200 – 425 Hz). The ideal contrast can be achieved at 290 Hz. 
 
Figure 62 confirms that the best contrast is achieved at 290 Hz. At that offset, VSOP1, VSOP2 
and VSOP3 have a higher signal intensity than the other vials. In particular, both water 
measurements and the oil vial have a very low signal intensity and are therefore suppressed. 
 
Figure 61 showed that an IRON pulse with a broader bandwidth resulted in a better result. As a 
next step, we evaluated the effect of the water/fat setting on the IRON TFE sequence (figure 
63). Scan 201 was conducted with water/fat = 2, scan 301 had the water/fat parameter set to 
minimum. 
 
Figure 63: Evaluation of the effect of the water/fat parameter on the IRON image quality. 201: 
Water/fat =2. 301: Water/fat = minimum. 
 
Scan 201 achieved a better background suppression and became our standard scan for future 
comparisons. We tested a few more sequences with different scan parameters and compared 
these to scan 201 from figure 63. A new sequence we tested was an IRON TFE with a flip angle 
of 15 degrees, an echo time of 1.38 ms, repetition time of 2.7 ms, water/fat set to minimum and 





Figure 64: Comparison of two IRON TFE sequences. 201: FA = 15, TE = 3.3 ms, TR = 6.8 ms, 
water/fat = 2. 401: FA = 15, TE = 1.38 ms, TR = 2.7 ms, water/fat = min. 
 
The different scan parameters resulted in the best images at a very different frequency offset, i.e. 
405 Hz, 420 Hz and 435 Hz. While the background suppression was very similar for both scans, 
401 also produced hyperintensity at VSOP2 vial. However, the frequency offset had to be 
changed to achieve good positive contrast images and a direct comparison is therefore difficult. 
We also tested an IRON TFE with the following parameters: flip angle of 15 degrees, echo time 
of 1.54 ms, repetition time of 3.9 ms and water/fat set to minimum (figure 65). 
 
Figure 65: Comparison of two IRON TFE sequences. 201: FA = 15, TE = 3.3 ms, TR = 6.8 ms, 




Despite the good background suppression, the hyperintensity was inconsistent with VSOP4 
having a stronger signal than VSOP2 or VSOP3. 
The next TFE sequence we tested was based on a sequence described by Stuber et al. [153] with 
an IRON bandwidth of 300 Hz (figure 66). The scan parameters were: flip angle = 18 degrees, 
echo time = 3.1 ms, repetition time = 24 ms, water/fat = minimal and SPIR fat suppression. This 
sequence delivered the best results with almost complete suppression of the water phantom to 
the edges and hyperintense signal from all VSOP vials. Vials with higher Fe concentration 
appeared to have a stronger signal. The oil vial in the centre was visible suggesting that fat 
suppression was not effective. The control water vial on the other hand completely disappeared 
and blended into the suppressed phantom water. 
 
Figure 66: IRON TFE sequence with FA = 18, TE = 3.1 ms, TR = 24 ms, water/fat = min, 
IRON BW = 300 Hz and SPIR fat suppression. 
 
We repeated this experiment but increased the IRON bandwidth to 679 Hz (figure 67). The 
increased IRON bandwidth had a significant effect on the ability to suppress the signal of the 





Figure 67: IRON TFE sequence with FA = 18, TE = 3.1 ms, TR = 24 ms, water/fat = min, 
IRON BW = 679 Hz and SPIR fat suppression. 
 
Because the SPIR fat suppression was not effective, we tested the same sequence but used 
Dixon as a fat suppression method. The water images are shown in figure 68 for the same 
frequency offsets the above. 
 
Figure 68: IRON TFE sequence with FA = 18, TE = 3.1 ms, TR = 24 ms, water/fat = min, 
IRON BW = 679 Hz and Dixon fat suppression (water images are displayed). 
 
Using Dixon as a fat suppression technique was very successful. The oil vial is almost 
completely suppressed. The vial with the lowest Fe concentration (VSOP4) still achieved a 
signal intensity > 500 for frequency offsets larger than 234 Hz (figure 69) which allowed it to be 
very visible on the darkened background. All four VSOP concentrations are visible and display 





Figure 69: Analysis of signal intensities for different vials within the phantom for IRON TFE 
sequence with Dixon fat suppression (figure 68). 
 
Using the much increased IRON bandwidth of 679 Hz, we went back to our initial TFE 
sequence (FA = 10, TE = 3.3 ms, TR = 6.8 ms, water/fat = 2) with SPIR fat suppression (figure 
70). Between 249 Hz and 258 Hz frequency offset, good positive contrast images were 
achieved. 
 
Figure 70: IRON TFE sequence (FA = 10, TE = 3.3 ms, TR = 6.8 ms, water/fat = 2, IRON BW 
= 679 Hz, SPIR fat suppression) and analysis. a: MR images for four frequency offsets, 249 Hz, 
252 Hz, 255 Hz and 258 Hz. b: Analysis of signal intensities for different vials within the 
phantom over the frequency offset (ideal range highlighted). c: Zoomed in version of (b). 
 
Another TFE sequence we tested had much shorter echo time of 1.36 ms (TR = 6.8, FA = 10, 
water/fat = min, SPIR fat suppression) (figure 71). As shown in figure 71c, this sequence 




Figure 71: IRON TFE sequence (FA = 10, TE = 1.36 ms, TR = 6.8 ms, water/fat = min, IRON 
BW = 679 Hz, SPIR fat suppression) and analysis. a: MR images for four frequency offsets, 234 
Hz, 244 Hz, 254 Hz and 264 Hz. b: Analysis of signal intensities for different vials within the 
phantom over the frequency offset. c: Signal intensities over Fe concentration (VSOP1, VSOP2, 
VSOP3, VSOP4 and water vial) for three frequency offsets (244 Hz, 254 Hz and 264 Hz). 
 
In figures 70 and 71, SPIR fat suppression was successfully applied on an IRON sequence. We 
went back to the Dixon fat suppression technique but with a very short echo time of 1.36 ms 
(TE2 = 2.5 ms), a slightly increased excitation angle of 18 degrees. The repetition time was 
varied from 8 ms (figure 72), 10 ms (figure 73), 12 ms (figure 74) to 24 ms (figure 75). 
 
Figure 72: IRON TFE sequence (FA = 18, TE1 = 1.36 ms, TE2 = 2.5 ms, TR = 8 ms, water/fat 
= min, IRON BW = 679 Hz, Dixon fat suppression) and analysis. a: MR images for six 
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frequency offsets, 204 Hz, 214 Hz, 224 Hz, 234 Hz, 244 Hz and 254 Hz. b: Analysis of signal 
intensities for different vials within the phantom over the frequency offset. c: Signal intensities 
over Fe concentration (VSOP1, VSOP2, VSOP3, VSOP4 and water vial) for two frequency 
offsets (244 Hz and 254 Hz). 
 
 
Figure 73: IRON TFE sequence (FA = 18, TE1 = 1.36 ms, TE2 = 2.5 ms, TR = 10 ms, water/fat 
= min, IRON BW = 679 Hz, Dixon fat suppression) and analysis. a: MR images for six 
frequency offsets, 204 Hz, 219 Hz, 234 Hz, 249 Hz, 264 Hz and 279 Hz. b: Analysis of signal 
intensities for different vials within the phantom over the frequency offset. c: Signal intensities 
over Fe concentration (VSOP1, VSOP2, VSOP3, VSOP4 and water vial) for three frequency 





Figure 74: IRON TFE sequence (FA = 18, TE1 = 1.36 ms, TE2 = 2.5 ms, TR = 12 ms, water/fat 
= min, IRON BW = 679 Hz, Dixon fat suppression) and analysis. a: MR images for three 
frequency offsets 244 Hz, 254 Hz and 264 Hz. b: Analysis of signal intensities for different 
vials within the phantom over the frequency offset. c: Signal intensities over Fe concentration 
(VSOP1, VSOP2, VSOP3, VSOP4 and water vial) for three frequency offsets (244 Hz, 254 Hz 
and 264 Hz). 
 
 
Figure 75: IRON TFE sequence (FA = 18, TE1 = 1.36 ms, TE2 = 2.5 ms, TR = 24 ms, water/fat 
= min, IRON BW = 679 Hz, Dixon fat suppression) and analysis. a: MR images for six 
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frequency offsets, 204 Hz, 219 Hz, 234 Hz, 249 Hz, 264 Hz and 279 Hz. b: Analysis of signal 
intensities for different vials within the phantom over the frequency offset. c: Signal intensities 
over Fe concentration (VSOP1, VSOP2, VSOP3, VSOP4 and water vial) for three frequency 
offsets (204 Hz, 219 Hz and 234 Hz). 
 
The best differentiation between the different VSOP vials is achieved with a TR of 24 ms. The 
best linear correlation between signal intensity and Fe concentration was achieved with a TR of 
either 10 or 12 ms.  
 
6.5. Susceptibility gradient mapping technique 
We did not have to implement SGM as it had already been implemented in Matlab by a former 
staff member and available in the department. Important parts of the SGM implementation are 
the program files (m-files) readpar.m and readraw.m. The former reads the scan parameters (i.e. 
slice number, echo number, dynamic number, phase number, image type, echo time and slice 
orientation) from exported PAR files. The file readraw.m reads REC files using the information 
specified in the PAR file. If the parameters from the PAR file are given, the data is reshaped to a 
specific format, i.e. frequency encoding steps/phase encoding 
steps/phases/dynamics/echoes/image type. The program file noise_roi.m allows the user to draw 
a region of interest in the noise area of the image that will be taken into account during the SGM 
calculations. 
 
The SGM calculation produces a KMAP that includes the echo shift due to the field 
inhomogeneity and produces the positive contrast image as output. A screenshot of the 




Figure 76: Graphical user interface of SGM implemented in Matlab. 
 
The ‘Open’ button allows to select a PAR/REC file (either can be selected) and the respective 0"∗-weighted gradient echo image is loaded in the left window in figure 76. Two scroll bars 
allow to scroll through slices and echoes (i.e. images). When clicking on ‘Tools’ in the menue 
bar, it is possible to select a region of interest to be considered as noise. Finally, the SGM 
window could be defined. This determines the number of neighbouring pixels that are taken into 
account when the SGM window is scanning the image. The calculation can be started with 
‘Apply’ and the positive contrast image is shown in the right window. The scroll bar allows to 
look at the positive contrast image when only considering the echo shift in one direction (1D, 




6.6.1. Water phantoms 
For the optimisation of our positive contrast sequences, we have used four different phantoms. 
All phantoms are water phantoms to minimise susceptibility effects from the air to liquid 
(SPION solution) interface. However, it is impossible to eliminate all inhomogeneities that 
could affect the measurements. In terms of background suppression, i.e. suppressing the signal 
from the on-resonant protons (not affected by SPION/steel ball bearing) in our water phantom, 
it is hardest to achieve a full background suppression around the edges of the phantom. The 
reason for that is the slightly different Larmor frequency of protons in that region as the 
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magnetic field is less homogenous as a result of the water/air interface. This was particular 
apparent in the head/toe direction for the GRASP sequence as that is the direction of the slight 
select gradient we modified and used for the positive image generation. 
 
We just discussed the inhomogeneity introduced at the edge of the phantom due to the phase 
interface. Similar inhomogeneities need to be taken into account for phantoms A, B and C that 
all contained PCR tubes filled with either a SPION solution or olive oil. Inhomogeneities are 
present at the interface between the water phase of the phantom body and the PCR tube and then 
again at the interface of the PCR tube with the SPION solution. Because the 1.5 ml PCR tubes 
we used are thin-walled (approximately 1 mm), inhomogeneities from the two interfaces cannot 
be differentiated at the resolution we scanned. Phantoms A, B and C had 5 identical PCR tube 
positions. When these are filled with PCR tubes of different SPION concentrations (including 
no SPION, i.e. water), it allowed us to estimate the effect of the PCR tube on any visible 
hyperintensity. In order to minimise PCR tube effects, other researchers have used very thin 
films shaped as tubes [331] or moulded tube-shaped cavities in a block of hardened gelatine in 
which they then filled the SPION solution [152]. However, these researchers still reported 
susceptibility effects as there was still an interface transition. Other researchers have used glass 
tubes for SPION measurements [332]. It is currently unclear if glass or a polymer material as 
used for PCR tubes is preferred in reducing susceptibility effects and this might be an 
interesting question to explore in the future. Furthermore, quantifying the susceptibility effect 
exerted depending of the wall thickness has not yet been explored and reported in the literature. 
 
The reason we have tested and optimised our sequences on four different phantoms is the 
following. The difference between phantoms A and B is merely the addition of a PCR tube 
filled with olive oil which allowed us to test fat suppression techniques in combination with our 
positive contrast implementations. For this optimisation, we have used vials containing VSOP 
solutions of different concentrations with the largest being 1.2 mM. We used phantom C which 
contained five PCR tubes filled with water and one centre vial filled with a SPION solution of 
very high concentration (135.37 mM) as a control. For once, the water-filled PCR tubes allowed 
us to estimate the effect the PCR tubes had on a particular sequence and whether there were any 
differences in the magnetic field strength in the different vial positions within our water 
phantom. Secondly, the vial with the high concentration SPION solution meant we could test if 






Our implementation of GRASP was straightforward. We initialised three parameters, one to 
switch GRASP on or off, the strength of the GRASP gradient (i.e. slice-select refocusing 
gradient) and the gradient step by which the user can make changes to that gradient. As the 
GRASP technique relies on changing the slice-select refocusing gradient until the off-resonant 
water protons are refocused, the key is to provide functionality in the code so that the user can 
exactly do that. The run-time strength of any gradient can be calculated with the equation: º/1 7t! = º/M 7t! + 	º/ æ§Çtc! ∗ º/[7tg\] 
Any run-time gradient can be achieved by adding a gradient step to the current gradient 
strength. Introducing a gradient factor in this allows for automation by scanning through a range 
of gradient strengths. If the gradient factor is zero, the gradient does not change, is the factor 
equal to one, then the gradient increases by the amount defined by the gradient step, for a factor 
of two the gradient increases by an amount two times the step and so on. In our first 
implementation, the user could determine the gradient strength on the GUI. However, 
depending on the sequence, the original slice-select refocusing gradient strength will change. It 
would therefore be difficult for a user without detailed knowledge of the sequence to be run to 
select a sensible value for the gradient strength. 
In our second implementation, instead of providing gradient strength and step in mT, this was 
now provided as a percentage of the original gradient. The gradient factor was equal to the 
number of the dynamic scan variable that starts at zero and increases by one up to a defined end 
point, e.g. 10 dynamics means the variable increases from zero to nine in steps of one. With this 
implementation, if the original gradient was 5 mT and the step was selected to be 10%, this 
would mean for each dynamic scan the gradient would be increased by 0.5 mT. 
For the implementation to work, it is crucial to correctly identify the relevant slice-select 
refocusing gradient variable within the gradient echo and spin-echo code. Providing the gradient 
strength, step and factor is sufficient for the code then determine the new gradient strength for 
each dynamic scan. 
Our implementation is simple and does not interfere with any other scan functionality or 
parameter. It allows the user complete control over the GRASP scan in an intuitive measure 
(percentage) that does not require previous knowledge of the exact gradient strength. 
 
During the optimisation of our GRASP implementation, we initially focused on fast imaging 
sequences (i.e. turbo field echo and turbo spin echo) with an emphasis on turbo field echo 
sequences. The sequence had a low excitation angle, an echo time of 3.1 ms and a repetition 
time of 6.8 ms. We experimented with increasing the flip angle to 19 degrees or the repetition 
time to 12.8 ms. This sequence failed to produce a good quality positive contrast image of the 
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phantoms containing VSOP vials. However, when applied to phantom C with the high Fe 
concentration vial, the introduced dipole field by the SPION solution was depicted hyperintense 
on a signal suppressed background (figure 37). The dipole field was not symmetric and showed 
a more protruding lobe in the head-direction. This is likely because of SPION accumulation 
within the vial as that particular SPION did show a strong tendency to accumulate. The SPION 
solution did not show any hyperintensity at different refocusing gradient strengths. It could be 
that the optimal gradient strength was in between the steps we tested or that we did not cover a 
large enough range of different gradient strengths. However, from -0.5 mT up to 10 mT 
refocusing gradient strength, the background was suppressed and hyperintensity visible we 
stopped our measurement at 10 mT). The on-resonant water protons did not recover their signal 
as the refocusing gradient increased further. Moreover, the off-resonant protons remained 
hyperintense long after the optimal refocusing gradient. According to the theory, it would be 
expected that once the gradient is increased beyond the optimal strength for the off-resonant 
protons, those lose their hyperintensity and eventually the on-resonant protons will increase 
their signal intensity [151]. This sequence was also able to produce positive contrast images on 
phantom D (steel bearing embedded in gelatine) (figure 38). A complete background 
suppression was achieved starting at -2 mT as in the above discussed experiment on phantom C 
and the dipole field of the steel bearing is visible on the gradient echo as well as GRASP 
images. The optimal refocusing gradient strength within the values we tested appeared to be -1 
mT. In accordance with the above discussed results, the hyperintensity remained as the gradient 
strength was further increased. These two experiments demonstrate that the sequence was able 
to produce positive contrast images but not sensitive enough to highlight the different VSOP 
concentrations (figure 39). 
 
The second set of TFE sequences was based on a sequence described by Vonken at al. [150], 
excitation pulse of 10 degrees, echo time of 1.64 ms and a repetition time of 3.1 ms (figure 42). 
A variation of this sequence had an increase echo and repetition time (figure 45). At a 
refocusing gradient strength of 50% of the original strength, we achieved positive contrast 
image that showed a VSOP concentration dependence and a satisfactory background 
suppression. Contrary to the images obtained with our first TFE sequence, here the SPION 
solution appeared hyperintense and no dipole field was visible on the positive contrast images 
that protruded outside of the PCR tube walls. The PCR tubes did not produce visible 
inhomogeneity. However, in figure 47 the content of the water-filled PCR tube has a much 
higher signal intensity than the phantom water. This suggests that the magnetic field inside the 
PCR tube is slightly different compared to the rest of the water phantom. The other PCR tubes 
containing VSOP solutions displayed an increased signal intensity as a result of the VSOPs that 
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was dependent of the VSOP concentration. The overall concentration dependence showed a 
linear relationship. 
 
The final TFE sequence we tested had a much increased flip angle of 30 degrees, an echo time 
of 23 ms and a repetition time 1.36 ms (figure 50). This experiment further clarified the 
detection limit. Positive contrast images were obtained for a range of different refocusing 
gradient strengths and throughout the two lower VSOP concentrations could not be 
differentiated from the water vial by visual inspection of the images. This suggests that for a 
given sequence implementation and iron oxide nanoparticle, an experiment should be designed 
determining the detection limit before proceeding to any further measurements or in vivo work. 
 
In contrast to the previously discussed TFE experiments, we also tested a field echo sequence 
with a flip angle of 25 degrees, a short echo time of 1.36 ms and a repetition time of 100 ms/50 
ms. This sequence showed a much improved hyperintensity of the VSOP vials compared to 
water-filled tube. As shown in figure 49, the concentration dependence shows a linear 
correlation. VSOP particles also display a 01 effect [243]. A gradient echo sequence with a flip 
angle of 25 degrees and a very short echo time (1.36 ms) has a strong 01 weighting which 
contributed to the hyperintensity of the VSOP vials. SPIONs with a small !1 value and therefore 
low 01 effect are unlikely to show the same effect when scanned with this sequence.  
 
6.6.3. IRON 
We implemented IRON by using the already available SPIR code in the pulse programming 
environment. There were three SPIR implementations, spir1, spir2 and spir3. The former is used 
for the SPIR fat suppression functionality. Spir2 is used for the respiratory navigator. We used 
spir3 to be able to use spir1 for fat suppression together with our IRON pulse. The majority of 
the implementation was therefore done in the global source file mpuspir_g.c. Our 
implementation satisfies two important criteria: First, we utilise existing code framework which 
minimises the margin for error and usually results in a mode solid scan performance. Second, 
we were able to implement IRON while allowing for fat suppression functionality through SPIR 
or Dixon. 
 
From our optimisation experiments it is clear that our IRON implementation can be used in 
combination with gradient and spin echo sequences. However, there is a strong difference in the 
quality of the background suppression when using a TFE sequence compared to a TSE 
sequence. While the amount of background suppression for a given IRON bandwidth was 
comparable between both types of sequences, background suppression with a TSE sequence 
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was a lot less dense and allowed for the underlying structures to be seen. We are unsure about 
the origin of this difference. Positive contrast experiments using IRON reported in the literature 
use predominantly gradient echo sequences and our results agree with that. 
 
From testing various sequences with different parameters, the IRON bandwidth needs to be 
larger than 600 Hz (we used 679 Hz) in order to achieve a complete background suppression of 
our phantom (diameter 14 cm). As expected, the bigger the IRON bandwidth the larger the area 
which can be covered with the IRON pulse. The protons in a phantom will not all “see” the 
same magnetic field. Those protons closest to the phantom edges or around structures such as 
vials will experience a slightly different magnetic field. Moreover, the magnetic field in a MRI 
scanner is never perfectly homogenous and even within a small phantom such as ours, slight 
spatial differences exist. It is therefore important to select an IRON bandwidth that is wide 
enough account for those magnetic field imperfections and therefore is able to effectively 
suppress signal from on-resonant protons. However, the IRON bandwidth must not be too wide 
or it will otherwise also suppress the protons affected by the SPIONs. Depending on the SPION 
and the magnetic inhomogeneity they introduce, the IRON bandwidth will need to be optimised. 
 
In figure 24, only the lobes of the dipole field of the VSOP1 vial are shown hyperintense. In 
figure 25, the same sequence was used but here the VSOP solution within the vial is shown 
hyperintense. The main difference between both scans was the frequency offset. Using a higher 
frequency offset around 250 Hz and above, hyperintensity could be induced in the VSOP vial. 
Not all vials were visible in figure 25 which meant that a higher VSOP concentration would 
also result in increased positive contrast. 
 
Table 1: Selection of turbo field echo sequences that provided the best positive contrast IRON 
images. 












1 TFE 10 3.3 6.8 2 679 SPIR 
2 TFE 10 1.36 6.8 min 679 SPIR 
3 TFE 18 3.1 24 min 679 SPIR 
4 TFE 18 TE1=1.36 
TE2=2.5 
24 min 679 Dixon 
 
In terms of image quality, the four sequences do not differentiate by much. The detection limit 
for the three sequences that used SPIR fat suppression was the concentration of the VSOP2 vial 
(0.6 mM). VSOP2 was visible and according to the figure 36c and figure 37c, the signal 
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intensity of VSOP3 and VSOP 4 did not differentiate much and had a similar signal intensity 
then the water vial. When using Dixon as fat suppression (figure 39) VSOP3 has a much higher 
signal intensity than water and also VSOP4 (0.15 mM) can be differentiated from water for 254 
Hz and 264 Hz. The relation of the signal intensities between the different VSOP vials in figure 
39 is linear. This suggests that the optimal range for quantitative imaging would be towards the 
upper end of the frequency spectrum, just before the background suppression starts to break up 
again in the centre of the phantom. At that frequency, even lower SPION concentrations can be 
detected while still maintaining a good suppression of the on-resonant protons. 
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7. Positive contrast imaging using a Dixon-based technique 
7.1. Introduction 
In this chapter the implementation and optimisation of Dixon as a positive contrast imaging 
technique is described. MR images were acquired of a water phantom loaded with a range of 
different SPION concentrations. Dixon was compared with other, more established positive 
contrast methods such as GRASP, IRON and SGM which were described in the previous 
chapter. 
 
The Dixon method is a technique developed for effective fat suppression in MR imaging. It was 
first described by Thomas Dixon in 1984 for spectroscopic imaging [333]. In 1991, Glover and 
Schneider demonstrated the use of Dixon for the decomposition of water and fat signal in MRI 
[334], [335]. The technique relies on the chemical shift difference between the water and fat 
resonant frequencies. Ultimately, the Dixon method is a postprocessing technique as it translates 
the chemical shift difference in a signal phase. In the original two-point Dixon method, two 
images are acquired to separate water and fat. The phase angle + of the fat signal relative to the 
water signal is given as 
 + = =LM¨∆0[ (167) 
where ¨ is the chemical shift of fat with respect to water and = is the gyromagnetic ratio of 
protons. The images are acquired at different echo times which are selected so that for one 
image the water and fat resonant frequencies will be in-phase (+ = 0) and for the other they will 
be out-of-phase (+ = 180°, opposed-phase). The complex in-phase (≈M) and out-of-phase (≈1) 
images can then be mathematically combined to receive a water (W) and a fat (F) image  
 ≈M = (_ + …)gu`p (168) 
 ≈1 = (_ − …)gu(`pî`) (169) 
with Ω = 	= ΔLM Δ0[ being the accumulated phase during the echo shift Δ0[ due to field 
inhomogeneities (ΔLM) and ΩM contains all other phase errors. The in-phase and out-of-phase 
echo times can be determined from the phase angle by knowing that the main contributor to the 
fat signal is methylene whose resonance frequency is 3.5 ppm away from that of water [91], 
[336]. 
 
The two-point Dixon method has the disadvantage that it works under the assumption that water 
is perfectly on resonance. Limitations therefore exist if LM-field inhomogeneities are present. A 
further development of the two-point Dixon method is the three-point Dixon technique [334] 
where three rather than two images are acquired for postprocessing [336]. As in the original 
method, in-phase and out-of-phase images are acquired by selecting the TEs accordingly. In 
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case of large magnetic field variations, three-point Dixon still suffers from errors in the 
assignment of water and fat pixels. In order to overcome this problem Szumowski et al. [337] 
have suggested a phase unwrapping technique. However, phase unwrapping techniques are 
limited due to their low SNR [338]. Several methods have been reported [339]–[342] that also 
estimate a field map in addition to the water and fat images. The advantage of these methods is 
that they are more robust than phase unwrapping and that TEs can be selected arbitrarily making 
the sequence design more flexible. The main applications for the Dixon technique remain fat 
suppression and fat quantification. However, with the development of above mentioned field 
map techniques, other applications can be considered as well. 
 
If the Dixon technique is capable of successfully separating the frequencies of water and fat, it 
may also be possible to use Dixon to separate on- and off-resonant protons as a means to 
produce a positive contrast image of off-resonant protons affected by the dipole field of 
SPIONs. The 0"∗ shortening effect of SPIONs means that the signal decay is of the order of the 
Dixon echo shift. As described above, the Dixon fat suppression is inaccurate when the 0"∗ is 
very short [343], [344]. If modified appropriately, the Dixon method should be able to visualize 
magnetic susceptibility markers [345]. An example is Iterative Decomposition of water and fat 
with Echo Asymmetry and Least-squares estimation (IDEAL) [339], [340]. IDEAL was 
developed for effective water and fat decomposition and uses an iterative reconstruction 
algorithm that allows for multiple echoes with flexible TEs. IDEAL however is unable to 
measure the transverse relaxation time because 0"∗ mapping could interfere with the 
quantification of the fat signal. 
 
Yu et al. [346] have described a development of the IDEAL reconstruction algorithm capable to 
estimate 0"∗, fat and water content. The algorithm was modified in order to allow for the 
simultaneous estimation of a complex field map that would allow 0"∗ estimation in addition to 
water and fat decomposition.  
 
The 0"∗-IDEAL reconstruction makes the assumption that in the presence of SPIONs, water and 
fat have similar 0"∗ values. For k number of echoes that are acquired at echo times 0[u	(] =1, 2, 3 … V), the signal (2u) of any given voxel is 
 
2u = d + æ ∙ 	ga";´jhÎ ∙ ga";bjhÎ ∙ gm≠©∗jhÎ + ^u= 	 d + æ ∙ 	ga";´jhÎ ∙ ga"bjhò + ^u (170) 
The LM field inhomogeneity and noise are represented by œ and ^u, respectively. With œ, a 
complex field map can be estimated 
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 œ = œ + c /"∗29 (171) /[{œ} is the field offset usually given in Hz and /"∗ 29 is the imaginary part (≈C{œ}). 
Applying the 0"∗-IDEAL implementation for the imaging of susceptibility marker such as 
SPIONs, d would refer to on-resonance protons instead of water while æ would refer to the off-
resonance signals affected by the dipole field of the SPIONs [150], [346]. 
 
7.1.1. Purpose of present work 
The purpose of this study was to implement and test Dixon as a method for positive contrast 
imaging. We aimed to assess the imaging capabilities of a simple implementation that utilises 
all of the pre-installed and optimised functionality on a Philips Achieva MRI scanner. Our 
Dixon positive contrast method will be tested on three different SPIONs of different coatings, 
size and magnetic moment. We investigated the feasibility to produce positive contrast images 
using the Dixon technique and compared it to already established techniques such as SGM, 
GRASP, and IRON. Finally, we compared the fat suppression ability of SPIR and Dixon when 
acquiring positive contrast images with the IRON technique. 
 
7.2. Methods 
7.2.1. Dixon implementation 
We used a simple implementation to test whether positive contrast images could be generated in 
vitro using the already available Dixon functionality. The idea was to change the user interface 
so that the water-fat shift could be changed manually. This would therefore no longer represent 
the water-fat shift and could potentially be used to display water protons affected by the dipole 
fields of superparamagnetic iron oxide nanoparticles.  
 
As a first step, we created a new parameter that we called EX_ACQ_Dixon_freq_shift. The 








We added the parameter to the text file mpiacqtxt.txt where it was given a name tag 
(XNIACQ128) and a label (“Freq Shift”) for its display on the user interface. 
 
In the file mpuacqrcd.h, the parameter was further defined as a float with a set range, default 
value and adjust value. The previously defined name tag was provided to link the parameter 
properties to the parameter name in the mpiacqtxt.txt file and the user interface. 
 
 
The water-fat shift parameter (MGG_PPM_WATER_FAT_SHIFT) is defined in the file 
mggrcd.h. 
 
MGG_PPM was defined as 0.000001 which is the equivalent of one part per million (ppm). The 
water fat shift was defined as 3.4 ppm. Our parameter had to be enabled in the file mpuacq_g.c. 
It was added to the uacq1_Dixon group. When the Dixon functionality is activated on the user 
interface, the Dixon parameter EX_ACQ_dixon is enabled as well as our Dixon frequency shift 
parameter. 
Code/Research material redacted due to 3rd party copyright
Code/Research material redacted due to 3rd party copyright




In order to control the frequency shift manually whenever Dixon is used, we replaced 
MGG_PPM_WATER_FAT_SHIFT with our frequency shift parameter, e.g. mparc.h: 
 
and in the file mpudef_comb_g.c: 
 
and in the file mpiffe_sq_g.c: 
Code/Research material redacted due to 3rd party copyright
Code/Research material redacted due to 3rd party copyright






7.2.2. Superparamagnetic Iron Oxide 
We compared four different SPIONs (table 2) in vitro to investigate their behaviour as positive 
MR contrast agents. Two SPIONs (MF66-DMSA and MF66-PEG) were synthesised as part of 
the MultiFun project (European Community’s Seventh Framework Programme, grant 
agreement number 262943). Ferumoxytol is a commercially available and clinically approved 
MR contrast agent and VSOP-C200 is a very small superparamagnetic iron oxide particle 
(Ferropharm, Teltow, Germany) that is no longer available. 
 
Table 2: Superparamagnetic iron oxide nanoparticles investigated in this study with their core 
size, hydrodynamic diameter, coating material, surface charge, pH in water, and transverse 
relaxivity !". 













fg∗  Relaxivity himjkmj  
Ferumoxytol 3.25 23.6 PSC -43.2 7 90.8 
MF66-DMSA 11.7 85 DMSA -47 4.9 243.1 
MF66-PEG 12 111.3 PEG -28.3 7.4 307.0 
VSOP-C200 5 9 Citrate anionic 7.4 49.8 
   
7.2.3. Experimental Setup 
For each SPION we prepared eight different concentrations (1.6 mM, 1.2 mM, 0.8 mM, 0.6 
mM, 0.4 mM, 0.2 mM, 0.1 mM and 0.05 mM) by two-fold serial dilution in 2 ml non-conical 
Eppendorf tubes. We used inductively coupled plasma mass spectrometry (ICP-MS) to 
determine the exact iron concentration. All contrast agents were treated for 15 minutes in an 
ultrasound bath before scanning to avoid agglomeration. The Eppendorf tubes containing the 
SPION solutions were placed in a 5 mm thick custom-made Perspex holder perpendicular to the 
main magnetic field and suspended in water within a 140 mm crystallising dish (Technische 
Glasswerke Ilmenau GmbH, Ilmenau, Germany) (figure Figure 77). To assess the homogenous 
distribution of the SPIO nanoparticles in solution, we visually inspected the phantom before and 
after the scan session to ensure that there were no accumulations. The slice orientation for all 
scans was chosen to be coronal. Imaging was performed with a slice in the middle of the water 
level to achieve optimal magnetic field homogeneity. The phantom was positioned between the 
two elements of a medium-sized SENSE flex coil to receive the MR signal. Imaging was 
performed on a clinical 3T Philips Achieva MRI scanner (Philips Healthcare, Best, The 
Netherlands). 
 
Figure 77: MRI water phantom containing eight SPION concentrations and an Eppendorf tube 
containing olive oil in the centre. a: Photos illustrating the design of the phantom and the 
Perspex disc used to hold the Eppendorf tubes. b: Coronal MR image (gradient-echo 




7.2.4. Positive Contrast Imaging 
All scans were performed with a 2D gradient-echo acquisition where k-space was filled in a 
Cartesian fashion. The acquisition pixel size was 1 x 1 mm2 with a field of view of 170 x 170 
mm2. Apart from the 0"∗-weighted imaging sequence used for the SGM technique, all 
acquisitions had a reconstructed pixel size of 0.53 x 0.53 mm2 and the SGM input data had a 
reconstructed pixel size of 0.27 x 0.27 mm2. The readout direction was foot-head. Shimming 
was performed using the build-in volume shim function where the region of interest included 
the entire water phantom. We saved modulus, real, and imaginary DICOM images from all 
acquisitions for future analysis. 
 
For the GRASP and IRON implementations we devised and developed a dynamic preparation 
phase to optimise the positive contrast imaging parameters by dynamically loop through the 
user-defined rephasing gradient strengths (GRASP) or frequency offset (IRON).   
 
7.2.4.1. SGM 
The postprocessing technique was applied to images acquired with a 0"∗-weighted multi-shot 
fast gradient echo sequence (five echoes) with a TFE factor of 1, a user defined shot interval of 
300 ms (170 shots), TR/TE1/∆TE = 10/2.2/1.7, a flip angle of 25°, and 3 mm slice thickness.  
 
7.2.4.2. GRASP 
Images were acquired with a user defined TR of 50 ms and the shortest TE possible (1.36 ms). 
The flip angle was 25° and the slice thickness was 7 mm. GRASP was run with SPIR fat 
suppression. We ran two acquisitions with 11 dynamics each. The first acquisition started at a 
rephasing gradient strength of 100% which was reduced by 10% with each dynamic. The 
second acquisition was based on the most promising area for positive contrast achievement. In 
our case, the second acquisition contained 11 dynamics and started at a rephasing gradient 
strength of 60% of the original strength which was decreased by 2% with each dynamic. 
 
7.2.4.3. IRON 
IRON was acquired with a multi-shot turbo field echo sequence (TFE factor = 12) with ten start 
up echoes and a user defined shot interval of 1000 ms (14 shots), TR (user defined)/TE 
(shortest) = 10/1.36, a flip angle of 18°, and 20 mm slice thickness. The IRON pulse was 
selected with an offset frequency of 135 Hz and a bandwidth of 679 Hz. We used six dynamics 
and for each dynamic the frequency was increased by 15 Hz. We ran IRON with SPIR and 
multi-echo Dixon in order to compare both fat suppression techniques with respect to effective 
fat suppression for positive contrast imaging. For the Dixon technique (figure 78) the number of 
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echoes was increased to two with TE2 (shortest) = 2.5 ms and the Dixon frequency shift set to 
3.4 ppm, to account for the water-fat frequency shift. 
 
Figure 78: Sequence diagram IRON. a: Gradient-echo sequence with SPIR pre-pulse followed 
by a frequency-selective IRON pre-pulse. One echo is acquired in the imaging part. b: Only one 




The Dixon technique used for the acquisition of positive contrast images was performed with a 
multi-shot turbo field echo sequence (TFE factor = 12) with ten start up echoes and a user 
defined shot interval of 1000 ms (14 shots), TR (user defined)/0[1 (shortest)/0[" (shortest) = 
24/3.5/9.3, a flip angle of 18°, and 3 mm slice thickness. We saved the water, in-phase, out-of-
phase, and fat images for each acquisition for further analysis in DICOM format. The Dixon 
frequency shift was varied from 3.4 ppm to 0 ppm in steps of 0.1. The water fat shift was set to 
2 pixels (108.45 Hz/pixel).  
 
7.2.5. Image Analysis 
Regions of interest (0.12 cm2) were centred over the coronal images of the Eppendorf tubes to 
obtain the signal intensity (SI) for each ROI. The operator ensured to stay clear of the tube edge 
in order to avoid local inhomogeneities caused by the Eppendorf tubes which could distort the 
measurement. In order to measure the noise, a ROI of 10.20 cm2 was placed outside the 
phantom in the background of the MR image. The area of positive contrast enhancement was 
determined by visual inspection and a region of interest was drawn by an operator in 




7.3. Dixon optimisation 
To get an indication for the positive contrast imaging capacity of Dixon for a given SPION 
water phantom, we manually altered the frequency shift between the in-phase and out-of-phase 
images from 0.1 ppm up to 3.4 ppm in steps of 0.1 ppm. The SPION used were VSOPs (VSOP-
C200, anionic citrat coating, 5 mm core, 9 mm hydrodynamic diameter) of 1.2 mM, 0.6 mM, 
0.3 mM and 1.5 mM. In addition, the phantom contained a vial filled with water as a control and 
a centre vial filled with olive oil. The aim of this optimisation step was two-fold. First, we 
wanted to test if with the simple code alteration we implemented that allows us to manually 
change the frequency shift, we could generate positive contrast images where the VSOPs would 
be hyperintense while the signal from water phantom would be suppressed. Second, we wanted 
to find the optimal frequency shift for which the difference in contrast between VSOPs and 
water was maximised.  
 
Figure 79: Depiction of Dixon fat images for a range of frequency shifts from 3.2 ppm to 0.2 
ppm and the resulting change in contrast behaviour. As the frequency shift was changed, the 
out-of-phase echo time increased. 
 
Figure 79 shows that Dixon is in general able to produce positive contrast images. There appear 
to be several ranges of frequency shift where good positive contrast images are possible. Each 
of these is followed by a range of less well suited frequency shifts. The ideal frequency shift for 
positive contrast imaging was determined by quantifying the signal intensity of the vial with the 
highest VSOP concentration (1.2 mM), olive oil, and water and to identify regions where the 
VSOP signal intensity was greatest while those of olive oil and water were low (figure 80). We 
measured the water signal in the phantom body as well as within the control PCR tube to detect 




Figure 80: Graphical representation of the signal intensity of the highest VSOP concentration, 
olive oil mimicking fat, water, and the signal intensity of the phantom water for frequency shifts 
ranging from 0.1 ppm to 3.4 ppm in steps of 0.1 ppm. 
 
Figure 80 confirms that there are several ranges of frequency shifts where the iron oxide 
particles display a higher signal intensity compared to the water phantom. The ideal imaging 
range lies between 1.5 and 2.0 ppm as well as 2.4 ppm and 2.5 ppm where the VSOP vial 
possess the highest signal intensity. 
 
All of the above was done on the so-called fat images. However, Dixon produces in total 4 
different images. It records the in-phase and out-of-phase images from which it calculates the 
water and fat images. Even though we are not looking to employ Dixon for fat suppression, we 
will keep the terminology of water and fat images. Below we show the water, in-phase and out-





Figure 81: Depiction of Dixon water, in-phase and out-of-phase images. Selection of images 
with a frequency shift between 3.4 ppm and 0.1 ppm. 
 
The signal from water protons in the phantom appear to be low at frequency shifts of 1.3 ppm 
and 0.1 ppm. Contrary to the Dixon fat images from figure 79, the VSOP solutions themselves 
are not highlighted in any of the images. Instead, the dipole field of VSOP1 and VSOP2 are 
visible on several images across water, in-phase and out-of-phase images. Neither the on-
resonant signal suppression nor the hyperintensity of off-resonant protons is comparable to the 
Dixon fat images. 
 
7.4. Results 
In order to explore our simple Dixon implementation for SPION positive contrast imaging, we 
conducted a range of experiments assessing the contrast behaviour of different SPIONs with 
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Dixon, compared Dixon to other more established positive contrast imaging methods in terms of 
image appearance and SPION concentration dependence of hyperintense contrast. 
 
7.4.1. Comparison of Ferumoxytol, MF66-DMSA and MF66-PEG with Dixon 
positive contrast imaging 
Based on the above described optimisation experiments, we selected a frequency shift at which 
we felt optimal positive contrast images could be achieved. We compared three different 
SPIONs in terms of their contrast behaviour, Ferumoxytol, MF66-DMSA and MF66-PEG. The 
MF66 particles are identical apart from their coating which determines surface charge and 
hydrodynamic diameter.  
 
Dixon fat images were acquired at a frequency shift of 1.9 ppm for ferumoxytol and MF66-
DMSA and at 1.8 ppm for MF66-PEG. Figure 82 shows the positive contrast images obtained 
with the Dixon method for eight different SPION concentrations (1.6 mM, 1.2 mM, 0.8 mM, 
0.6 mM, 0.4 mM, 0.2 mM, 0.1 mM, and 0.05 mM). The higher SPION concentrations display 
the dipole field as positive contrast.  
 
Figure 82: Positive contrast images Dixon fat images of eight different concentrations of 
ferumoxytol, MF66-DMSA, and MF66-PEG. Higher SPION concentrations display the lobes of 
the dipole field extending outside of the tube hyperintense whereas lower concentrations show 
hyperintensity inside the tube compared to the dark, signal suppressed water of the phantom. 
 
On first sight, there appears to be a difference in terms of contrast behaviour and detection limit 
for the two types of SPIONs, ferumoxytol and the MF66 nanoparticles. Differences between the 
different SPIONs are also visible on Dixon water images at a frequency shift of 2.5 ppm. The 
images of figure 83 show good background suppression of the water signal while displaying 




Figure 83: Dixon water images at a frequency shift of 2.5 ppm for ferumoxytol (a,d), MF66-
DMSA (b,e) and MF66-PEG (c,f). Images a-b are the original with the default window width 
and level. For images d-f the window width and level was altered to highlight features. 
 
Compared to the whole phantom fat images from figure 79, the background suppression 
achieved is more convincing and only fails at the edge of the phantom in the head-toe direction. 
The SPIO nanoparticles and their associated dipole fields are clearly visible as hyperintense 
signal while the vial containing water is not. 
 
7.4.2. Comparison of SGM, GRASP, IRON, and Dixon for Novel MRI Contrast 
agents 
An overview of the different positive contrast imaging techniques for three different SPIONs is 
presented in figure 84 which also includes 0"∗ -weighted gradient echo images that are the input 
for the calculation of the SGM images. Ferumoxytol, MF66-DMSA, and MF66-PEG were 
measured with a phantom that allowed to fit up to nine PCR tubes while the phantom used for 
the VSOP measurements only caters for up to six PCR tubes. The SGM images were calculated 
by taking into account three neighbouring pixels. The GRASP images were acquired at a 




Figure 84: Summary of four different positive contrast techniques (SGM, GRASP, IRON, and 
Dixon) for four different superparamagnetic iron oxide nanoparticle (ferumoxytol, MF66-
DMSA, MF66-PEG, VSOP). 
 
We were unable to obtain good positive contrast images with GRASP for the MultiFun SPIONs 
(MF66-DMSA and MF66-PEG). The IRON images were acquired at a frequency shift of 180 
Hz which led to good background signal suppression while preserving the hyperintense signal 
of the SPION vials. In the case of ferumoxytol and VSOP, the signal intensity appears to be 
concentration dependent. Suppression of signal from the centre tube that contained olive oil was 
achieved by using the SPIR technique. The Dixon images were acquired at frequency shifts of 
1.9 ppm (ferumoxytol, MF66-DMSA), 1.8 ppm (MF66-PEG), and 1.6 ppm (VSOP). 
Background suppression with the Dixon technique was compromised in the phantom used to 
measure ferumoxytol, MF66-DMSA, and MF66-PEG.  
 
7.4.3. Concentration Dependence of Positive Contrast Techniques 
We investigated the relationship between the positive contrast achieved (i.e. SNR or 
hyperintense area) and the concentration of the SPIONs investigated. For GRASP and IRON, 
the positive contrast does not normally extend outside of the borders of the measurement tube. 
We determined the signal-to-noise ratio (SNR) and plotted that over the concentration of the 
SPION. For the SGM and Dixon techniques where the positive contrast is mostly visible in 
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form of a dipole field that extends outside of the tube border, we determined the volume of the 
hyperintensely enhanced area and plotted that over the SPION concentration. Figure 85. 
summarises the results of concentration dependent measurements. 
 
Figure 85: Relationship of positive contrast and SPION concentration for SGM, GRASP, IRON, 
and Dixon fat image for ferumoxytol (a), MF66-DMSA (b), and MF66-PEG (c). A linear 
relationship is observed for ferumoxytol whereas GRASP and IRON for MF66-DMSA and 
MF66-PEG behave in a non-linear fashion. 
 
It can be seen from figure 85 that ferumoxytol follows a linear relationship for all positive 
contrast techniques. The MultiFun samples MF66-DMSA and MF66-PEG produce a linear 
relationship only for those techniques that measured the area of positive contrast. 
 
7.4.4. Fat suppression for positive contrast imaging with IRON: SPIR vs Dixon 
In the previous sections, we have introduced Dixon as a new positive contrast imaging 
technique that allows visualising iron-oxide based contrast agents. In the literature however, 




Figure 86: Comparison of SPIR and Dixon fat suppression in combination with IRON positive 
contrast imaging. a: IRON image of eight ferumoxytol concentrations and a tube containing 
olive oil (centre) using SPIR and Dixon, respectively. b: Comparison of SNR of each vial 
(SPION concentration and fat) for IRON. c: Percentage difference of the SNRs from figure 86b 
showing the largest difference for the fat signal. 
 
The positive contrast methods presented in figure 84 used SPIR as a fat suppression technique. 
Instead, Dixon can also be used to effectively suppress fat signal in GRASP and IRON 
acquisitions as it is a highly effective fat suppression technique [347]–[349]. Here we compare 
IRON acquisitions with SPIR and Dixon fat suppression for positive contrast imaging. Figure 
86a presents two images of the ferumoxytol phantom acquired with IRON. The two scans only 




Figure 87: Positive contrast images acquired with IRON for ferumoxytol, MF66-DMSA, MF66-
PEG, and VSOP. The top row shows images acquired with SPIR fat suppression and the bottom 
row shows water images acquired using Dixon. For all SPIONs, the Dixon fat suppression is 
superior to SPIR. 
 
The tube with olive oil sits in the centre and a better signal suppression is achieved when Dixon 
is used. For quantification we determined the SNR of all eight SPION vials as well as the oil 
and water signals and presented these in a bar diagram in figure 86b. The biggest difference in 
SNR between the two images is observed for the oil tube. This becomes clearer from figure 86c 
where we have plotted the percentage difference between the SNR bars from figure 86b. This 
illustrates that the SNR difference between the ferumoxytol vials are very small while there is a 
large difference between the SNR of the oil tube when using Dixon instead of SPIR. 
Furthermore, figure 87 shows that for positive contrast imaging with IRON, Dixon results in 
superior fat suppression than SPIR irrespective of which SPION is used. 
 
7.5. Discussion 
7.5.1. Dixon optimisation 
The Dixon fat images of figure 79 demonstrate that positive contrast imaging using Dixon is 
feasible. A problem at all frequency shifts in vitro is the lack of water suppression at the edge of 
the phantom near the air/water interface along the readout direction (foot-head). The ideal 
frequency shifts to achieve a positive contrast image were between 1.5 – 2.0 ppm and 3.0 – 3.2 
ppm. At 3T, these frequency shifts correspond to 189 – 252 MHz and 378 – 403.2 MHz, 
respectively. At these frequency shifts, the signal from fat remained high. Between 0.5 – 0.6 
ppm, 0.8 – 1.1 ppm, 2.3 – 2.6 ppm and 3.4 ppm, fat had a stronger signal intensity than VSOP1. 
At the other frequency shifts, the VSOP signal was superior but the fat signal remained high. As 
163 
 
lower VSOP concentrations will result in weaker signal intensity, it will be challenging to 
differentiate fat from those. 
 
The best image was obtained at a frequency shift of 1.6 ppm. The overall appearance of the 
image is that the signal from the water phantom is predominantly suppressed resulting in a 
darkened image. There are bands towards the phantom edges in the head-toe direction where the 
signal increases. A bright patch is visible towards the right-toe edge of the phantom. As the 
edge of the phantom is an area of inhomogeneity due to the phase transition, the overall signal 
suppression of on-resonant protons was successful. The PCR tubes containing VSOP1 and 
VSOP 2 (i.e. 1.2 mM and 0.6 mM) are hyperintense. VSOP3 and VSOP4 appear similar to the 
control vial containing water. The small increase in signal in these three vials must be attributed 
to the PCR vial itself rather than the VSOP solution. Looking at figure 80, the signal intensity of 
the control vial is more than 5 times higher than that of the phantom water and similar to the 
signal intensity of fat. The signal intensity of the phantom water was measured in the space 
between the centre tube (fat) and the control vial filled with water. Comparison of the SNR in 
the control tube and the surrounding water in the phantom demonstrates that the PCR tubes 
change the local magnetic field which results in a frequency offset.  
 
The detection limit of any SPION-based contrast agent depends on the concentration and the 
special resolution of the MRI scan. The latter is predominantly determined by the strength of the LM field [350]. The detection threshold for VSOP particles is 0.6 mM. VSOP1 and VSOP2 
introduce field inhomogeneity that protrudes outside the PCR tubes visible in the hyperintense 
dipole field lobes. The vial containing fat also shows small dipole lobes in the left-right 
direction. A small band of hyperintensity is visible towards the edge of the PCR tube in the toe-
direction. A key challenge for further development will be an effective fat suppression method.  
 
It is not surprising that the water, in-phase and out-of-phase images did not lead to superior 
positive contrast images compared to the fat images. For a given chemical shift value, the in-
phase image is acquired at a TE so that the two signal components separate by that given 
chemical shift are in phase. The out-of-phase image is acquired at a ∆0[ later where those two 
components are 180∘ out of phase. The signal that leads to the in-phase image is therefore a 
combination (i.e. addition) of the two signal components that are separated by a given chemical 
shift value. The opposite is true for the out-of-phase image where the overall signal is a 
subtraction of the two signal components. The resulting images still display various shades (i.e. 
signals) because we never operate in a perfectly homogenous magnetic field and there are many 
more than just two signal components. By definition, neither the in-phase nor the out-of-phase 
acquisition should result in the isolation of a particular proton signal. The water and fat images 
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are obtained from mathematically combining the in-phase and out-of-phase images. As the 
chemical shift we change is always in relation to a set standard, in this case water, the water 
image will be the same as for any Dixon fat suppression acquisition and highlight the on-
resonant water protons. The water image obtained for a frequency shift of 1.3 ppm is interesting 
in that respect. The range of different signals in a water phantom like we used is obviously 
complex. There are not just two or three different, sharply defined signals. While the two signal 
components that are separated by a chemical shift of 1.3 ppm are being perfectly in-phase and 
out-of-phase, signals slightly off of that will not be. This is not surprising as the PCR tubes, the 
phantom walls and the inhomogeneity of the magnetic field itself contribute to a range of 
different resonant frequencies. The display of the water image at 1.3 ppm supports this as the 
VSOP itself in the PCR tubes are not shown while the background suppression is a lot weaker 
compared to the fat images. Apart from that, the images shown in figure 81 confirm what was 
expected that for the correct chemical shift that relates to the off-resonant protons affected by 
the SPIONs, the fat images will be displayed as positive contrast images for a given SPIO 
nanoparticle. 
 
7.5.2. Comparison of Ferumoxytol, MF66-DMSA and MF66-PEG with Dixon 
Positive Contrast Imaging 
The lower the concentration of the SPIONs, the more signal appears to be within the PCR tube. 
We used the shortest echo time possible for the Dixon imaging experiment. As a result, the 
sequence was 01-weighted which explains the 01 effect we observed for lower SPION 
concentrations. The main difference between ferumoxytol and the two MF66 nanoparticles is 
that ferumoxytol exhibits a 01 effect even at higher concentrations. The hyperintense signal as a 
result of the off-resonant protons due to the SPIONs that affected the magnetic field is clearly 
visible for the three highest concentrations (0.8 mM, 1.2 mM and 1.6 mM) in the form of dipole 
field lobes. Dipole field lobes are still visible for 0.6 mM and 0.4 mM for all three SPIONs but 
significantly less distinct. For the lowest concentrations (i.e. below 0.2 mM), these are absent as 
the magnetic moment of the SPIONs is not strong enough to extend outside of the PCR tube. 
Not considering the contrast resulting from the 01 effect, the detection limit is at 0.4 mM for all 
three SPIONs. Both are lower than the detection threshold of VSOP used for the optimisation. 
The reason for the detection limit is that very small concentrations might only lead to intravoxel 





7.5.3. Dixon Water Images 
The water images of Ferumoxytol and the MF66 particles at 2.5 ppm (315 MHz) compare to the 
water image of the VSOP phantom at 1.3 ppm in terms of contrast quality. In the unaltered 
images (figure 83a-c), a 1 cm grey band is visible along the edge of the phantom in head-
direction where the on-resonant water suppression failed. The reason for that is the change in 
the magnetic field strength across the phantom that is less homogenous towards the phantom 
edges. A much narrower grey band is observed in the toe-direction suggesting the phantom has 
not be perfectly placed the isocentre of the magnet. By slightly altering the window width and 
level, we obtained figure 83d-f where the features of a positive contrast image for SPION 
detection are enhanced. Figure 83 confirms the results of figure 82 with regards to the different 
positive contrast behaviour of the three SPIONs. Both MF66 particles display a very similar 
contrast. This was expected as the particle and its magnetic moment that is responsible for 
changing the Larmor frequency of surrounding water protons is the primary driver for the 
contrast behaviour. The coating on the other hand seems almost negligible with regards to 
contrast behaviour and is primary responsible for stabilising the nanoparticle, functionalisation 
and physiological targeting. At lower concentrations, the MF66 solutions are hyperintense while 
at higher concentrations, only the only the lobes of the dipole field affecting the surrounding 
protons are visible. The ferumoxytol phantom displayed a different behaviour. As the SPION 
concentration increases and the hyperintense dipole fields become larger and more pronounced, 
the positive contrast of the ferumoxytol solution increases as well. MF66 particles have a higher 
transverse relaxivity value than ferumoxytol (table 2) which means they have a stronger 
magnetic moment. For the highly concentrated vials, the offset is likely to be too high to register 
and instead the surrounding water protons affected by the SPION solution are hyperintense as 
the effect is weaker there and the Larmor frequency lies within the range that is being 
highlighted. As the concentration is decreased, the MF66 solution itself will fall within the 
visible range. For MF66-PEG, the optimal concentration appears to be at 0.6 mM where the 
solution has the strongest signal. As ferumoxytol has a weaker magnetic field, the signal from 
the ferumoxytol solution increases with concentration. The control water vial is not visible in 
figure 83 indicating effective on-resonant water suppression. 
 
7.5.4. Comparison of SGM, GRASP, IRON, and Dixon for novel MRI contrast 
agents and assessment of their concentration dependence 
In figure 84 we compared the different SPIONs for their positive contrast imaging capabilities 
across a range of different positive contrast imaging techniques (i.e. SGM, GRASP, IRON and 





The 0"∗-weighted gradient-echo images (5th echo) of figure 84 show a stronger darkening of the 
MF66 nanoparticles. This is in agreement with the above discussion and the higher magnetic 
moment of the MF66 nanoparticles. Furthermore, these SPIONs also have higher transverse 
relaxivities compared to ferumoxytol and VSOP as shown by table 2. With the 0"∗ mapping 
images as input for the SGM algorithm, the MF66 nanoparticles produce larger hyperintense 
areas. Comparing the SGM images of the different SPIONs, the signal intensity and area of the 
hyperintense signal does not correspond to transverse relaxivity or the negative contrast 
achieved on GRE images. The MF66 particles have a much stronger magnetic moment and also 
show a much more intense darkening on GRE images. However, the positive contrast achieved 
on the SGM images is only marginally stronger than that of ferumoxytol and VSOP. Looking at 
the capability to quantify, we plotted the area of positive contrast over iron concentration (figure 
85) which showed a linear relationship. Visual inspection of the SGM images does not initially 
suggest that the method can be used for quantification due to the small positive contrast area for 
all MF66 concentrations tested here. The detection limit with SGM appears to be quite low. For 
all SPIONs, the vial with the lowest concentration produces a hyperintense rim and is visible on 
the SGM images. The control vial filled with water is also visible demonstrating that the PCR 
tube has an effect. However, the vial with the lowest SPION concentration had a clearly 
increased positive contrast for ferumoxytol and the MF66 nanoparticles. Hence, a detection 
threshold of at least 0.05 mM (possible lower) can be assumed. For the much weaker VSOP 
particles, a clear difference between the control vial and the VSOP vial was only visible at an 
iron concentration of 0.3 mM. 
 
We were unable to obtain good positive contrast images using GRASP for the MF66 
nanoparticles. Strong hyperintensity is observed for the ferumoxytol vials containing 1.6 mM, 
1.2 mM, 0.8 mM and 0.6 mM. A small hyperintense dipole lobe is visible in the head-direction 
at two highest concentrations. Apart from that, the contrast in those four vials appear similar 
(visual inspection of GRSAP image) and unrelated to the SPION concentration which was 
confirmed with figure 85. At 0.4 mM, hyperintensity within the PCR tube disappears and 
instead a hyperintense rim is visible. The PCR tube containing 0.2 mM is only marginally more 
pronounced than the control vial. In comparison to the control PCR tube, 0.4 mM can be seen as 
the detection limit. However, given the change in contrast leading to hyperintensity of the 
ferumoxytol solution itself, a detection limit of 0.6 mM is more convincing. Plotting the signal-
to-noise ratio measured with ferumoxytol over the iron concentration (figure 85) displays a 




We achieved IRON images with all four nanoparticles. Fat suppression of centre vial (olive oil) 
was successful for all SPIONs. In comparison with ferumoxytol and VSOP, the signal intensity 
of the MF66 nanoparticles was lower and did not correlate with the SPION concentration 
(figure 85). As the concentration increases, more MF66 nanoparticles will be contained within 
the PCR tubes. As the particles have a strong magnetic moment, it is likely that at higher 
concentrations, they start to accumulate very quickly. This will affect the 0"∗ measurements but 
not the negative contrast on GRE images as the tubes overall will still introduce strong 
inhomogeneities in the main magnetic field. As the particles accumulate, it is likely that the 
frequency offset changed and we did not have the correct setting to accurately image the off-
resonant protons for the vials with higher concentrations. In figure 85 we can see a linear 
relationship for the MF66 nanoparticles up to 0.4 mM/0.6 mM which is the tipping point. For 
higher concentrations, the SNR decreases again linearly as the concentration is increased 
further. 
 
Dixon is a phase-based technique and we have discussed the image appearance above. In 
comparison to the other positive contrast techniques, Dixon shows a greater tendency to also 
display the dipole field lobes which is the dominant feature for Dixon across all SPIONs 
investigated in this study. To assess its capability of iron quantification, we plotted area of the 
hyperintensely displayed dipole lobes over the iron concentration (figure 85) which gave a 
linear relationship. However, there are several limitations with that result. For once, lower 
concentrations display almost no dipole lobes. Secondly, for the MF66 nanoparticles there is a 
change in contrast appearance from showing the lobes hyperintensely to also displaying the 
MF66 solution itself when moving towards lower concentrations. In the case of ferumoxytol, 
the SPION solutions themselves have increased signal intensity for all concentrations but these 
are not concentration dependent and our results rely on the dipole field area alone. As discussed 
above, it is likely that for the range of SPION concentrations that we had within our phantom 
(not considering the VSOP phantom which contained a narrower range), one setting (here: 
phase difference) is not able to provide the optimal imaging parameter that leads to the optimal 
contrast for all concentrations. This suggests that our simple implementation of Dixon positive 
contrast imaging could potentially be used to detect SPIONs but is unlikely to provide reliable 
results for iron quantification. 
 
7.5.5. Fat Suppression for Positive Contrast Imaging with IRON: SPIR vs Dixon 
We investigated the merits of SPIR and Dixon for fat suppression in combination with the 
IRON technique (figure 86a). The vial containing olive oil was suppressed more successfully 
with Dixon than with SPIR. To demonstrate that the Dixon fat suppression does not have a 
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negative effect on signal generation of protons affected by SPIONs, we measured the SNR of all 
vials for Dixon and SPIR (figure 86b). SNR of the bulk water was determined from the average 
of four ROIs placed around the centre tube. For seven out of eight vials (i.e. vials 1-7), the SNR 
of IRON with Dixon was higher than that with SPIR which demonstrates that Dixon achieves a 
better fat suppression while simultaneously increasing the positive contrast effect of the iron-
based nanoparticles. Even though the same ROI was used for the analysis, a limitation is that 
the ROI had to be placed manually on the hyperintense SPION vials and position variation 
could have attributed differences in the signal intensity between the two scans. From visual 
comparison of figure 86a, the only noticeable difference is in the fat suppression. This is 
confirmed in figure 86c where we show the percentage difference between the SNRs measured 
with Dixon and SPIR (figure 86b). These findings confirm that Dixon was superior to SPIR and 
thus the preferred fat suppression method in combination with the IRON sequence. As a 
chemical-shift based technique, SPIR is affected by susceptibility effects introduced by field 
inhomogeneities (e.g. SPIONs, PCR tubes etc) in both the LM and L1 fields [351]. These can 
lead to incomplete fat suppression and also water suppression. Dixon on the other hand is 
known to be less sensitive to LM and L1 field inhomogeneity [352] which leads to improved 
SPION signal and superior fat suppression compared to SPIR. 
 
In order to expand the validity of these results, we also compared IRON scans with Dixon and 
SPIR for other iron-based MR contrast agents (VSOP, MF66-DMSA, MF66-PEG). These are 
shown in figure 87 and confirm that for all SPIONs, a superior fat suppression was achieved 




8. Measurement of fg/fg∗  and fj relaxivities in novel iron-
oxide nanoparticles 
8.1. Introduction 
When brought into an applied magnetic field, different materials display different magnetic 
properties. In chapter 5 the different types of magnetism that molecules and materials can adopt 
have been described. These are diamagnetism, paramagnetism, ferromagnetism and 
superparamagnetism. Iron oxides can be synthesised in many forms with different 
stoechiometric relations between iron and oxygen. They are characterised by a large magnetic 
moment when brought into an external magnetic field. The two most prominent forms for MRI 
applications as contrast agents are magnetite and maghemite [224] whose inverse spinel 
structure and general characteristics are described as well in chapter 5. 
 
8.1.1. Relaxation 
Molecules and particles in a fluid diffuse at temperatures above absolute zero. In an aqueous 
solution of iron oxide nanoparticles, the diffusion correlation time for water is 
 ùÚ = /"⁄  (172) 
with R being the radius of the nanoparticle and D being the diffusion coefficient of water [224]. 
Because the magnetic moment of the iron oxide nanoparticles is much larger than the nuclear 
moment of the hydrogen atoms of the surrounding water molecules, magnetic dipole 
interactions occur [353] which is explained by the outer-sphere relaxation theory [354], [355]. 
According to that, proton relaxation is based on the diffusion of water molecules in the vicinity 
of the iron oxide nanoparticles. The nuclear spins of the water protons dephase due to the 
inhomogeneous magnetic field established by the iron oxide nanoparticles. The relaxation due 
to the outer sphere theory extends to large distances due to the large size of iron oxide 
nanoparticles [354]. The magnetic moment of the nanoparticles increases as the external 
magnetic field is increased. Changing the magnetic moment of the nanoparticles can induce 
proton relaxation and this is referred to as Curie spin relaxation [356]. 
 
When water molecules diffuse in the magnetic field of the iron oxide nanoparticles, the water 
protons experience a magnetic field difference of ΔLãuyy = − 1. Δm¤LM with LM being the 
external magnetic field strength and ∆m¤ being the difference in magnetic susceptibility 




In aqueous solution the magnetic moment of iron oxide nanoparticles is influenced by two 
different rotation modes, Néel [357] and Brownian [358] relaxation. Néel relaxation is the basis 
of the iron oxide nanoparticles’ superparamagnetic behaviour. A characteristic of iron oxide 
nanoparticles is that they are smaller than a single magnetic domain. The magnetic moment of 
each nanoparticle aligns along certain preferred axes which are called easy axes or easy 
directions. This would mean that the nanoparticles are permanently magnetised even when not 
exposed to an external magnetic field. However, the magnetisation vector fluctuates between 
different easy directions which mean the time-averaged magnetisation is equal to zero. This 
fluctuation is described with a correlation time ùQ and called Néel relaxation. ùQ becomes 
infinite when an external magnetic field is applied and the magnetic moments align with the 
external magnetic field. 
 
Néel relaxation describes any rotation of the magnetisation vector within the nanoparticle, 
whether it is fluctuation between different easy axes or the rotation associated with the 
alignment with an externally applied magnetic field [357]. The Néel rotation correlation time is 
given by 
 ùQ = 10mng hoîhR i‰j (173) [õ is the anisotropy energy of magnetite and [O is an additional anisotropy energy term that 
accounts for the fact that in reality iron oxide nanoparticles are not perfect spheres [353]. While 
Néel relaxation describes the rotation of the magnetisation vector within the nanoparticle, 
Brownian relaxation is the rotation of the whole nanoparticle which consequently also rotates 
the magnetisation vector [358]. The Brown rotation correlation time is given by 
 ùo = 3ÀÁVÊ0 (174) 
with V being the volume of the nanoparticle and Á is the viscosity of the fluid. The overall 
rotation correlation time is defined by taking both the Néel and Brown relaxation correlation 
times into account. 
 
1ùõ = 1ùQ + 1ùo (175) 
The Néel contribution to the rotation of the magnetization of a magnetic nanoparticle in a 
colloidal suspension goes up exponentially as the volume of the nanoparticle increases. For that 
reason, the Brownian relaxation contribution becomes more dominant for larger nanoparticles 
[353]. 
 
8.1.2. pg relaxation 
Depending on the size of the iron oxide nanoparticles, different processes dominate the 
transversal relaxation behaviour in MRI. For small nanoparticles of less than 14 nm in diameter, 
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the 0" relaxation is governed by Néel relaxation and diffusion 1ñ = 1ñq + 1ñr. The water diffusion 
is extremely fast for small nanoparticles which means that the spatial variation of the magnetic 
field vector is averaged out. Relaxivity is therefore determined by the outer sphere theory. The 
ratio of the transversal and longitudinal relaxivities (see below) is low in this case [359].  
 
For larger nanoparticles up to a few hundred nanometres in diameter, Néel relaxation becomes 
negligible and 0" relaxation is predominantly governed by rapid diffusion 1j©st = §	æ	 Δw" ùÚ 
with æ being the effective volume fraction of nanoparticles in solution which depends on the 
nanoparticle concentration. The parameter § is a scaling factor which increases for larger 
particles as motional averaging becomes ineffective. Overall, the outer sphere theory governs 
the relaxation behaviour of nanoparticles of this size. 
 
Iron oxide nanoparticles that are bigger than a few hundred nanometers but less than a few 
micrometers fall within the intermediate regime where ùÚm1 is of similar order as the change in 
Larmor frequency (Δw). The behaviour of nanoparticles of this size presents a difficult case 
because the approximation of motional narrowing is not valid anymore due to the much slower 
water diffusion. However, the nanoparticles are not big enough to be considered static. 
Nanoparticles of this size produce a clear and distinct difference in the measurement of 0" (spin 
echo) and 0"∗ (gradient echo) [353]. 
 
For SPIONs that are larger than several micrometers, the static dephasing regime applies. 
Diffusion does contribute negligibly to the reorientation (ùÚm1 ≪ Δw) because the water protons 
can be considered static. In this case, 0"m1 is directly proportional to the change in the Larmor 
frequency [360]  
 
10"u„ = §	æ	Δw (176) 
For stationary nanoparticles, the scaling factor § is equal to 29(3 3) [361]. The same equation 
is valid for 0"∗ when using a gradient echo instead of a spin echo sequence.  
 
8.1.3. Comparing contrast agents – the relaxivity 
Contrast agents shorten the relaxation time constants 01, 0" and 0"∗. Some contrast agents 
shorten 01 and 0" to the same extend. These are called 01 agents or positive contrast agents. 
Others will mainly shorten the transversal relaxation time constant and they are called 0" agents 




10" = 10",M + !"[{µ] (177) 0",M is the 0" measured when no contrast agent is in solution, 0" is the relaxation time constant 
with contrast agent present. 0"m1 is called relaxation rate and [CA] is the contrast agent 
concentration. The constant of proportionality is the relaxivity which is the slope of the linear 
function obtained when plotting the relaxation rate with contrast agent over the the 
concentration of the contrast agent. The relaxivity is usually given in XCm17m1. The 
relaxivities for 01 and 0"∗ can be defined analogous to the above. Determination of the relaxivity 
provides a quantity independent of the contrast agent’s concentration that allows in vitro 
comparison of its efficiency to increase the respective relaxation rate [353], [356]. 
 
8.1.4. The effect of clustering on the relaxivity 
The formation of clusters through the aggregation of iron oxide nanoparticles has an effect on 
the 01, 0" and 0"∗ relaxivities. Clusters can be loosely or tightly packed. 0" and 0"∗ relaxivities 
generally increase through agglomeration. In the case of loosely packed clusters this increase is 
expected to be linear with cluster size. As long as water access to the iron oxide cluster is not 
limited through aggregation, longitudinal relaxation is expected to remain constant even when 
the cluster size increases. At the clinical field strength of 3T, 01 relaxivity is expected to 
decrease while 0" and 0"∗ relaxivities strongly increase. The latter to a much greater extend than !" [356].  
 
8.1.5. Compartmentalisation of iron oxide nanoparticles 
Compartmentalisation is another effect, observed in in vivo applications of contrast agents, that 
has an effect on the measured relaxivities. Compartmentalisation refers to the trapping of 
nanoparticles in a confined space where water exchange is limited. An example is the 
internalisation by cells where nanoparticles can be trapped in cytoplasmic, subcellular and 
vesicular (i.e. endosomal and lysosomal) compartments. It was observed that the relaxation time 
of iron oxide nanoparticles internalised by cells increases well beyond what was measured with 
the same contrast agent concentration in a control experiment. An increase in the relaxation time 
results in a decrease of the respective relaxivity. The reason for that is the limited water 
exchange which ultimately leads to a saturation of the relaxivity. When plotting the relaxation 
rate over the contrast agent concentration, the obtained graph would be no longer linear but start 
to plateau. 
 
Water exchange is an important concept when discussing compartmentalisation of MRI contrast 
agents. In the case of a fast exchange regime, water exchanges very quickly between 
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compartments, i.e. the water exchange rate is faster than the relaxation rate difference between 
different biological compartments. The result is that the relaxation behaviour of the contrast 
agent is as if it was distributed uniformly across the compartments. If the water exchange rate is 
considerably slower than relaxation rate difference between compartments, the concept of one 
relaxivity value for the tissue under consideration becomes meaningless. In this slow exchange 
regime, different compartments relax completely independently and have their separate 
relaxation times. The most common case however is that water exchange is neither slow nor fast 
(intermediate exchange regime) and the relaxation behaviour becomes bi-exponential [353], 
[356]. 
 
8.1.6. pg∗  relaxometry 0"∗ relaxometry allows to gain information about microscopic magnetic field inhomogeneities. 
At the same time, it is desirable to avoid macroscopic field distortions such as those intrinsic to 
the main magnetic field LM and inhomogeneities originating from air-tissue interfaces [141].  
Macroscopic susceptibility artefacts lead to an overestimation of /"∗. Reduction of the echo time 
and the selection of a high spatial resolution (i.e. small voxel size) minimise the macroscopic 
effects [362]. By analytically evaluating the background gradient and transverse relaxation it 
was shown that with the optimisation of three successive slice-refocusing gradients an optimal 
signal recovery at a particular TE can be achieved [147]. Calculation of the ∆LM values can also 
be used for a post-processing correction algorithm of the 0"∗ map. The advantage of this 
correction is that no additional scan is needed as the ∆LMvalues can be extracted from 0"∗ 
weighted multislice data [143]. It has recently been reported that the measurement of the LM 
field to correct for field inhomogeneities to perform /"∗ mapping has been extended to 3D 
acquisitions. This method also allows for water-fat separation by using a sequence based on the 
chemical-shift in combination with short echo spacing [363].  
 
8.1.7. Purpose of present work 
In this chapter the MRI characterisation (i.e. the 01, 0" and 0"∗ mapping in order to determine 
the SPIONs respective relaxivity value) of 23 novel iron-oxide nanoparticles is presented. These 
nanoparticles were developed by the MultiFun project and synthesised by collaborators from 
different laboratories. Four commercial samples (FeraSpin XS, FeraSpin XXL, Ferumoxytol 
and VSOPs) were also included in the study for comparison. The nanoparticles under 
investigation vary in terms of their core and hydrodynamic diameter, coating material and 
surface charge. 
We first optimised the experimental setup for the MRI characterisation. This consisted of the 
development and optimisation of the MRI phantom, the selection of the correct receiver coil 
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setup and the determination of the range of SPION concentrations and number of different 
concentrations. This was followed by the optimisation of the 01, 0" and 0"∗ mapping sequences 
in terms of number of echoes acquired, echo time, repetition time and resolution. 
In order to evaluate and optimise the technique used for analysing the MRI data and calculating 
the relaxivity values, we compared three techniques (1. In-house Matlab algorithm, 2. Free 
software ImageJ, 3. In-house Excel worksheet and algorithm). This was done with a commercial 
sample for which a reference relaxivity was available in the literature.  
The main purpose of this investigation was the determination of the !1, !" and !"∗ relaxivities of 
all 24 novel iron-oxide nanoparticles in water as well as the four commercial samples. This 
study provides the opportunity compare and discuss all three relaxivities (i.e. !1, !" and !"∗) for a 
wide range of iron-oxide nanoparticles of different sizes, coating materials and surface charges. 
Based on these results we selected SPIONs to be characterised in breast and pancreatic cancer 
cells. We looked at two things in particular, the first being the effect of sonication on the 
relaxivity of cancer cells incubated with iron-oxide nanoparticles. Furthermore, it has been 
reported in the literature that R2 and R2* mapping can be used to differentiate between free and 
cell-bound SPIONs by MRI. Cell-bound SPIONs show higher R2* values compared with free 
SPIONs whereas R2 is higher for free iron [118]. The second goal of our in-vitro study was 
therefore to reproduce these results with our novel iron-oxide nanoparticles. Literature reports 
suggest that this was only done in one type of SPION. We therefore aimed to extend this 
investigation by comparing five selected SPIONs of different characteristics (size, coating 
material) to evaluate if the type of SPION has any effect on this behaviour. 
 
8.2. Methods 
8.2.1. Superparamagnetic Iron Oxide 
We investigated 27 different SPIONs (table 3) regarding their 01, 0" and 0"∗ contrast 
characteristics using a 3T clinical MR scanner. Of those 27 SPIONs, four are commercially 
available (FeraSpin XS, FeraSPin XXL, Ferumoxytol and VSOP) and Ferumoxytol is also a 
clinically approved MR contrast agent. VSOP is the smallest particle in this study with a 
hydrodynamic diameter of 9 nm. Ferumoxytol has the smallest core with 3.25 nm. All other 
SPIONs are novel and were synthesised for use as multifunctionalised nanoparticles for cancer 
targeting, detection, and treatment [364]. Most SPIONs in this investigation were either coated 
with dimercaptosuccinic acid (DMSA), polyethylene glycol (PEG) or dextran. The intracellular 
and in vivo characteristics of MR iron-oxide based contrast agents strongly depend on the 
coating, charge as well as on the hydrodynamic particle size. Therefore, we investigated 
SPIONs with different hydrodynamic diameters ranging from 9 nm up to 1238 nm. Table 3 
summarises all SPIONs investigated in this study and lists their respective characteristics (i.e. 
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iron oxide core size, hydrodynamic diameter, coating, and surface charge). Anionic SPIONs 
were selected because they have been shown to have a high affinity for the cell membrane and 
are their efficiency to be internalised is therefore significantly higher compared to neutral or 
positively charged SPIONs [365]. DMSA, PEG, and Dextran coating has been proven to be well 
suited for biomedical applications due to their good stability and low toxicity [366]–[368]. 
 
Table 3: Superparamagnetic iron oxide nanoparticles investigated with their core size, 
















ADNH 6 150 Aminodextran 35 5.5 7 
ASi 8.5 60 Aminosilane 35 7.5 7 
A 35 175 No coating -10 20 7 
A22APS 17.5 98 
Aminopropyl-
silane (APS) 
--- 5 --- 
OD7 7 60 DMSA -40 13.5 7 
OD10 10 60 DMSA -40 1.9 7 
OD15 15 60 DMSA -40 0.5 7 
OD18 18 60 DMSA -40 2.6 7 
OD7-P2 7 ? PEG Anionic ? 7 
OD15-P5 15 95 PEG Anionic ? 7 
OD15-P10 15 103 PEG Anionic ? 7 
OD15-P20 15 110 PEG Anionic ? 7 
FF-NX-PAA 5 97 Polyacrylacid -37.8 4.19 7 
FF-NX-PVP 7 279 PVP ? 0.35 7 
F1566 8.5 45 Dextran -6.5 10 6.8 
F1563 10 1235 PEI -26.5 10 4.1 
F1706 11.7 159 Dextran T40 -18 10 7.1 
F1780 10 101 DMSA -44 3.3 ? 
MF66-DMSA 12 85 DMSA -47 10 4.9 
MF66-PEG 12 111.3 PEG -28.3 5.3 7.4 
MF66-N6L 12 140.8 DMSA -45.3 2.4 7.5 
MF71 12 203 CM-Dextran -35 7 5.1 
MF74 12 90 DMSA -49 10.4 5.6 
FeraSpin XS --- 18 Carboxy Dextran -24 0.56 7 
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FeraSpin XXL --- 65 Dextran -24 0.56 7 
Ferumoxytol 3.25 23.6 PSC -43.2 30 7 
VSOP 5 9 Citrate Anionic --- 7 
 
 
8.2.2. Phantom preparation 
We prepared five different concentration of each SPION by two-fold serial dilution (1.2 mM, 
0.6 mM, 0.3 mM, 0.15 mM and 0.075 mM). The dilutions were prepared to a volume of 1.5 ml 
and contained in 2 ml non-conical Eppendorf tubes. The exact concentration of iron was 
determined by inductively coupled plasma mass spectrometry (ICP-MS). All contrast agents 
were suspended in an ultrasound bath for 15 minutes shortly before the MR measurements. This 
ensured a homogenous distribution of the iron oxide particles and to avoid large agglomerations 
or sedimentation. 
 
We used a 140 mm crystallizing dish (Technische Glasswerke Ilmenau GmbH, Ilmenau, 
Germany) as a water phantom (figure 88). A 5 mm thick custom-made Perspex disk was used as 
tube holder. The Eppendorf tubes were immersed in the water phantom for all imaging 
experiments. A slice in the middle of the water volume was selected for all scans to minimise B0 
field inhomogeneity effects. 
 
 
Figure 88: MRI water phantom showing five SPIONs being measured at the same time each of 
them with five different concentrations. 
 
8.2.3. Cell Culture and Cell Labelling 
MDA-MB-231 cells (ATCC, Wesel, Germany) were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) 25 mM glucose, 1 mM sodium pyruvate and 44 mM sodium 
bicarbonate, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
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Glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. All reagents were purchased 
from Sigma, Poole, United Kingdom. Cultures were seeded into flasks containing supplemented 
medium and maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air. All cells 
used in this study were used at a low passage number (<13). For assays, MDA-MB-231 cells 
were sub-cultured in 6-well plates at a seeding density of 120000 cells per well. The following 
day, sterile stock solutions of the SPIONs were sonicated and serial dilutions were prepared in 
complete medium without FBS to prevent nanoparticle aggregation. Cells were then incubated 
for 24 h with 5 different concentrations of the SPIONs (1.2, 0.6, 0.3, 0.15, 0.075 and 0.038 
mMFe). After the incubations, cells were gently but thoroughly washed with PBS, detached and 
resuspended in 750 µl DMEM, transferred to polypropylene tubes and mixed with 750 µl of 5% 
polyvinyl alcohol (PVA; Sigma, Poole, United Kingdom) to increase viscosity and allow for 
MR imaging of a homogeneous distribution of cells inside the tubes. PVA is nontoxic and is 
currently used as eye lubricant. It has been shown to be suitable for various biomedical 
applications [369]–[374]. Sterile stock solutions of the SPIONs were sonicated again and new 
serial dilutions of the SPIONs (750 µl at the aforementioned concentrations: 1.2, 0.6, 0.3, 0.15, 
0.075 and 0.038 mM Fe) were freshly prepared in complete medium without FBS, mixed with 
750 µl of 5% PVA and placed in a phantom alongside the cell suspensions for MRI. 
 
8.2.4. MR Imaging of Phantom 
MR imaging was performed with a two element SENSE flex coil M on a clinical 3T Philips 
Achieva MRI scanner (Philips Healthcare, Best, The Netherlands). 01 maps were acquired by 
using a 2D sequence that employs two non-selective inversion pulses ranging from 20 to 2000 
ms, followed by eight segmented readouts for eight individual images [99]. The two imaging 
trains result in a set of 16 images per slice with increasing inversion times (3.2 repetition time 
[TR], 1.6 ms time to echo [TE], 10° flip angle, FOV 200x200 mm2, acquisition matrix 200x179, 
in-plane resolution 1x1.12 mm2, 3 mm slice thickness = 3 mm). 0" maps were obtained with a 
2D multi-spin-echo sequence. For each spin-echo, the full k-space data was collected. Five 
images were reconstructed at five different echo times to provide equidistant samples along the 
decay curve of transverse magnetisation for 0" determination (725 ms TR, 10 ms echo spacing 
[TE], 90° flip angle, FOV 200x200 mm2, acquisition matrix 200x200, 3 mm slice thickness). 0"∗ 
maps were acquired with a 2D multi-gradient-echo sequence. We sampled the full k-space for 
each gradient-echo and acquired five echoes for 0"∗ determination (11 ms TR, 1.95 ms to first 
echo, 1.7 ms interval between subsequent echoes, 25° flip angle, FOV 200x200 mm2, 




The Eppendorf tubes were placed in the water phantom so they were perpendicular to the main 
magnetic field LM . The slice orientation for the 01, 0" and 0"∗ mapping sequences was chosen 
to be coronal because in axial acquisitions, corrections for through-slice field variations would 
need to be made. Whether in plane corrections for coronal and sagittal acquisitions are 
necessary is unclear [363]. For this reason we acquired coronal slices for the determination of 0"∗ to avoid macroscopic LM inhomogeneities in the slice direction which could corrupt our 
measurements. Regions of interest (ROI, mean size 14.29 ± 1.71 mm2) were centred over the 
coronal images of the Eppendorf tubes to obtain the signal intensity (SI) for each ROI. The SI 
was plotted over the echo spacing and a monoexponential general reduced gradient algorithm 
(Microsoft Excel, Microsoft, Redmond, Washington, U.S.) was used to determine the 0" and 0"∗ 
values for each SPION concentration. These transverse relaxation times were converted to 
relaxation rates /" and /"∗ and plotted over their respective concentrations for each SPION.  To 
assess the homogenous distribution of the iron oxide particles in solution and of the iron oxide 
incubated cells suspended in polyvinyl alcohol (PVA) we visually inspected the phantom before 
and after the scan session to ensure that there were no accumulations of SPIONs or SPION-
loaded cells in our Eppendorf tubes. 
 
8.2.5. Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
Iron concentrations of all the previously MRI scanned serial dilutions of SPIONs and cell 
suspensions were determined by ICP-MS. Briefly, samples were digested in 70% nitric acid 
overnight at room temperature, followed by dilution in deionised water. A standard curve was 
acquired with each sample set for iron concentration determination. 
 
8.3. Results 
8.3.1. Phantom development and optimisation for relaxivity measurements 
The first step for the accurate measurement of relaxivities was the development of a suitable 
MRI phantom. We used 0.5 ml Eppendorf tubes with five different SPION concentration that 
were arranged in a circle around a mass of blu-tec putty and pressed into the putty to stay in 
place (figure 89). The blu-tec putty was enclosing the Eppendorf tubes from one side which had 




Figure 89: First MRI phantom. 0.5 ml Eppendorf tubes arranged around blu-tec putty. a: Several 
phantoms, one for each SPION. b: Four phantoms in a flex receiver coil. c: Eight phantoms in 
two flex receiver coils. 
 
The next phantom was custom-built from two Eppendorf tube racks (for 0.5 ml tubes) made of 
plastic (figure 90). It allowed for easy exchange of the tubes and we produced prototypes in 
various sizes and shapes (squared, circular). The problem with this setup was the small volume 
of the Eppendorf tubes which made it difficult to accurately prepare the different SPION 
concentrations. The small cross section of the Eppendorf tubes meant that we had difficulties 
drawing a region of interest during data analysis by leaving sufficient space to the tube wall. 
The major limitation was the difficulty to transform this design to a water phantom. 
 
Figure 90: Second MRI phantom custom built from Eppendorf tube racks. a: Example of a 
squared phantom. b: Phantom in a flex coil setup. 
 
In order to achieve a more homogenous magnetic field within the measured samples, a water 
phantom was considered favourable. To overcome the limitations of the 0.5 ml Eppendorf 
tubes, they were replaced with 1.5 ml Eppendorf tubes. A circular tube holder was made from 
cork. The holder had holes drilled into it that would hold the Eppendorf tubes. The cork holder 
with sample tubes could stand in a 140 mm crystalizing dish that could be filled with water 
(figure 91). Sample tubes were arranged in a circle with enough distance between the edge of 
the phantom (air/water interface) and each other to minimise field interferences. During longer 
measurements the cork tube holder would start to soak up the water and increase in size which 




Figure 91: Third MRI phantom (water phantom). Tube holder made from cork with holes to 
hold 1.5 ml Eppendorf tubes. a: Water phantom from the side. Cork holder thickness was 1 cm. 
b: Phantom from the top showing circular arrangement of sample tubes. c: Water phantom 
shown in measurement setup with a flex coil. 
 
As a result, we replaced the cork tube holder with one made from Perspex (figure 92). In order 
to stay in place, the Eppendorf tubes were sealed with Parafilm that stopped the tubes from 
moving. We developed two Perspex holders, one with a circular arrangement that could hold up 
to six sample tubes for a single measurement and another one designed to measure several 
SPIONs at once with a total of 37 holes as sample holders (figure 88). 
 
Figure 92: Final water phantom using a Perspec tube holder. A: 1.5 cm Eppendorf tubes with 
SPIONs of different Fe concentrations. The top is sealed with Parafilm. 
 
In order to assess the homogeneity in the main magnetic field within the phantom (figure 93a) a LM field map (figure 93c) was acquired. A LM field map represents the phase difference of two 
images at different echo times acquired with a gradient-echo sequence (multishot TFE, 7.4 ms 
TR, 3.8 ms TE, 25° flip angle, FOV 200x200 mm2, acquisition matrix 400x400, 3 mm slice 
thickness). It depends on the phase evolution ΔΘ over ∆0[ under the local magnetic field and 
can be calculated with ∆LM |, }, E = 1";>∆jh 	∆Θ(|, }, E). By extracting the phase evolution 
from the difference of two images at different echo times, effects common to both images are 
eliminated and represent the field inhomogeneity [375], [376]. We have defined areas within the 
phantom for comparison that comprise a collection of Eppendorf tubes (phantom positions) as 
shown in figure 93b. The LM field susceptibility in the core9 area lies between -26.06 Hz and -
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8.67 Hz, the core16 area is ranges from -6.78 Hz to 41.11 Hz, and the core25 area which is 
core9 and core16 combined therefore contains LM field susceptibility values from -26.06 Hz up 
to 41.11 Hz. The averages of the outerHEAD and outerTOE area are 76.03 ± 3.28 Hz and 90.12 ± 3.05 Hz, respectively. Both averages are higher than the highest phase value from the core25 
area which is 41.11 ± 12.10 Hz. The average phase value of the outerLEFT and outerRIGHT 
areas are 13.62 ± 1.98 Hz and 23.33 ± 2.14 Hz, respectively. These are similar to the phase 
values of the core25 area. LM field susceptibility measurements directly at the edge of the 
phantom close to the water/air interface for the head, toe, left, and right positions were 224.43 ± 
25.38 Hz, 261.97 ± 28.90 Hz, 34.61 ± 11.38 Hz, and 47.75 ± 12.91 Hz, respectively. 
 
 
Figure 93: Assessment of water phantom for LM homogeneity. a: 2D gradient-echo image 
displaying the water phantom with 37 Eppendorf tubes filled with tap water. b: Areas defined in 
the phantom in order to compare phase values and assess LM homogeneity. c: LM field map used 
to assess the homogeneity of the main magnetic field inside the water phantom. 
 
8.3.2. MRI sequence optimisation 
The 01 mapping sequence had been optimised by previous lab members and a detailed sequence 
description is available in the literature [99]. The sequence had to be used in combination with a 
patch and required a heart rate simulator as it was initially developed for cardiovascular 
imaging. We adapted the field of view to our phantom size. No further optimisation was 
required. 
 
For 0" and 0"∗ mapping the literature suggests to treat even and odd echoes separately in order to 
avoid phase influences that could impact the measurement [143]. In order to evaluate this effect 
on our measurements, we changed our mapping sequences to allow an echo train with 20 
echoes. This results in 10 echoes that can be used for the relaxivity calculations for either even 
or odd echoes. For the turbo spin echo sequence (0"), the time to first echo, echo spacing and 
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repetition time were set to shortest. For the turbo field echo sequence (0"∗), the repetition time 
was set to 420 ms while the time to first echo and echo spacing were set to shortest. 
 0" mapping parameters: Multishot TSE (20 echoes), TSE factor = 20, TE1 = 16 ms, echo 
spacing = 3.9 ms TR = 786 ms, slice thickness = 6 mm. 
 0"∗ mapping parameters: Multishot TFE (20 echoes), TFE factor = 1, TE1 = 2.4 ms, echo 
spacing = 1.8 ms, TR = 420 ms, FA = 25. 
 
We measured the !" and !"∗ relaxivities with above described sequences in three SPIONs. Two 
novel SPIONs, i.e. OD7-P2 and MF66-PEG, and one commercial sample (Ferumoxytol). The 
results are summarised in figure 94 presented as a bar diagram for easy comparison. The second 
graph shows the percentage difference of the above sequence using only even or odd echoes 
compared to using all echoes. 
 
 
Figure 94: Comparison of even and odd echoes for relaxivity determination. The comparison 
was conducted for three SPIONs, OD7-P2, MF66-PEG and Ferumoxytol. The second graph 
shows the percentage difference of using only even or odd echoes compared to using all echoes 





According to figure 94, the biggest variation in percentage difference is shown for the 0"∗ 
mapping result of MF66-PEG where the relaxivity measured with only even or odd echoes is 
38% and 16% lower compared to when using all echoes, respectively. For all other SPIONs 
tested, the percentage difference between considering only even or odd echoes compared with 
using all echoes was between 2% and 12%. We concluded that the effective impact on our 
measurements when using all echoes was low enough to consider all echoes in future 
measurements. 
 
8.3.3. Optimisation of data analysis 
We had three different methods available to us to analyse relaxation time mapping data. For one 
commercial particle (VSOP) all three methods were tested and compared. Literature values for 
the relaxivities of VSOP at 3T was available. 
 
8.3.3.1. Matlab algorithm 
Two Matlab applications were available in the department, one for the analysis of 01 mapping 
data and one for 0" mapping data. The application reads either the PAR or REC file recorded 
during data acquisition. The file formats of PAR or REC are favourable for image analysis 
applications over Dicom and can be read into our Matlab application using a specific read 
algorithm. 
 
Figure 95: Graphical user interfaces for 01 mapping data (a) and 0" mapping data (b). 
 
The Matlab application opens with a graphical user interface (figure 95). Scroll bars allow to 
scroll through slices (vertical) and echoes/images (horizontal) of the loaded dataset. The 
application allows the calculation of a 01 or 0" map (figure 96). Drawing a ROI on the 01/0" 




Figure 96: Graphical user interfaces for 01 mapping data (a) and 0" mapping data (b). 
 
8.3.3.2. ImageJ software 
ImageJ is an image analysis software tool freely available for download. Several add-ons are 
available to extent the basic functionality of the software package. Dicom images can be loaded 
in the software and ROIs can be drawn. A specific add-on was installed and used to for the 
calculation of /1 and /" maps. ImageJ requires the user to input time delays between echoes 
(images) as well as a cut off value. 
 
8.3.3.3. Osirix and Excel worksheet 
Instead of a Matlab algorithm, the relaxation rates can also be calculated using an MS Excel 
spreadsheet. Both templates (01 mapping, 0" mapping) are available in the appendix of this 
thesis. We first used Osirix to read in the Dicom files. ROIs were drawn and the signal 
intensities from all relevant vials were exported. The signal intensities were imported into 
Excel. 
 
The signal intensities from the 0" and 0"∗ mapping sequences provided by Osirix for each vial 
should decrease as the echo number increases. Should this not be the case (outliers), the 
operator can choose to disregard a value. The decrease of signal intensity with increasing echo 
number is described using an exponential equation from which the relaxation rate can be 




Figure 97: Summary of manual data analysis of 0"(∗) data. 
 
The 01 mapping data is acquired with a sequence of two trains of 8 acquisitions. The echo times 
are chosen so that the two trains are interleaved. Therefore, the images need to be sorted in the 
correct order upon loading into Excel. 
 
We used a Leven-Marquadt algorithm to model CW t = CM∗ − CM + CM∗ gmv jò∗ to the signal 
intensity data for each vial. The data is modelled by minimising the sum of squared differences 
between the measured and predicted signal intensity by changing CM, CM∗ and /1∗. From that, we 




Figure 98: Summary of manual data analysis of 01 data. 
 
8.3.3.4. Comparison of analysis techniques 
The relaxation rates obtained from the different analysis techniques have been plotted over the 
SPION concentrations (figure 99). This comparison shows that we are getting a very good 
correlation for all plots. The same set of mapping imaging data was used for all three analysis 
techniques and any differences in relaxivity are due to the different technique used. 
16	Images	along	the	T1 recovery	curve
Image	1 Image	2 Image	3 Image	4 Image	5 Image	6 Image	7 Image	8
Image	9 Image	10 Image	11 Image	12 Image	13 Image	14 Image	15 Image	16
Signal	intensity	over	echo	time	for	each	Fe	concentration
Signal	intensity	is	fitted	to	a	three-parameter	equation ! " = !$∗ − (!$ +!$∗)*+, -.∗⁄
01∗ can	be	calculated	by	using	a	least	squares	Levenberg-Marquardt	curve	fitting	algorithm
23 is	calculated	from	23∗ and	its	inverse	(43)	plotted	over	the	Fe	concentration
01 = 01∗ !$ +!$∗!$∗ − 1




Figure 99: Comparison of methods for calculating the relaxation rates used for relaxivity 
determination. a: Matlab algorithm (!1). b: Matlab algorithm (!"). c: ImageJ add-on (!1) – The 
data point for the 2nd highest Fe concentration was omitted (outlier). Only four data points were 
used for this relaxivity which can impact robustness of the result. d: ImageJ add-on (!"). e: 
Osirix and MS Excel (!1). f: Osirix and MS Excel (!"). 
 
The preferred data analysis technique for us was the combination of Osirix and MS Excel. The 
Matlab application might be accurate at times but we also had occasions where it failed to 
record a value or was not able to calculate a relaxivity map. The handling of ImageJ, especially 
the drawing of ROIs, was cumbersome and not as straight forward to use. 
 
Table 4: VSOP relaxivity values calculated with three different techniques, a Matlab 
application, ImageJ and Osirix in combination with MS Excel. 
 vj	mMm1sm1  vg	mMm1sm1  
Matlab 11.3 59.4 
ImageJ 21.4 51.5 
Osirix & Excel 16.5 49.9 





Table 4 shows a wide range of values for measuring the same relaxivities with different 
techniques. As the ROIs were drawn manually for each technique, this is likely to account for 
the discrepancies. To overcome ROI differences, we calculated the average for !1 and !" from 
the values in table 4 as 16.4 XCm17m1 and 53.6 XCm17m1, respectively. The linear plots 
(figure 99) of relaxation rate over SPION concentration had an /" of more than 0.97 for all 
three techniques (figure 99c only used 4 data points due to an outlier) indicating good precision. 
The !1 and !" values were summarised in table 4. The literature reports 20.1 XCm17m1 and 37.1 XCm17m1 for the longitudinal and transverse relaxivities of VSOP at 0.94 T, respectively [377]. 
Reference values at 3 T were not available in the literature. With increasing magnetic field 
strength, !1 decreases and !" increases [378]. Comparing the average values (at 3 T) with the 
literature values at 0.94 T shows that the measured values are within the expected range 
according to the literature. The advantage of the manual Excel method was that we had full 
control over the analysis, could select outliers if necessary and had confidence in the accuracy 
which is why we selected that method for all future measurements. 
 
8.3.4. Relaxivities in water 
The measured relaxivities (!1, !" and !"∗) of SPIONs investigated in this study are summarised in 
table 5. The longitudinal relaxivities vary from below 1 to 17.5 mM-1s-1. Transverse relaxivities 
are significantly larger and in most cases are of the order of several hundreds. For all SPIONs, !"∗ is larger than !" relaxivity. This is expected as 0"∗ should always be shorter than 0" because 
of the lack of a refocusing RF pulse in gradient echo sequences. 
 
Table 5: Summary of longitudinal and transverse relaxivities in aqueous solution of a wide 
range of SPIONs investigated in this study. Commercial particles are marked with an asterix 
(*). 
SPION 
vj	mMm1sm1  vg	mMm1sm1  vg∗	mMm1sm1  
ADNH 8.0 289.9 929.2 
ASi 11.1 118.0 272.0 
A 1.3 340.5 6207.2 
A22APS 0.01 15.1 77.3 
OD7 17.5 375.0 270.8 
OD10 5.6 63.0 144.7 
OD15 9.0 142.3 508.2 
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OD18 7.8 282.6 518.4 
OD7-P2 6.84 232.3 297.5 
OD15-P5 6.0 246.8 302.1 
OD15-P10 2.7 109.6 317.5 
OD15-P20 8.2 510.1 794.0 
FF-NX-PAA 5.0 40.5 49.7 
FF-NX-PVP 0.7 --- --- 
F1566 14.8 63.0 88.7 
F1563 5.6 150 861.9 
F1706 3.1 145.1 289.2 
F1780 6.7 275.2 370.2 
MF66-DMSA 2.4 242.5 390.1 
MF66-PEG 7.72 306.7 1082.2 
MF66-N6L 0.18 7.5 68.0 
MF71 1.4 110 287.8 
MF74 0.9 98.8 264.0 
FeraSpin XS* 9.0 58.0 75.9 
FeraSpin XXL* 5.8 130.0 502.8 
Ferumoxytol* 11.8 90.8 103.7 
VSOP* 13.0 49.7 51.5 
 
For comparison, we have included four commercial particles that are displayed at the bottom of 
table 5 and marked with an asterix (*). For better illustration, the measured relaxivity values 




Figure 100: Comparison of longitudinal (a) and transversal (b and c) relaxivities in aqueous 
solution for a variety of SPIONs. The !"∗ relaxivity of particle A has been excluded for scaling 
reasons of the ordinate axis in graph c. 
 
From figure 100 it is obvious that both transversal relaxivities generally follow a similar pattern, 
i.e. a particle that displays a high !" relaxivity also has a high !"∗ relaxivity compared to the 
other particles investigated. The !"∗ relaxivity of particle A has been excluded in figure 100c due 
to scaling reasons of the ordinate axis. The commercial samples generally have a lower 
transverse relaxivity compared to the other novel particles. This is not the case for the 
longitudinal relaxivities where the commercial samples show a stronger !1 effect. 
 
8.3.5. Relaxivities in cells 
A selection of SPIONs was incubated in breast (MDA-MB-231) and pancreatic (PANC-1) 
cancer cells. In vitro measurements in living cells contain cell media. To assess the influence of 
cell media on the relaxivity measurements we prepared SPION concentrations in cell media and 
measured !1, !" and !"∗ (table 6). 
 
Table 6: Transverse relaxivities (!1, !" and !"∗) of selected SPIONs (different coatings, sizes and 
charges) measured in cell media and polyvinyl alcohol. 
SPION 
vj	mMm1sm1  vg	mMm1sm1  vg∗	mMm1sm1  
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A22APS 1.4 93.8 4122.8 
OD10 1.0 40.1 605.3 
OD15 1.1 47.3 1187.5 
OD18 2.0 217.6 5874.3 
F1563 3.8 187.2 4770.7 
F1706 1.5 369.0 407.2 
F1780 3.2 254.5 1348.1 
MF66-DMSA 4.0 121.9 2084.5 
MF66-PEG 0.5 8.9 913.1 
MF71 15.0 1184.9 6705.6 
MF74 1.2 77.7 1040.0 
Ferumoxytol 23.4 151.2 170.7 
 
From table 6 it is obvious that the order of magnitude of !1 and !" measurements is similar to 
the results in water (table 5). The !"∗ measurements however are several orders of magnitude 
larger. To allow a better comparison, figure 101 compares the relaxivity measurements in water 
and cell media. 
 
Figure 101: Comparison of longitudinal (a) and transversal (b and c) relaxivities in water and 
cell media  for a variety of SPIONs. 
 
Figure 101a shows that there is no general trend for the longitudinal relaxivity. For some 
particles !1 decreases in cell media compared to the measurement in water and for other it 
increases. Figure 101b and c show a different situation for the transverse relaxation. Except for 
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MF66-PEG and MF71, the !" relaxivity in cell media and water are in good agreement, i.e. the 
same order of magnitude. For the !"∗ relaxivity, the cell media measurement is significantly 
larger than the one in water. The only exception to that is MF66-PEG. 
 
Table 7: Transverse relaxivities (!1, !" and !"∗) of selected SPIONs (different coatings, sizes and 
charges) measured after incubation in cancer cells in cell media and polyvinyl alcohol. 
 Breast Cancer Cells Pancreatic Cancer Cells 
SPION 
vj	mMm1sm1  vg	mMm1sm1  vg∗	mMm1sm1  vj	mMm1sm1  vg	mMm1sm1  vg∗	mMm1sm1  
A22APS 2.2 156.4 6330.3 1.4 472.2 3643.3 
OD10 1.0 28.6 3392.9 2.0 17.5 157.2 
OD15 1.7 --- 1583.5 1.6 65.3 1929.4 
OD18 1.4 116.2 931.7 1.5 114.8 3397.4 
F1563 --- 251.6 8222.0 0.7 29.8 2733.6 
F1706 9.1 21.9 160.6 --- --- --- 
F1780 35795 153.7 8174.7 --- --- --- 
MF66-DMSA 2.7 185.8 3414.9 --- --- --- 
MF66-PEG 0.5 138.8 1157.8 --- --- --- 
MF74 1.3 42.3 1081.9 --- --- --- 
Ferumoxytol 0.4 5.1 95.0 --- --- --- 
 
The relaxivity measurements in living breast and pancreatic cancer cells are summarised in table 
7. To allow for better comparison of the relaxivities presented in table 7, the results were 
summarised in figure 102. We show three bar diagrams for !1, !" and !"∗ where we compare 




Figure 102: Comparison of longitudinal (a) and transversal (b and c) relaxivities in cell media, 
incubated in MB-MDA-231 breast cancer cells and PANC-1 pancreatic cancer cells for a 
variety of SPIONs. 
 
Particle F1706 stands out as displaying a strong longitudinal relaxivity when incubated in 
cancer cells (figure 102a). The !" values of cell incubated particles are generally lower than 
those particles measured in cell media or water. Figure 102c shows that the !"∗ values of 
particles incubated in MD-MBE-231 cancer cells increases compared to measurements in 
media. 
 
8.3.6. Effect of cell sonication on relaxivity measurements 
Sonication of living cells in an ultrasound bath results in cell death. To determine whether 
relaxivity is the same in living and death cells, cancer cells incubated with nine different 
SPIONs was sonicated and their relaxivity measured again. All cancer cells were thoroughly 
washed before any imaging experiment commenced to ensure all SPIONs we detect with MRI 
are either internalised by the cells or stably bound to the surface of the cells. Results are 
summarised in table 8. 
 
Table 8: Longitudinal and transversal relaxivities of a selection of nine SPIONs measured after 
incubation in cancer cells (living) and then again after sonicating the SPION-incubated cells for 
10 min in an ultrasound bath. For two particles, marked with an asterix (*), not all relaxivities 




To compare pre- and post-sonication relaxivities for the above listed SPIONs, these have been 
illustrated in a bar diagram (figure 103).  
 
Figure 103: Comparison of pre- and post-sonication relaxivity measurements in a selection of 
different SPIONs. a: Longitudinal relaxivities. b: Transversal relaxivities. 
 
As can be seen from figure 103, post-sonication relaxivities are different from the pre-sonication 
measurements. Out of ten SPIONs, the !1 relaxivity increased for six after sonication. 60% of 
SPIONs had a post sonication !1 that was more than 50% different to the pre-sonication value. 
For !", eight of nine SPIONs showed a higher relaxivity post sonication. More than 50% of 
SPIONs were measured with a post-sonication value which was more than 50% different to its 
pre-sonication value. There does not appear to be a general trend and sonication seems to be 
more important for some SPIONs compared to others. The effect of sonication on the relaxivity 
measurement will be dependent on the colloidal stability of a particular SPION. 
 
vj	mMm1sm1  vg	mMm1sm1  
SPION Before After Before After 
A22APS 2.2 2.3 156.4 194.5 
OD10 (BCC) 1.0 7.7 28.6 300.1 
OD10 (PCC) 2.0 1.5 17.5 105.5 
OD15 (BCC)* 1.7 2.5 --- --- 
OD15 (PCC)* --- --- 65.3 364.7 
OD18 1.4 6.1 116.2 167.6 
F1563 0.7 4.9 29.8 1139.1 
F1780 3.6 2.8 153.7 81.7 
F1706* 9.1 2.0 --- --- 
MF66-DMSA 2.7 1.2 185.8 235.3 




8.3.7. Free vs cell-bound SPIONs 
It was reported in the literature that relaxivity behaviour is different between free SPIONs and 
particles bound to cells [118]. It was attempted to reproduce these results with a selection of five 
SPIONs, i.e. OD10, MF66-DMSA, MF66-PEG, F1706 and Ferumoxytol (table 9). 
 
Table 9: Superparamagnetic iron oxide nanoparticles investigated with their core size, 












n [mg Fe/ml] 
pH 
Ferumoxytol 3.25 23.6 PSC -43.2 30 7 
OD10 10 60 DMSA -40 1.9 7 
MF66-DMSA 11.7 85 DMSA -47 10 4.9 
MF66-PEG 12 111.3 PEG -28.3 5.3 7.4 
F1706 11.7 159 
Dextran 
T40 
-18 10 7.1 
 
Of those five SPIONs, Ferumoxytol is a commercially available and clinically approved MR 
contrast agent. The iron-oxide core of ferumoxytol is coated with polyglucose sorbitol 
carboxymethyl ether (PSC) and is the smallest of all SPIONs in this study with 23.6 nm. The 
other four SPIONs (OD10, MF66-DMSA, MF66-PEG, and F1706) are novel and were 
synthesised for use as multifunctionalised nanoparticles for cancer targeting, detection, and 
treatment [364]. Apart from PSC, SPIONs in this investigation were either coated with 
dimercaptosuccinic acid (DMSA), polyethylene glycol (PEG) or dextran T40. The intracellular 
and in vivo characteristics of MR iron-oxide based contrast agents strongly depend on the 
coating, charge as well as on the hydrodynamic particle size. Therefore, we investigated 
SPIONs with different hydrodynamic diameters ranging from 23.6 nm up to 159 nm. Table 9 
summarises all SPIONs investigated in this study and lists their respective characteristics (i.e. 
iron oxide core size, hydrodynamic diameter, coating, and surface charge). Anionic SPIONs 
were selected because they have been shown to have a high affinity for the cell membrane and 
are their efficiency to be internalised is therefore significantly higher compared to neutral or 
positively charged SPIONs [365]. DMSA, PEG, and Dextran coating has been proven to be well 




The measured !" and !"∗ values of all five SPIONs investigated in this study are summarised in 
table 10. The !"∗ relaxivity is always larger than the !" relaxivity. Because of the lack of a 
refocusing RF pulse 0"∗ is always shorter than 0" for gradient echo sequences. The problem is 
that the background gradient produced by the iron oxide particles is not cancelled by the GRE 
sequence [141]. Therefore, the relaxation rate (inverse of relaxation time) /"∗ will always be 
larger than /". The same is true for the relaxivities as they are simply the relaxation rates made 
independent of the iron concentration. 
 
Table 10: Transverse relaxivities (!" and !"∗) of ferumoxytol, OD10, MF66-DMSA, MF66-PEG, 
and F1704 measured in aqueous solution, cell media, and bound to or internalised by MDA-
MB-231 breast cancer cells. 
SPION Water Cell Media MDA-MB-231 
 vg	mMm1sm1  vg∗ mMm1sm1  vg	mMm1sm1  vg∗ mMm1sm1  vg	mMm1sm1  vg∗ mMm1sm1  
Ferumoxytol 90.8 103.7 165.2 174.3 5.1 95.0 
OD10 108.2 144.7 43.3 658.9 46.9 1256.3 
MF66-
DMSA 
243.1 391.7 145.1 1567.7 185.8 3414.9 
MF66-PEG 307.0 1081.6 8.9 913.1 138.8 1157.8 
F1706 144.8 291.4 363.1 572.2 21.9 160.6 
 
The MR signal intensity, which is related to the 0" and 0"∗ relaxation times in spin echo and 
gradient echo MR sequences, varies for different concentrations of the same SPION as well as 
from one sample to another. As the SPION concentration in water, media or cells increases in a 
sample vial, the MR signal decreases. In the magnetic field of an MRI scanner, SPIONs 
introduce field inhomogeneities within their microenvironment which leads to a shortening of 
the 0" time constant as the magnetic moments of protons dephase. From comparison of the free 
SPIONs in aqueous solution with the free SPION measurements in cell media, both transverse 
relaxivities of ferumoxytol and F1706 increased while MF66-PEG decreased. For OD10 and 
MF66-DMSA !" decreased and !"∗ increased. When comparing the relaxivities of free SPIONs 
in water with bound SPIONs (i.e. bound to the cell surface of the cell membrane or internalised 
and compartmentalised by the cell), ferumoxytol and F1706 behave in the same way as both 
transverse relaxivities decrease. OD10, MF66-DMSA, and MF66-PEG show the behaviour 
described by Kuhlpeter et al. [118] where !" decreases and !"∗ increases. The relaxivities of 
these three nanoparticles increase from the free state in media to the bound state. In cells, these 
three SPIONs achieve extremely high !"∗ values which is different for OD10 and MF66-DMSA 
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to their free !"∗ values in aqueous solution. MF66-PEG was measured with high relaxivity 
values in all three states (free in water, free in media, and bound in cells) but in particular the !"∗ 
value in water is unusually high. 
 
The aforementioned decrease of !" and increase of !"∗ when SPIONs are bound to cells is 
illustrated in figure 104. We have plotted the /"(∗) values of each SPION over the iron oxide 
concentration. The gradient of the linear fit is the relaxivity !"(∗) summarised in table 10. 
Ferumoxytol shows a decrease in its !"∗ value from free to bound. However, there is a clear 
increase in the angle between the /" and /"∗ fits (figure 104a). This is also the case for OD10 
(figure 104b), MF66-DMSA (figure 104c), and to a lesser extent for MF66-PEG (figure 104d). 
The !"(∗) values of F1706 decrease from free to bound conditions with no noticeable change in 











Figure 104: Graphs displaying linear relationship of /" and /"∗ for ferumoxytol (a), OD10 (b), 
MF66-DMSA (c), MF66-PEG (d), and F1706 (e) in aqueous solution (free SPION) and cells 
(bound SPION). When bound, !" decreases and !"∗ increases compared to the free state which 










8.4.1. Phantom development and optimisation 
The phantom used for the relaxivity measurements has developed from an improvised Blu Tack 
mould core surrounded with sample tubes to a water phantom. A water phantom was used to 
minimise all magnetic field distortions (e.g. at phase transitions between air and aqueous 
solution) except those caused by the superparamagnetic contrast agents. All distortions cause 
intra-voxel spin dephasing and a reduction in signal. It is therefore essential to minimise LM 
inhomogeneities to measure SPION relaxivities accurately. 
 
Spatial variation of LM can originate from the different magnetic susceptibilities in the various 
tissues in the body to be scanned. For in vitro studies, the phantom’s shape and composition are 
major factors influencing main magnetic field homogeneity. 
 
Inhomogeneities in the main magnetic field (e.g. in a body or around an object such as a MRI 
phantom) can be assessed with a LM field map [379], [380]. Two gradient echo images are 
acquired at different echo times and the phase difference is calculated [380], [381]. The LM 
phase map will be skewed from intrinsic 0"∗ decay, imperfections in the excitation phase or if 
the signal maximum is not recorded in the centre of k-space [375]. 
 
Phantom development for this study was motivated by three considerations. First, to minimise 
sharp edges. All objects or bodies introduced in a magnetic field causes field distortions to a 
certain extent. Objects that are round without any sharp edges and made up of a homogenous, 
non-magnetic material cause minimal LM field disturbance. Second, the size (volume) of the 
tubes or vials containing the SPION solutions needed to be big enough to prepare solutions of 
different SPION concentrations with a two-fold serial dilution and to conveniently draw regions 
of interest during the later analysis while avoiding the tube edges. Finally, the difference of 
magnetic susceptibility of the medium surrounding the tubes and the SPION solution needed to 
be minimised. Susceptibility effects are known to occur on phase interfaces such as air / 
polypropylene tube / SPION solution. By measuring the SPION vials in a water phantom we 
achieve more homogenous phase interfaces. 
 
A limitation of the final water phantom with Perspex holder that was used for all measurements 
are the larger 1.5 ml Eppendorf tubes which have a thicker polypropylene tube wall than other 
tubes that could have been used. Thin-walled NMR tubes made of glass might have been a 
suitable alternative to further minimise susceptibility effects. As shown in our LM field map 
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(figure 93), a larger phantom should have been used to ensure greater distance of the tubes from 
the phantom edges. Finally, the effects the magnetised SPION solutions could potentially have 
on each other was not evaluated. SPIONs can establish a strong magnetic moment when brought 
in a magnetic field and the magnetic field effects of each SPION tube in relation to the 
neighbouring tubes should have been evaluated. 
 
In this phantom study, the highest spatially varying susceptibility gradients were present at the 
edge of the curved phantom at the air/water interface (figure 93c). This is particularly 
pronounced in the head-toe direction along the field lines of the main magnetic field. The 37 
water-filled Eppendorf tubes can also be seen in the LM field map due to the susceptibility 
gradients at the water/Eppendorf tube/water interfaces. These gradients do not extent into the 
tube centre and have therefore negligible influence on the relaxivity measurements.  
 
The greatest homogeneity of LM field susceptibility values is present in the innermost core9 
area. The homogeneity is greatly improved in the core25 area compared to the entire phantom 
because of the strong susceptibility effects at the phantom edge. The four phantom positions at 
the corner of the core25 area have slightly higher LM field susceptibility values then all other 
core25 position because of the lack of shielding from other Eppendorf tubes as well as their 
position towards the head and toe edge of the phantom. The core25 area offers sufficient 




We have measured a range of different SPIONs in water, cell media and cells. But how does the 
medium in which the superparamagnetic iron oxide nanoparticles are dispersed effect the 
relaxivity measurements? 
 
Multiple studies have shown that the characteristics of a SPION contrast agent, whether for MR 
imaging, cell internalisation and tracking or simply in terms of biocompatibility depend on 
magnetic susceptibility, shape, size, size distribution and surface modification [382]–[385]. 
 
SPION relaxation is the result of a dipolar mechanism as fluctuating dipoles can result in spin 
relaxation due to the induction of spin transitions. This dipolar coupling depends on the distance 
between the magnetic moment of the hydrogen nucleus of the surrounding water and the 
electron magnetic moment of the iron II/iron III ion [386]. The Curie spin relaxation is the result 
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of Néel relaxation and water diffusion [356]. The former describes the flipping of the magnetic 
moment of the SPION particle from one anisotropy state to another [386].  
 
The medium in which the SPIONs are dispersed does not affect the Néel relaxation which 
depends on the particle size and the magnetic field strength. If the field strength becomes too 
high, the magnetic moment of the SPIONs will become locked onto the direction of the 
magnetic field in which case Neél relaxation is not possible [386]. 
 
For the relaxation of gadolinium complexes, the concepts of inner and outer sphere relaxation 
are relevant. There is no inner sphere relaxation for SPIONs. Outer sphere water does not 
conjugate to the particles as it is the case for Gd-complexes but is diffusing near the crystals. 
Important for SPION relaxation is the second sphere water. These water molecules hydrate the 
SPION crystals and their exchange constant is larger than that for water diffusion. Relaxivity 
relates to the number of water molecules that hydrate the SPION and for how long the water is 
coordinated to the nanoparticle [387], [388]. 
 
8.4.3. Relaxivities in water 
We observed a linear relationship between the iron concentration and the /1 and /"(∗) values in 
the phantom. Comparison of the relaxivity data presented in table 5 display considerable 
differences among the different SPIONs. This is because of different susceptibility effects 
exerted by the examined SPIONs which cause the shortening of the relaxation times. 
 
The highest longitudinal relaxivities were recorded from ASi, OD7, F1566, Ferumoxytol, 
FeraSpinXS and VSOP. From the range of SPIONs tested, these were the smallest particles 
according to SPION core (3.25 – 8.5 nm) and in solution (9 – 60 nm). Very low !1 values were 
measured for the A-series of particles, one without coating which showed immediate signs of 
agglomeration and sedimentation and one with APS coating. FF-NX-PVP was also observed to 
strongly agglomerate in solution. MF66-N6L is the MF66 particle functionalised with an anti-
cancer drug. The functionalisation had a clear effect on the particles ability to enhance 01 
contrast. The particle’s increased size and functionalisation has in impact on the water exchange 
capability which results in a lower !1 value. 
 
The background gradient produced by the iron oxide nanoparticles is not cancelled by the GRE 
sequence [141]. As a result, the relaxation rate (inverse of relaxation time) /"∗ will always be 
larger than /". The same is true for the relaxivities as they are simply the relaxation rates made 
independent of the iron concentration. The highest !" relaxivity was measured for OD7, OD15-
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P20 and MF66-PEG. These were closely followed by ADNH, OD18, OD7-P2, OD15-P5, 
F1780 and MF66-DMSA. The OD-particles were synthesised according to a co-precipitation 
method described by Salas et al [364]. The MF66-particles were synthesised according to the 
same method with the aim to reproduce the favourable OD-particles. The highest !"∗ relaxivity 
was measured for ADNH, OD15-P20, F1563 and MF66-PEG. Other particles of high !"∗ 
relaxivity were OD15, OD18, F1780, MF66-DMSA and FeraSpinXXL. Nanoparticles 
synthesised according to above mentioned method [364], i.e. OD-particles, MF66-particles as 
well as F1780, showed the strongest !"∗ relaxivity. 
 
Looking at the four commercial samples it is obvious that these have a stronger 01 effect than a 0" effect. FeraSpinXXL has the lowest !1 value among the four but the highest !" and !"∗ value. 
As FeraSpinXS and FeraSpinXXL were synthesised identically, the difference in transverse 
relaxivity is due to the larger particle size of FeraSpinXXL. It is known that nanoparticle 
aggregation leads to an enhancement of 0" and 0"∗ contrast [389]. It is possible that among 
identically synthesised SPIONs, those with larger core sizes have more favourable !" 
characteristics. 
 
Interesting to compare are OD15-P5, OD15-P10 and OD15-P20. These are identical particles 
synthesised from the same batch but then coated with different PEG chain lengths, i.e. 5k Da, 
10k Da and 20k Da. OD15-P20 has the most favourable contrast behaviour across !1, !" and !"∗. 
The !"∗ value of OD15-P10 was slightly higher and of the same order of magnitude than that of 
OD15-P5. The !1 and !" values of OD15-P5 were much higher than that of OD15-P10. 
Comparing all three nanoparticles, OD15-P10 with a PEG chain length of 10k Da appears to be 
least suitable of the three as an MRI contrast agents based on its relaxation enhancement 
capabilities. This shows that the relaxivity behaviour of SPIONs does not increase or decrease 
linearly with polymer chain length of the coating material. Hanot et al. [390] compared 
PEGylated SPIONs of 2kDa, 5kDa and 20kDa chain length for their uptake kinetics and 
cytotoxicity. They did not measure the nanoparticles’ relaxivities but found that the smallest 
particle (2k Da) was taken up to a lesser extent than the others while all three SPIONs had a 
similar positive surface charge. Among identical particles only varying in terms of the chain 
length of their polymer coating and therefore overall size, one might think that the smallest 
particle is taken up the most. This makes it clear that further studies are required combining 
magnetic and relaxivity comparisons with physicochemical and kinetic studies of identical 
SPIONs with different coating lengths to gain further knowledge about underlying processes 




MF66-DMSA and MF66-PEG are the same iron oxide particle but different coating materials. 
When comparing the two for their relaxivity behaviour, MF66-PEG was measured with higher !1, !" and !"∗ values. MF66-PEG has a physiological pH in aqueous solution making it more 
suitable for in vivo applications compared to the more acidic MF66-DMSA particle. MF66-PEG 
was measured with an unusually high !"∗ value in water. In media and when incubated in cells, 
MF66-DMSA displays higher longitudinal and transverse relaxivities. It is likely that DMSA 
does not effectively protect the MF66-particle in cell media where serum is present. The very 
high !"∗ values in media and cells are most likely the result of agglomeration after the DMSA 
coating failed to stabilise the solution. The PEGylated particle has a larger hydrodynamic 
diameter due to the bigger size of PEG. This could negatively influence in vivo behaviour such 
as pharmacokinetics and target tissue uptake but these were not assessed in this study. The 
higher relaxivity values in aqueous solution of MF66-PEG can be attributed to its coating as that 
is the only difference between both particles. Why the particle coated with PEG has more 
favourable relaxivity characteristics compared to the identical particle coated with DMSA is not 
clear. PEG as a coating polymer has been shown to provide good stability of a colloidal SPION 
solutions via steric repulsion [391]. It enables the conjugation of targeting ligands [384] and 
reliably reduces interactions of the SPION with plasma and serum proteins and that would 
otherwise lead to undesired opsonisation [224]. The effect PEG coating has on the relaxivity of 
an iron oxide nanoparticle, in particular r2, is currently unknown. No consistent results have 
been reported with maximum transverse relaxivity values reported at different molecular 
weights [384], [385]. This indicates that further studies on the effects of coating materials on a 
nanoparticles relaxivity behaviour on a molecular and sub-molecular level are required. 
 
8.4.4. Relaxivities in media 
Not many studies have focused on determining the relaxivities of SPIONs in cell media and 
assessed the specific effects this has on the SPION and its relaxivity. The medium in which the 
magnetic nanoparticles are dispersed has an effect on the water diffusion. Particles in a more 
viscous suspension diffuse at a lower rate than in a solution of lower viscosity [392]. For the 
measurements of cell media and cells, PVA was added to the medium to increase viscosity and 
keep the cells from sedimenting. This should have little effect on the in vitro cell measurements 
as SPIONs are either tightly bound to the cell surfaces or internalised when clustering and 
compartmentalisation effects are more relevant. However, for the relaxivity measurements of 
free SPIONs in cell media, the increase in viscosity results in a decrease of diffusion and a 




For the majority of SPIONs measured, !1 is smaller in cell media mixed with PVA than in 
water. Exception to this are A22APS, MF66-DMSA, MF71, MF74 and Ferumoxytol. In 
particular the particles MF71 and Ferumoxytol stand out. The !1 in cell media of the latter is 
almost twice as much compared to the water measurement and the !1 of MF71 is more than ten 
times larger in cell media compared to water. The reason for the strong increase in !1, especially 
that of MF71 is not clear. A small discrepancy from the expected behaviour could be attributed 
to measurement errors. The fact that the !1 in cell media is considerably larger than in water 
makes a measurement error unlikely. The characteristics of MF71 do not give any reason to 
suspect such a behaviour. The particle is quite large in solution with a hydrodynamic diameter 
of 203 nm and might be prone to agglomeration. However, agglomeration would decrease the 
longitudinal relaxivity, not increase it [394].  
 
For SPIONs up to a few hundred nanometres in diameter, the transverse relaxation depends 
mainly on diffusion. Néel relaxation becomes less relevant. A decrease of !" in the more viscous 
cell media would be expected compared to the water measurements. Overall, the !" values in 
media are similar to those in water. MF71 shows a strong increase in transverse relaxivity in cell 
media compared to water. It is not clear why MF71 displays this behaviour. A strong tendency 
to cluster could provide an explanation for the !" increase if the cluster size is of such that 
supports an increase in transverse relaxation. As MF71 displayed unexpected relaxation 
behaviour for both, !1 and !", it would worth to further investigate the origin of that behaviour. 
 
For all measured SPIONs except MF66-PEG, !"∗ in cell media is considerably larger than in 
water. Particles with PEI coating undergo direct agglomeration in the presence of fetal calf 
serum [395] which explains the very high !"∗ values for F1563 in media and cells.  
 
Due to the reduction in diffusion, transverse relaxivity is expected to decrease in cell media. 
Cell media contains a range of components such as nutrients, carboxyhydrates, various metals 
and minerals (calcium, magnesium, sulphates) and buffering agents (phophates, acetates). These 
co mponents have an impact on the clustering behaviour of SPIONs. Park et al. [396] reported 
that SPIONs start to aggregate in DMEM over a time period of hours due to the high salt 
content. Aggregation occurs because the salt blocks electrostatic repulsion between particles. 
The same authors reported that no aggregation was observed for hours when bovine calf serum 
was added to the DMEM. This effect was more pronounced for SPIONs with a negative zeta 
potential. Further studies have concluded that the adsorption of serum on superparamagnetic 
iron oxide nanoparticles could potentially hinder cell internalisation [395]. SPIONs in media 
containing fetal calf serum could undergo depletion stabilisation as a result of the serum 
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proteins that have a similar size as the SPIONs. Small negatively charged biomolecules could be 
adsorbed on the SPIONs surface giving the complex a neutral charge and therefore decreased 
electrostatic interactions and increased stabilisation [397]. Petri-Fink et al. [395] concluded that 
the serum in cell media had a clear and immediate effect on the agglomeration of some SPIONs 
but not on others. However, no clear tendency to higher !" relaxivities was observed. 
Superparamagnetic iron oxide nanoparticles are 0"∗ contrast agents combining the local 
inhomogeneities introduced by the SPIONs with the reversible main magnetic field dephasing 
effect. Our results suggest that agglomeration of SPIONs has a much stronger effect on 0"∗ 
where the reversible bulk field dephasing effects are not eliminated by a 180° inversion pulse. 
For future relaxivity studies in cell media it would be interesting to investigate the 
agglomeration behaviour in cell media containing serum and then discussing relaxivity 
measurements within the context of SPION stability in media with and without serum. 
 
8.4.5. Relaxivity in cells 
The aim of SPIONs as MRI contrast agents is to be taken up by target cells in a specific manner. 
Nonspecific cell internalisation may also occur which is undesired as it will make it difficult to 
target specific regions and deliver a particular diagnostic or therapeutic modality. In both cases, 
the uptake of the SPIONs by cells changes with size and shape of the SPION and the 
physicochemical properties of its surface (e.g. zeta potential) [398]–[401]. 
Non-specific uptake, which is what has been investigated in this study, occurs via SPION 
adsorption on the cell surface. We investigated a range of different SPIONs of different core and 
hydrodynamic sizes, different surface charges and coatings and performed in vitro experiments 
in two different cancer cell lines. Certain coating materials can be synthesised (e.g. PEG [402]) 
to avoid non-specific uptake by steric hindrance. This would require a particular spatial 
structure as our PEGylated SPION (MF66-PEG) was adsorbed by cancer cells. 
The relaxivity behaviour of SPIONs in cells is inhomogenous. When SPIONs are internalised 
by cells via the various processes described in the literature [403], a nanoparticle agglomeration 
or clustering happens within the cells. The clustering as part of a cell internalisation affects the 
relaxation behaviour. Longitudinal and transverse relaxation respond differently to the 
clustering of SPIONs and the measured !1, !" and !"∗ relaxivities strongly depend on the size of 
the cluster [404], [405]. 
For nanoparticles taken up by the cancer cells, the !1 value should decrease compared to free 
SPIONs. This is due to clustering and the confinement in cells and the limit this puts on the 
outer water exchange (water diffusion) [389]. According to Bulte et al. [394], this trend 
206 
 
continues as the SPION cluster grows bigger. With the exception of F1706, this behaviour was 
observed in this study for a range of different SPIONs measured in pancreatic and breast cancer 
cells. The core or hydrodynamic size of F1706 nor its Dextran coating would provide a reason 
that this nanoparticle behaved differently. The surface charge of F1706 is -18 mV which is 
lower than many other SPIONs in the study. A possible explanation could be that F1706 was 
not internalised by the breast cancer cells and instead attached to the surface of the cells. This 
could potentially have happened because of its less anionic surface charge. This bound state 
would still influence the relaxation behaviour but not in the same way predicted by the theory 
from post internalisation clustering. The relaxivities strongly depend on whether the cells are 
internalised by the cells or merely adsorbed/attached to the surface of the cells. For SPIONs 
smaller than 120 nm in hydrodynamic diameter, endocytosis has been reported to be the 
mechanism of uptake [406]. Other SPIONs such as ferucarbotran which is negatively charged as 
all SIONs in this study, nonspecific phagocytosis was reported for the uptake mechanism in 
human umbilical vein endothelial cells [407] and carcinoma cells [408].  
 
The behaviour of the transverse relaxivity is more complicated than that of the longitudinal 
relaxivity. During agglomeration of SPIONs to clusters, the !" relaxivity increases. However, 
the !" increase will eventually reach a maximum. After further increase of the SPION cluster, !" 
will decrease again [404], [405]. Rad et al. [409] and Simon et al. [410] also showed that the 
transverse relaxivity in cells strongly depends of the type of cell. The extremely high relaxivity 
values of F1563 are consistent with previous reports of SPION particles with a PEI coating 
agglomerating in serum media [411]. OD10, MF66-DMSA, and MF66-PEG show the 
behaviour described by Kuhlpeter et al. [118] where !" decreases and !"∗ increases. The 
relaxivities of these three nanoparticles increase from the free state in media to the bound state. 
In cells, all SPIONs except F1706 and Ferumoxytol achieve extremely high !"∗ values which is 
different to their free !"∗ values in aqueous solution. 
 
The behaviour of SPIONs when interacting with cells depends predominantly on the coating. 
The interaction of the coating polymer with the SPION surface is determined by the bonds 
between the charge carrying functional groups of the coating polymer and the protonated and 
hydroxylated surface of the iron oxide [412]. The configuration of the coating polymer has a 
key role in the biological behaviour of the particle but is difficult to control or determine [413]. 
It is controlled by the molecular weight of the polymer, its concentration, pH, surface charge 
and ionic strength. 
 
The magnetic relaxivity as well as toxicity of SPIONs depends on the stability of the particles as 
Park et al. [391] have demonstrated on !" measurements on PEG-coated SPIONs. SPION 
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colloidal stability is directly linked to its relaxation behaviour because cell media has an effect 
on the stability of SPIONs and their relaxation properties. SPIONs can also aggregate governed 
by pharmacokinetic processes to produce micron-sized clusters that destablisise the SPION. 
Several researchers have described this phenomenon [395], [414]–[419]. These clusters might 
be coated again with a layer of biomacromolecules or proteins which determine the interaction 
with cells. Furthermore, the characteristics of micron-sized SPION clusters a fundamentally 
different to single SPIONs in terms of their diffusion and sedimentation and therefore show a 
different behaviour towards cells. The destabilisation of SPIONs in biological fluid is believed 
to be due to the adsorption of biomolecules and the removal or exchange of coating polymers 
with other biomolecules. Due to these processes, the original coating is no longer able to hinder 
the electrostatic van der Waals forces (attraction) and SPION clustering results. The most 
important factor to stop destabilisation and therefore not only maintain the nanoparticles 
physicochemical properties but also its magnetic relaxation characteristics is a well-designed 
and robust polymer coating [395], [414], [419], [420]. 
 
In this study, we only evaluated the SPIONs relaxivity behaviour in vitro. For in vivo studies 
additional factors need to be taken into account such as the dependency between the shape of 
the physiological uptake area and the 0" shortening of the SPION [421]. Qualitative and 
quantitative studies reported in the literature suggest that SPIONs are taken up by cancer cells in 
a dose-dependent matter that possess a saturation [422]. 
 
Future studies should focus on providing more general conclusions on how each SPION 
characteristic influences in vitro relaxation behaviour. This would allow the synthesis of a 
SPION particle with the exact magnetic relaxation properties required for a given purpose. 
Furthermore, many researchers explored SPION biocompatibility. Often, this is understood as 
cytotoxicity [423], [424]. However, studies should also focus on the effects SPIONs have on 
signal transduction of normal cell physiology [425], [426]. Apart from passively interacting 
cells and their membranes, SPIONs can also interact with membrane receptors which leads to 
modulation of the signal transduction pathways [427]. 
 
8.4.6. Effect of cell sonication on relaxivity 
Ultrasound sonication causes cell death. We therefore wanted to compare relaxivity 
measurements pre- and post-sonication to evaluate the effect of cell death on the relaxivity. The 
results for the longitudinal relaxivity are inconclusive. For some particles, i.e. A22APS, OD10 
(PCC), OD15 (BCC) and F1780, the pre- and post-sonication relaxivities are similar. For other 
particles such as OD10 (BCC), OD18, F1563, F1706, MF66-DMSA and MF74, pre- and post-
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sonication !1 values are considerably different. The cells were scanned 15 min post-sonication. 
SPIONs that have been internalised by cells are not immediately released upon cell death. A 
clear difference between pre- and post-sonication relaxivity measurements are therefore likely 
to be seen on cells where the SPIONs mainly adsorbed onto the cell surface which will be 
released upon sonication. However, the result for the longitudinal relaxivity pre- and post-
sonication are inconsistent. There is no clear trend that longitudinal relaxivity increases or 
decreases post-sonication. Four out of six SPIONs have a higher !1 value post-sonication. This 
is expected when more SPIO nanoparticles are freely suspended in solution after release from 
the cell surface. The additional free SPIONs lead to an increased water exchange.  
 
The !" results are more consistent. Except for F1780, the transverse relaxivity increased post-
sonication. This result is consistent with Kuhlpeter et al. [118] who described a decrease in !" 
when the SPIONs were bound by cells compared to free SPIONs. The increase in !" is most 
pronounced for F1563. A likely explanation is that F1563 quickly aggregated in media [396] 
which would explain the very high transverse relaxivity that is normally only achieved for 
SPION aggregates. 
 
8.4.7. Free vs cell-bound SPIONs 
Summary of the relaxivity data for five selected SPIONs presented in table 10 display 
considerable differences among the different SPIONs. This is because of different susceptibility 
effects exerted by the examined SPIONs which cause the shortening of the 0"∗ relaxation time. 
A reason that the MF66 particles have a stronger transverse relaxivity is due to the larger crystal 
size which leads to an increase in magnetisation for magnetite nanoparticles [428], [429]. 
 
For superparamagnetic iron oxide nanoparticles, !" and !"∗ are particularly important because of 
the rapid water exchange and diffusion within the surrounding of these particles [430]. 
Ferumoxytol and F1706 display a 01 effect on 0"- and 0"∗-weighted MR images. Because the 
signal intensity also depends on 0/ 01, this can disturb the signal decay for a 0"(∗)  contrast 
agent at concentrations where the condition 01 ≪ 0/ does not apply any more [378]. Therefore, 
the signal enhancement does not only depend on !"(∗) but also on the longitudinal relaxivity !1. 
That means that in addition to a high !"(∗) value, a lower !1 !" ratio can be useful for 0"(∗)-
weighted contrast enhancement with SPIONs. The transverse relaxivity depends on the 
characteristics of the SPION, e.g. as the coating thickness increases, transverse and longitudinal 
relaxivities decrease. A change in pH on the other hand does not impact relaxivities [431]. 
Particles with a positive zeta potential usually have a higher !"/!1 ratio [432]. In terms of type 
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of coating, silica was shown to lead to very high transverse relaxivities within a clinical 
magnetic field strength (1.5T) when compared to other common coating materials [433]. 
Furthermore, transverse relaxivity increases as hydrophilicity of the coating increases which 
makes hydrophilic Polyethylenimine (PEI) a very good choice for SPION coatings [430]. The 
coating of a SPION can hinder water molecules from diffusing to the particle surface. Coating 
molecules can also bind to nearby water and therefore immobilise it. Both processes have an 
impact on the proton relaxation and therefore the relaxivity. Due to the impact the SPION 
coating can have, even identical SPION cores but with different coatings can exhibit very 
different magnetic relaxivity behaviours. But in general, the effect of the coating on transverse 
relaxivity is not fully understood [385]. According to the outer-sphere theory, the transverse 
relaxivity improves if the thickness of the polymer coating increases while the water diffusion 
coefficient decreases [354], [355], [359]. 
 
It was reported by Bowen et al. [434] that for cell-bound SPIONs, /"∗ measurements have a 
much higher sensitivity than /" measurements. When comparing the free and bound SPIONs, 
the latter display much higher !"∗ values and significantly lower !" values. Therefore, the 
measurement of both quantities provides information of whether a particular iron-based contrast 
agent has been bound and compartmentalised by cells. The relaxivities for free SPIONs are 
much closer together in magnitude. This separation indicates that it is possible to determine 
whether SPIONs have been internalised by cells or are tightly bound to the surface of cells by 
MRI. Upon compartmentalisation of SPIONs in cells, a nonuniform field distribution is 
generated. As a result, the influence of diffusion on the signal is changed [435]. This can be 
explained with the static dephasing regime [360].  
 
The majority of linear fits of /"(∗) vs. the different SPION concentration (relaxivities reported in 
table 7) have an !" > 0.9 with the quality of all fits being higher than 0.7 (figure 104). 
Ferumoxytol and F1706 did not behave as described by Kuhlpeter et al. [118] where a decrease 
of !" and increase of !"∗ occur from a free to a bound state. A reason for that could be the short 
TR we used in our 0"∗ mapping sequence. Ferumoxytol and F1706 displayed a 01 effect on 0"- 
and 0"∗-weighted MR images. Because the signal intensity also depends on 0/ 01, this can 
disturb the signal decay for a 0"(∗) contrast agent at concentrations where the condition 01 ≪ 0/ 
does not apply any more [378]. Therefore, the signal enhancement does not only depend on !"(∗) 
but also on the longitudinal relaxivity !1. That means that in addition to a high !"(∗) value, a 
lower !1 !" ratio can be useful for 0"(∗)-weighted contrast enhancement with SPIONs. In figure 
104, MF66-PEG and F1706 show the smallest increase in angle between the /" and /"∗ curves. 
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These two SPIONs have a large hydrodynamic diameter compared to the other particles 
investigated. This means that compartmentalisation has a lesser effect on larger nanoparticles. 
MF66-DMSA and MF66-PEG are the same iron oxide nanoparticle but with different coatings. 
They displayed the highest !" and !"∗ values both in aqueous solution and compartmentalised in 




9. In vivo MRI of novel nanoparticles in an animal model of 
cancer 
9.1. Introduction 
Superparamagnetic iron oxide nanoparticles (SPIONs) have been widely studied for their 
potential as MRI contrast agents since it was shown in 1997 that magnetically labelled cells can 
be detected by MRI [436]. In decreasing the size of the iron oxide core below a single magnetic 
domain they become superparamagnetic which allows them to be detected by MRI while not 
having a remnant magnetic moment outside the scanner’s magnetic field  [191]. SPIONs are not 
stable in aqueous solutions and therefore need to be coated to ensure that they do not aggregate 
or precipitate [187] (common coating materials are described in chapter 5). A hydrodynamic 
diameter between 10 – 50 nm is desirable for a long blood retention time. Particles with a size 
greater than approximately 50 nm are metabolized by the RES (Kupffer cells, macrophages). 
Particles smaller than approximately 10 nm are removed from the vasculature by renal filtration 
[437]. A long blood circulation time increases the probability that particles accumulate in the 
tumour through leaky neovascularisation combined with reduced lymph drainage at the tumour 
(EPR effect) [438]. 
 
For the in vivo testing of SPIONs, both in terms of cancer targeting capability and MRI contrast, 
human cancer xenografts are often used. In this model, immunodeficient rodents (e.g. athymic 
nude mice) are being transplanted human cancer cells. This heterotransplantation can be done 
subcutaneously or directly into the organ from which the cells originated [439], [440]. For the 
assessment of cancer therapeutics, it was reported that the predictive value of a human cancer 
xenograft is variable. In particular, the activity of an agent was vastly different in vitro, in a 
subcutaneous xenograft model and a clinical trial [441]–[443]. Others have reported good 
predictions from xenograft studies that were later confirmed in phase 2 clinical trials [444]. The 
use of continuous cell lines as a source for a human cancer xenograft is a potential limitation 
[445]. Cancer xenografts are used in a range of MRI studies, such as the assessment of volume 
and size of lesions [446], measurement of parameters of the tumour environment such as 
perfusion, vascular function [447], hypoxia and pH [448]–[453] as well as metabolic studies 
[454]. 
Another model is that of genetically engineered mice (GEM). Through the alteration of the 
genetic profile, genes are overexpressed or mutated that are likely to play a part in tumour 
malignancy/transformation. The GEM model can be superior to the human cancer xenograft 
model in some aspects. However, it also has a set of disadvantages and the interested reader is 




Overall, cancer MRI studies with multifunctional nanoparticles aim to develop targeted imaging 
agents and therapeutic vehicles that prove successful in theranostic applications. Part of that is 
the development of new imaging technology (see chapter 7). In this chapter, we will describe 
the testing of our novel iron oxide nanoparticles in a human cancer xenograft model. We 
compare five different SPIONs in terms of their suitability as MRI contrast agents with respect 
to their size, coating material and surface charge. Further, it has been reported elsewhere that R2 
and R2* mapping can be used to differentiate between free and cell-bound SPIONs by MRI. 
Cell-bound SPIONs show higher R2* values compared with free SPIONs whereas R2 is higher 
for free iron [118]. The aim of the present work has been to extend this by investigating a 
relationship between the chemical nature of the SPION (i.e. particle size, charge, coating, 
functional groups) and the ability to differentiate whether a particular particle is cell-bound or 
free by MRI.   
 
9.2. Methods 
9.2.1. Superparamagnetic Iron Oxide 
We investigated two different SPIONs (table 9) regarding their 0" and 0"∗ contrast 
characteristics in vivo using a 3T clinical MR scanner.  
 
Table 11: Superparamagnetic iron oxide nanoparticles investigated with their core size, 












n [mg Fe/ml] 
pH 
Ferumoxytol 3.25 23.6 PSC -43.2 30 7 
MF66-PEG 12 111.3 PEG -28.3 5.3 7.4 
 
Ferumoxytol is a commercially available and clinically approved MR contrast agent. The iron-
oxide core of ferumoxytol is coated with polyglucose sorbitol carboxymethyl ether (PSC). The 
other SPION (MF66-PEG) is a novel PEGylated particle which was synthesised for cancer 
targeting, detection, and treatment [364]. The intracellular and in vivo characteristics of MR 
iron-oxide based contrast agents strongly depend on the coating, charge as well as on the 
hydrodynamic particle size. Therefore, we investigated SPIONs with different hydrodynamic 
diameters. Table 9 summarises the SPIONs investigated in this study and lists their respective 
characteristics (i.e. iron oxide core size, hydrodynamic diameter, coating, and surface charge). 
Anionic SPIONs were selected because they have been shown to have a high affinity for the cell 
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membrane and are their efficiency to be internalised is therefore significantly higher compared 
to neutral or positively charged SPIONs [365]. PEG coating has been proven to be well suited 
for biomedical applications due to its good stability and low toxicity [366]–[368]. 
 
9.2.2. MR Imaging in vivo 
All procedures used in these studies were performed in accordance with the European 
Communities Council Directive 2010/63/EU on the protection of animals used for scientific 
purposes, and with the British legislation (The Animals (Scientific Procedures) Act 1986). All 
efforts were made to minimize animal suffering and to reduce the number of animals used. 
Female athymic nude mice (Hsd:Athymic Nude-Foxn1nu, 8 weeks old) were purchased from 
Harlan Laboratories (Blackthorn, United Kingdom). Subcutaneous xenograft tumours were 
induced by injection of 2x106 MDA-MB-231 cells (ATCC, Wesel, Germany) in 100 µl 
Matrigel™ (BD Biosciences, Bedford, USA) into the right flank of the mice. The experiments 
were started when the tumour size reached 300 mm3, as calculated by the formula V = π/6 x 
(length x width x height of the tumour) [457]. 
 
In order to test two selected SPIONs in vivo, two tumour-bearing mice were intravenously 
injected with 11 mgFe/kg of either MF66-PEG or ferumoxytol, and MR images were acquired 
using 0"∗ mapping sequences. Mice were anaesthetised with 5% and maintained with 1-2% 
isoflurane in oxygen under spontaneous breathing during the MR imaging experiments. We 
used a custom-made single-loop surface coil (47 mm diameter) for signal reception. Mice were 
imaged in prone position before the SPION injection (baseline), 30 min and 48 h after the 
injection. 
 
The scan protocol consisted of an anatomical scan and a 0"∗ mapping sequence. In order to 
display the anatomy of the mice and plan subsequent scans, 44 coronal slices were acquired 
with a 3D gradient-echo sequence (26 ms TR, echo time 8.4 ms, 25° flip angle, FOV 40x40x22 
mm3, acquisition matrix 160x160, slice thickness 1 mm, in-plane resolution 0.25x0.25 mm2, 3 
averages, duration 4.32 min). 0"∗ mapping was performed with a 2D turbo gradient-echo (2D 
TFE) sequence (100 ms TR, 4.6 ms to first echo, 6.9 ms interval between subsequent echoes, 6 
k-space lines per shot, 35° flip angle, FOV 50x50 mm2, acquisition matrix 72x69, slice 
thickness 3 mm, in-plane resolution 0.69x0.72 mm2, 4 averages, duration 3.12 min). 
The 0"∗ weighted images were post-processed with the SGM technique where short term Fourier 
transforms in x- and y-directions are applied to all pixels individually. This technique also takes 
into account a certain number of neighbouring pixels which is three in our case. A susceptibility 
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gradient map was calculated from the value of the VÔ$wÏ vector (two-dimensional shift in k-
space from the maximum) at every pixel location.     
 
9.3. Results 
For the in vivo study we acquired three coronal slices in tumour bearing mice. All three slices 
contained the tumour area and liver. The tumour is the intended target area for our SPIONs and 
the liver is where most SPIONs accumulate due to the uptake by the mononuclear phagocytic 
system. Figure 105 shows an anatomical scan illustrating the two areas of interest. 
 
Figure 105: Anatomic scan (coronal) showing the organs of interest for the in vivo study. 
 
We injected mice with ferumoxytol (n = 6) and MF66-PEG (n = 3) and acquired coronal 0"∗ 
maps pre-contrast, 30 min post-contrast and 48 hours post-contrast. We determined the 
transverse relaxation time 0"∗ for three slices in the tumour and liver area at all three time points. 
The mean values are summarised in table 12. 
 
Table 12: Mean transverse relaxation time of three coronal slices in tumour and liver before 
injection of the contrast agent and at 30 min and 48 hours post-injection. xg∗		hk  Pre-contrast 30 min post-contrast 48h post-contrast Liver Tumour Liver Tumour Liver Tumour 
Ferumoxytol 
mouse 































The mean 0"∗ values were plotted in figure 106 showing the statistical significance of changes at 
the 30 min and 48 hour time points compared to the pre-contrast measurement. 
 
 
Figure 106: Mean 0"∗ values of mice injected with ferumoxytol (n = 6) and MF66-PEG (n = 3) 
for two areas of interest (i.e. liver and tumour. The bar diagrams indicate whether the change at 
the post-injection time points was significant compared to the pre-contrast measurement. 
 
The decrease in 0"∗ recovers slightly after 48 hours for ferumoxytol while both post-contrast 
time points of the MF66-PEG mice are similar. We have measured the iron content in liver (n = 
3) and tumour (n = 2) of mice injected with ferumoxytol (figure 107). There is significantly 
more iron in the liver at 48 hours post injection whereas no significant increase in iron content 
could be detected in the tumour. 
 
Figure 107: Mean iron content in liver (n = 3) and tumour (n = 2) measured with ICP-MS in 





Coronal 0"∗ maps of the two mice, one injected with ferumoxytol and one with MF66-PEG are 
shown in figure 108 and 109, respectively. In both cases a clear darkening of the liver can be 
observed 30 min post injection. The presence of SPIONs in the liver is still visible 48h post 
injection with a clear increase in negative contrast in the case of ferumoxytol and a slight 
increase with MF66-PEG. We determined the transverse relaxation time 0"∗ for three slices in 
the tumour and liver area at all three time points. The mean values are summarised in table 12. 
Positive contrast images have been generated from the GRE images of the mice injected with 
ferumoxytol and MF66-PEG in a postprocessing step with the susceptibility gradient mapping 
tool. No direct uptake of the two SPIONs is seen in the tumour area. 
 
Figure 108: Results of a mouse injected with ferumoxytol. a – c: Coronal 2D gradient-echo 
images before injection with ferumoxytol, 30 min and 48h post injection. d – f: SGM images 
constructed from their respective gradient echo images highlighting areas of large susceptibility 
gradients in white (positive contrast). g – h: Bar diagrams showing the 0"∗ values in the liver (g) 




In figure 108a, a dark patch at the inferior edge of the tumour can be seen that increases in area 
and intensity with time after injection (figure 108b and 108c). This contrast behaviour is 
consistent with the liver where the contrast agent is expected to be found because of removal 
from the circulation due to macrophages. The SGM images confirm this observation (figure 
108d – f). 
 
Figure 109: Results of a mouse injected with MF66-PEG. a – c: Coronal 2D gradient-echo 
images before injection with MF66-PEG, 30 min and 48h post injection. d – f: SGM images 
constructed from their respective gradient echo images highlighting areas of large susceptibility 
gradients in white (positive contrast). g – h: Bar diagrams showing the 0"∗ values in the liver (g) 
and tumour (h) pre-contrast, 30 min and 48 hours post contrast. 
 
The SGM images of the mouse injected with MF66-PEG (figure 109d - f) are less convincing 
despite the obvious negative contrast effect in the liver of the GRE images (figure 109a – c). No 
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SPIONs, like all contrast agents and therapeutic drugs administered intravenously, need to 
prove that they do not suffer from major disadvantages that would disqualify them for further 
use. These are toxicological characteristics, low dose delivery and a resulting low therapeutic 
efficacy. A key consideration is also the pharmacokinetic profile as SPIONs need to pass 
various physiological barriers in order to reach the intended target site within the body. These 
barriers are clearance by the mononuclear phagocyte system (MPS) also referred to as the 
reticuloendothelial system (RES) in the form of macrophages, monocytes and Kupffer cells, 
kidney filtration, extravasation from the diseased site and crossing nuclear and plasma 
membranes [458]–[460].  
 
9.4.1. Liver uptake 
We have presented 0"∗-weighted in vivo images of two mice which were acquired at three 
different time points; images were acquired before as well as 30 minutes and 48 hours after the 
injection of a SPION contrast agent (i.e. ferumoxytol and MF66-PEG). Anatomical areas of 
interest in the tumour bearing mice are the tumour, liver and any other regions that show signs 
of SPION accumulation. SPIONs and other nanoparticles developed for biomedical applications 
are taken up by macrophages when injected into the bloodstream. Tissues that are rich of 
macrophages are the bone marrow, spleen and liver (Kupffer cells). A key aim for SPIONs 
designed for passive tumour targeting is therefore to increase blood circulation time by 
decreasing the uptake rate by macrophages (“stealth” characteristics). Blood half-lives of 
SPIONs depend on various factors such as particle size, coating (e.g. hydrophilic polymers), 
charge and dose and can vary considerably from 1 to 36 hours [461]. Several authors have 
reported that as the size of the SPION increases so does the liver uptake [462]. However, this 
might not be a general rule as other studies have also presented contradictory results [463].  
 
The negative contrast produced by ferumoxytol in the liver in figure 108 increases in area and 
decreases in signal intensity at 48 hours post injection. A reason that SPIONs accumulate in 
large amounts in the liver is due to phagocytosis of scavenger molecules of the RES [464]. The 
liver uptake of MF66-PEG in figure 109 is similar to ferumoxytol with a visible presence of 
SPIONs 30 min after the injection. SPIONs are very quickly (i.e. within minutes) recognised by 
the RES after intravenous injection and therefore cause changes in contrast in the liver shortly 
after injection [465], [466]. The negative contrast in the liver weakens over time. The time it 
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takes for the contrast to come back to baseline can vary from one SPION to another and 
depends on a particular SPION’s size, composition, coating and charge. However, some 
SPIONs might be retained by organs for a very long time which could potentially lead to 
toxicity effects [466]. In our mouse injected with MF66-PEG, no difference in area or signal 
intensity can be seen between the 30 min and 48-hour time points. When comparing the 48-hour 
time points of both SPIONs, MF66-PEG produces more darkening. This is in agreement with 
table 10; MF66-PEG has a higher relaxivity. 
 
9.4.2. Tumour uptake 
In figure 108 the central tumour area does not darken on the GRE images post ferumoxytol 
injection at any time point. In contrast, in the inferior tumour periphery a dark patch becomes 
visible as early as 30 minutes post ferumoxytol injection and remains visible also on the 48 hour 
images. Moore et al. reported from experiments on brain tumours that dextran-coated SPIONs 
showed a higher accumulation in the periphery of the tumour with more heterogeneous particle 
locations in the tumour centre near supplying blood vessels [24], [270]. As passive targeting is 
governed by the EPR effect [467], this can be explained with a higher microvascular density in 
the tumour periphery. In figure 109 no negative contrast in either tumour core or periphery is 
observed post injection of MF66-PEG. A possible reason for that could be that the surface area-
to-volume ratio was too high that led to aggregation and interactions with plasma proteins. This 
would result in fast clearance from the vasculature by the RES [468], [469]. In general, this is 
an important consideration for in vivo biomedical applications of SPIONs. Proteins and other 
biomolecules will attach to the surface of the SPION which is referred to as the protein corona 
[470]–[472]. A result of the formation of the protein corona is that active targeting sites on the 
SPION surface may not be functional. But the protein corona can also lead to undesirable 
biodistribution including rapid RES clearance for SPIONs that relied on passive targeting 
[473]–[475].  
 
9.4.3. Size and coating 
Because of the defective blood vessel structure of tumours, as explained by the EPR effect 
[476], the hydrodynamic size of SPIONs is the key factor that determines passive tumour uptake 
and biodistribution. A hydrodynamic diameter in the range of 20-200 nm is best suited for 
molecular imaging. If SPIONs are too small (i.e. below 10 nm) and biodegradable, it is likely 
that they will be cleared from the vasculature by the kidneys [464]. Some authors have reported 
that within the range of 20-200 nm, smaller SPIONs (below 100 nm) show improved uptake 
efficiency while larger particles stay in the area where they were injected [477]–[480]. 
However, Natarjan et al. demonstrated that such a linear size-tumour uptake relationship may 
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not be true and that other factors need to be taken into consideration as well [481]. One of the 
novel SPIONs we used in this study was coated with PEG which together with dextran is among 
the most popular SPION coating materials [464]. PEGylated SPIONs have been reported to 
reduce interactions between plasma proteins and SPIONs in vivo which contributes to their 
“stealth” characteristic [479], [482]. Cui et al. reported that increasing the length of the PEG 
chains from 45 (2 kDa, positive zeta potential) to around 227 (10 kDa, negative zeta potential) 
of otherwise identical SPIONs does delay the clearance by the RES [479]. SPIONs coated with 
dextran have been reported to be more vulnerable to RES clearance due to the formation of 
protein corona [473], [483]. 
 
9.4.4. Cell biology 
Within a tumour, SPIONs have been identified in various different cell types such as tumour 
macrophages, tumour cells and to some extent in endothelial cells. SPIONs have been shown to 
transcytose in endothelial cells as a way to enter the interstitium of the tumour [287]. When a 
tumour grows, monocytes enter the neoplasm from the circulation which give rise to 
macrophages that infiltrate the tumour and internalise SPIONs [484]–[486]. Macrophages can 
make up 40-60% of a tumour. Phagocytic cell infiltration in tumours depends on tumour 
angiogenesis and developmental stage [487], [488] and in situ cytokine production [489] among 
others. Because cell uptake of SPIONs in tumours is not saturable [490], cell internalisation of 
SPIONs within the tumour is likely governed by endocytosis as has been proven for the 
transport of other hydrophilic biomolecules. Cells such as macrophages absorbs SPIONs 
through enclosure in vesicles. There are different types of endocytosis and the exact 
internalisation process depends on the particular SPION and its characteristics such as shape, 
size, composition, surface charge and chemistry [491].  
 
9.4.5. Relaxation time constant pg∗  in tumour and liver 
In the case of ferumoxytol the mean 0"∗ in the tumour drops 30 min after contrast injection from 
35.87 ± 11.75 ms to 25.99 ± 9.56 ms (table 12). A more significant drop in  0"∗ is observed in 
the liver from 22.13 ± 1.70 ms to 7.52 ± 2.62 ms. Liu et al. reported an enhancement of the 
tumour after 60 min post injection of superparamagnetic polymersomes in normal and nude 
(bearing HeLa tumours). This is up to six times longer than for the liver [492]. It is well known 
from pre-clinical studies, particularly in mice, that SPIONs become measurable and visible in 
MR images after a very short time window (e.g. 10 min) post injection in the tail vein. In the 
above mentioned study by Liu et al, the negative contrast in the liver after intravenous injection 
was strongest at 50 min post injection. The same authors compared liver and spleen uptake. The 
later was only half as fast which is another indication that SPIONs are taken up by macrophages 
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via phagocytosis. The 0"∗ value increased again at 48 hours post injection compared to the 30 
min time point in the tumour and liver. This is surprising as the liver still shows a significant 
negative contrast at 48 hours indicating the presence of SPIONs. Several processes are involved 
in the clearance of SPIONs. The iron particles themselves are being degraded followed by 
binding to serum proteins such as transferrin. The iron might also be redistributed to other cells 
and eventually is eliminated. This can be measured through a decline of the serum iron levels. 
Jain et al. reported SPION clearance required more than 3 weeks [493]. Bourrinet et al. reported 
more than 7 weeks for the clearance of Fe-Ferumoxtran-10 (dextran coated) [494]. However, 
other authors have also reported faster clearance times [495]. The reasons for the difference in 
reported clearance times are different sizes and coatings which have a direct effect on 
biodistribution but also degradation. In the case of slow clearing SPIONs, it is worth 
considering that iron from injected and degraded SPIONs has been reported to add to the body’s 
iron storage. The iron will be incorporated into haemoglobin [493]. A slightly different 
behaviour can be observed in the average 0"∗ values of mice (n = 3) injected with MF66-PEG. 
There is almost no change in the 0"∗ in the tumour at 30 min and 48 hours post injection 
indicating that MF66-PEG does not accumulate in the tumour within that time frame. The liver 
region shows a rapid drop in 0"∗ at 30 min post injection and the 0"∗ further decreases slightly at 
the 48 hour time point. 
 
We did not measure the 0"∗ in blood in order to compare it to our measurements in liver and 
tumour tissue. Tanimoto et al. reported that the 0" in the liver was lower than in blood after 
USPIO injection. The likely reason is intracellular compartmentalisation that restricts the water 
diffusion. Furthermore, iron oxide nanoparticles are distributed more heterogeneously in tissue 
compared to blood [496]. As the SPION concentration in tissue increases, a saturation effect 
would be expected based on water exchange [359]. 
 
Before we have discussed the formation of the protein corona on SPIONs in vivo. With regards 
to 0" and 0"∗ measurements in vivo, the protein corona can also alter the magnetic properties of 
SPIONs which would lead to changes in the MRI contrast behaviour [497]–[499]. The 
transverse relaxivity depends on water diffusion and exchange in the SPION surrounding. If the 
functional groups of the coating material are covered with proteins and biomolecules, this will 
change the water diffusion rate, the hydrodynamic diameter as well as the surface charge. As 
discussed above, these changes will have a direct impact on the relaxivity characteristics of the 




9.4.6. Positive contrast images with SGM 
The positive contrast images constructed with the SGM method shown in figure 108 and 109 
highlight areas of susceptibility. The SGM images of the ferumoxytol injected mouse (figure 
108c – f) confirm the growing area of susceptibility inferior to the tumour. This positive 
contrast signal increases in accordance with the increasing positive signal in the liver at the 48 
hour time point. No positive contrast could be detected inside the tumour area. This shows that 
the presence of SPIONs in the tumour indicated in the decrease of the 0"∗ value in figure 108h is 
below the detection limit. The contrast behaviour in the liver is surprising. According to figure 
108g, the image at 30 min should show the highest positive contrast because the 0"∗ value 
recovers back to the baseline value thereafter. However, the SGM image at the 48 hour time 
point is the most convincing. In figure 104 the /"∗ curves decreased significantly upon 
internalisation of the ferumoxytol particles. A similar effect is seen in vivo where the 0"∗ value 
recovers after 48 hours because the SPIONs in the liver have been mostly internalised in cells. 
Evidently, this does not limit the detection capabilities of these SPIONs with the SGM 
technique. One problem could be the dilution of internalised SPIONs by tumour cells as the 
tumour growths and proliferates [161]. However, how rapid a particular SPION that 
successfully targeted tumorous tissue is cleared and falls below the detection limit depends on 
the SPION and the amount of SPIONs that make it to the tumour. In comparison, the GRE 
images (figure 108b and 108c) do not display the increased accumulation and internalisation of 
SPIONs at 48 hours. Thus, SGM images (figure 108e and 108f) are better suited to detect 
accumulation or internalisation of SPIONs over time which seems to be associated with a 
change in susceptibility. 
 
In the case of the mouse injected with MF66-PEG, SGM images show no contrast in the tumour 
and strong positive contrast in the liver at both post injection time points. This is in agreement 
with the GRE images (figure 109b and 109c) and the behaviour of the 0"∗ values (figure 109g) 
that show no difference in liver contrast between the 30 min and 48 hour time points. However, 
comparison of the in vivo images acquired with ferumoxytol and MF66-PEG suggest that 
MF66-PEG is better suited due to the much better positive contrast achieved. One potential 
reason could be that higher amounts of MF66-PEG particles have been accumulated in the liver 
48 hours post injection leading to a stronger signal void. This would mean that MF66-PEG was 
more effectively taken up by the MPS. Under the assumption that both SPIONs investigated 
predominantly accumulate in the liver, another effect could be responsible for the difference in 
contrast at 30 minutes. MF66-PEG has much stronger magnetic susceptibility effect as shown in 
table 10 compared to ferumoxytol. The drop in 0"∗ in the liver (figure 109g) remains consistent 
for both post injection time points which is reflected in similar amount of positive contrast in 
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figure 109e and 109f. Despite the higher 0"∗ values of MF66-PEG post SPION injection (figure 
109g) compared to ferumoxytol (figure 108g), the positive contrast achieved in the MF66-PEG 
injected mouse is more convincing. Overall the in vivo data demonstrates that the superior 
magnetic susceptibility characteristics of MF66-PEG evident through extremely high transverse 
relaxivity values measured in a phantom, translates to superior in vivo imaging behaviour over a 
commercial sample. Due to the greater susceptibility difference of MF66-PEG, this particle is 
more likely to be detected by SGM. The magnetic field disturbance caused by the SPIONs must 
spread beyond the imaging voxel in order to be detected by SGM [152]. For that reason, 
SPIONs with stronger magnetic moments and areas of higher SPION density are more likely to 
produce a change in contrast. 
 
A drawback of SGM is that it does not differentiate between susceptibilities introduced by 
SPIONs and other sources of field inhomogeneities (e.g. air cavities in the guts) [161]. This 
might be reduced by only taking into account a certain direction of the susceptibility gradients 
[501]. SGM offers the opportunity for retrospective parameter optimisation. The main 
advantage however is that SGM does not suffer from the problem to mistake an area of low 
signal intensity as negative contrast originating from a field distorting particle. In many cases 




In this chapter we have presented four novel superparamagnetic iron oxide nanoparticles for 
biomedical applications. We assessed these SPIONs for their suitability as MRI contrast agents 
and investigated the differentiation between free and bound states by MRI in vitro. We 
investigated one novel SPION that demonstrated superior magnetic susceptibility characteristics 
in vivo where it showed superior imaging behaviour on multi echo gradient-echo images and 
susceptibility gradient maps compared to a commercial sample. We did not assess the density of 
the SPIONs in the tissue or its distribution. However, it can be assumed that a stronger 0"(∗)/SGM effect would have been visible if the density of SPIONs was higher. Our study 
confirms reports the numerous reports in the literature that the liver is the organ that displays the 
strongest contrast enhancement and the contrast remains there for longest in an in vivo 
experiment. Even though the impact of the SPION coating is not fully understood yet, SPIONs 
are ideally smaller (less than 100 nm) and have a hydrophilic coating to provide good contrast 





This chapter will provide a concluding discussion on the results presented in this thesis. It will, 
chapter by chapter, provide information on the general role and novel aspects of the thesis 
within the field and conclude with an outlook. 
 
10.1. Chapter 6 – Implementation and optimisation of established 
positive contrast MRI sequences 
In chapter 6 the implementation and optimisation of three positive contrast MRI techniques, 
GRASP, IRON and SGM, was described. All three techniques are established and well reported 
in the literature. GRASP was first described by Seppenwoolde et al. [151] in 2003 under the 
name white marker imaging. The technique has been demonstrated in various applications since 
it was first described such as using GRASP to determine ferritin deposition in a thrombus model 
[156] or to dynamically track implanted stem cells in an in vivo mouse model of myocardial 
infarction [158]. The IRON technique was first described by Stuber et al. [153] and has proven 
to be successful in depicting particles and objects that possess a strong magnetic susceptibility. 
However, not much was published since Stuber first described the technique in 2007. 
Korosogiou et al. [159] showed that IRON images displayed strong positive contrast in 
paraaortic lymph nodes post SPION injection. The latest paper came from Gitsioudis et al. [160] 
in 2013 who investigated the suitability or IRON for vessel imaging (MR angiography) in 
conjunction with a suitable iron-based MR contrast agent. SGM is the youngest of the three 
techniques first described by Dahnke et al. [152] in 2008. It has been applied to successfully 
image prostate marker seeds (in a phantom study) [162], SPION-labelled C6 glioma cells in 
nude rats [161] and to assess the progression of atherosclerotic plaques in ApoE-/- mice [163]. 
Published papers so far have focused on the theoretical description of GRASP, IRON and SGM 
as well as demonstrating their application in vitro and in vivo. Detailed and practical 
descriptions of the implementation of these techniques is missing in the literature. We are aware 
that there are different ways to implement these techniques and implementation will also vary 
from MR scanner manufacturer. In this thesis we have presented our approach to implement 
GRASP and IRON in the pulse programming environment for the Philips Achieva scanner. We 
have incorporated the dynamic function to allow the iteration of a scan with increasing or 
decreasing one parameter by a pre-defined value for each iteration. 
 
We described the optimisation of GRASP and IRON using different phantoms. Because of the 
limited number of published positive contrast studies, this work provides an overview of the 
contrast capabilities of GRASP and IRON on a SPION water phantom as well as a steel ball 
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bearing in a block of hardened gelatine. For both positive contrast techniques, our results 
highlight the importance of thorough sequence optimisation. Optimal positive contrast images 
are only achieved at a particular set of parameters that need to be carefully determined and re-
determined when the setup or SPION concentration changes. As part of the optimisation 
documented in chapter 6, we also present a range of Null results. These are valuable in order to 
record what does not work. This is particularly important as some of the sequences we tested 
with our implementations were taken directly from published papers but used with a different 
MR scanner and setup. This demonstrates again that positive results often do not translate to a 
different setup/implementation. 
 
The majority of our phantom experiments were done with VSOPs that are no longer available. 
VSOP-C184 has been assessed by Taupitz et al. [243] who reported a !1 of 13.97 mM-1*s-1 and 
a !" of 33.45 mM-1*s-1 at 1.4T. This shows that the nanoparticle also has a strong 01 effect with 
a moderate 0" effect. In this thesis, we present the first positive contrast images obtained on a 
VSOP phantom where we showed that very convincing positive contrast images could be 
achieved with our GRASP and SPION implementations. Finally, chapter 6 provides a summary 
table of IRON sequences that gave in our optimisation the best positive contrast images. 
 
10.2. Chapter 7 – Positive contrast imaging with Dixon 
Following on from chapter 6, we implemented and tested a simple modification to the Dixon fat 
suppression technique for positive contrast imaging of SPIO nanoparticles. Dixon is able to 
separately image water and fat due to their different resonant frequencies. By modifying Dixon, 
it must therefore be possible to also separately image off-resonant protons whose Larmor 
frequency has been affected by the magnetic moment of nearby SPIO nanoparticles. Reeder et 
al. [339], [340] has described a modified Dixon technique termed IDEAL where water and fat 
signals are iteratively decomposed. Yu et al. [346] have described a development of the IDEAL 
reconstruction algorithm that allows 0"∗ estimation in addition to water and fat decomposition. 
This technique allows to image the off-resonance signals that result due to SPION presence. 
 
The IDEAL technique described by Reeder and Yu is a sophisticated post-processing technique 
that was initially developed for 0"∗ quantification while separating water and fat signals. It was 
never fully assessed and applied for positive contrast imaging of SPIONs. What we have done 
in this thesis is a simple proof of concept study that shows that the fat suppression 
implementation of Dixon on a Philips Achieva scanner can be used for to gain positive contrast 
images of a SPION phantom by changing the water-fat shift parameter. Compared to Reeder 
and Yu’s IDEAL technique, this is simpler to implement and very robust as we utilise the on-
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board Dixon implementation that is optimised by Philips. A disadvantage is in the quality of the 
images we obtained. The simpler approach meant there was less opportunity to specifically 
optimise the technique for positive contrast imaging. As a future project it might be worth 
looking into adding functionalities that would allow to control the bandwidth, run an automated 
optimisation scan that determines the optimal sequence parameters and optimise the artefacts we 
observed.  
 
As part of this thesis, Dixon as a positive contrast imaging technique was assessed in vitro with 
a VSOP water phantom. Our experiments involved free SPIONs but did not include cell 
internalised SPIONs as cell internalisation will only have a small effect on the field 
inhomogeneity introduced by the SPIONs (this is only true for as long as the SPIONs have not 
been degraded, i.e. short temporal frame). However, a vastly different scenario would be the in 
vivo imaging of localised subcutaneously injected SPIONs or the imaging of SPIONs injected 
intravenously. The question in this case would be to determine the detection threshold at which 
the modified Dixon sequence is able to detect any SPION accumulations. Furthermore, the more 
complex in vivo situation which will include air cavities and different types of tissues are 
another aspect to consider and investigate. As part of this thesis we merely aimed to conduct a 
proof of concept study that shows that Dixon in its “off-the-shelf” implementation is capable of 
displaying SPIONs with positive contrast images when modifying the water-fat shift to 
accommodate the resonant frequencies of protons affected by the dipole field of SPIONs and 
those that are not (on-resonant protons). 
 
Apart from VSOPs, Dixon was applied to three other SPIONs, one commercial and two novel 
SPIO nanoparticles. The commercial samples have been described before but to our knowledge 
were never used for positive contrast imaging. The novel SPIONs were synthesised by the 
MultiFun consortium (European Community’s Seventh Framework Programme, grant 
agreement number 262943) and this is the first time that they are tested with established positive 
contrast techniques to test their contrast behaviour and detection limit for positive contrast 
imaging. We compared our Dixon positive contrast implementation to established methods 
(implementation and optimisation was described in chapter 6) such as GRASP, IRON and SGM 
in terms of contrast and SPION concentration dependence. 
 
Originally, Dixon is a fat suppression technique. During the optimisation of our IRON 
implementation, we used SPIR for fat suppression. SPIR and Dixon have been compared before 
but to our knowledge, have never been tested on the same positive contrast imaging sequence. 
Here we compared both fat suppression techniques for IRON imaging using a gradient echo 
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sequence. We showed that while changing the fat suppression technique did not affect SPION 
contrast, fat suppression was superior with Dixon.  
 
10.3. Chapter 8 – r2/r2* and r1 relaxivities 
In chapter 8 the development of a water phantom was described that was used for all in vitro 
relaxivity measurements. We tested a variety of self-made phantoms using different materials 
and sample tube sizes. There is little information available in the literature about MRI phantoms 
for relaxivity measurements. Descriptions that do exist are too specific for general use or too 
sophisticated making these descriptions inaccessible for many labs. Furthermore, MRI 
phantoms that minimize magnetic field inhomogeneity can be purchased from a range of 
manufacturer. However, we could not find a simple phantom description that would allow to 
build an MRI phantom with resources available in most labs.  Our objective therefore was to 
develop an MRI phantom for relaxivity measurements that was easy and cheap to build, 
minimising customisation and using equipment available in most labs. The phantom should 
allow for easy handling including the convenient preparation of samples to be measured, the 
changing of samples and most importantly deliver reliable results by minimising the magnetic 
field inhomogeneity within the phantom. We appreciate that such a description might be 
available elsewhere as part of a larger contrast agent study but unless the authors provide 
relevant keywords, it is almost impossible to find such descriptions. We are therefore 
considering to make the phantom description and evaluation available by publishing these 
results as a brief research note about an effective and easy way to build an MRI water phantom 
for a variety of contrast agent measurements. 
 
This thesis is part of the MultiFun project (European Community’s Seventh Framework 
Programme, grant agreement number 262943) that had the goal to develop and validate a novel 
and minimally-invasive nanotechnology system to improve cancer diagnosis and treatment. The 
ultimate goal was to develop multifunctionalised magnetic nanoparticles to selectively target 
and eliminate breast and pancreatic cancer cells. The nanoparticles should have improved 
magnetic features which lead to potential medical applications such as contrast agents and 
magnetic heating inductors. As part of that project, we have assessed a large collection of novel 
SPIO nanoparticles and reported their longitudinal and transversal relaxivity values in water, 
media and cells. Similar work has been done in the past by Rohrer et al. [378] who have 
characterised and compared commercially available contrast agents (Gd chelates and SPIONs) 
at different field strengths in water, plasma and blood. The novelty in what is presented her is 
the MRI characterisation of a range of newly developed superparamagnetic iron oxide 
nanoparticles. The article by Rohrer et al. published in 2005 was cited more than 1,000 times 
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showing the interest of the contrast agent community in studies that focus on the MRI 
characterisation without describing the SPION development or in vivo assessment and 
application. Descriptive publications where several contrast agents, either novel or commercial 
ones, are summarised and compared for their characteristics such as coating, size, surface 
charge and relaxivity behaviour add value. It allows other researchers to gain an overview of 
described SPIONs without having to consult multiple publications. Furthermore, other 
researchers can look up the MRI behaviour of a SPION that shows otherwise similar 
characteristics than the one they are working on and use that information for predications, 
comparisons and discussion. We therefore plan to publish the contents of chapter 8 in a brief 
and descriptive research note or simply deposit the data in a citeable format in order to make it 
available to other research groups. 
 
10.4. Chapter 9 – In vivo MRI in animal model of cancer 
In chapter 9 we assessed four novel superparamagnetic iron oxide nanoparticles previously 
presented in chapter 8 and one commercially available SPION (Ferumoxytol) and investigated 
the differentiation between free and bound states by MRI in vitro. We reproduced the results of 
Kuhlpeter et al. [118] who showed that SPIONs bound to cells can be differentiated by MRI 
from free SPIONs using /"(∗) imaging. To our knowledge, the results of Kuhlpeter et al., who 
have only drawn the above conclusion based on measurements with one SPIO nanoparticle, 
have not been confirmed or reproduced elsewhere. We showed that similar results and effects 
can be achieved in a different lab with a different set of SPIONs. Our extension of Kuhlpeter’s 
results is also valuable as we confirmed the in vitro behaviour with several SPIONs of different 
sizes, coatings and surface charges. 
 
We investigated one novel SPION (MF66-PEG) that demonstrated superior magnetic 
susceptibility characteristics in vivo where it also showed superior imaging behaviour on multi 
echo gradient-echo images and susceptibility gradient maps compared to a commercial sample 
(ferumoxytol). Even though the impact of the SPION coating is not fully understood yet, 
SPIONs are ideally smaller (less than 100 nm) and have a hydrophilic coating to provide good 
contrast on T"-weighted images and avoid rapid RES clearance. Because of its size, MF66-PEG 
is likely to have almost exclusively accumulated in the liver. Together with its high transverse 
relaxivity values reported in chapter 9, this explains the strong negative and positive contrast 
observed on gradient-echo and SGM-processed images, respectively. 
 
We did not assess the biodistribution of MF66-PEG or ferumoxytol and focused on assessing 
presence of SPIONs via relaxometry. However, it can be assumed that a stronger 0"(∗)/SGM 
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effect would have been visible in the tumour if the concentration of SPIONs was higher to 
overcome the detection threshold. A surprising result was presented in chapter 9 where the 
increased 0"∗ value for ferumoxytol in the liver 48h post injection suggested SPION clearance 
which does not align with the negative and positive contrast on the MR images. We have 
discussed this and all other observations thoroughly in chapter 9. There are numerous reports in 
the literature that the liver is the organ that displays the strongest contrast enhancement and the 
contrast remains there the longest in an in vivo experiment because SPIONs that are not 
functionalised are predominantly taken up by the mononuclear phagocyte system. Our results 
confirm that this is also the case for the novel SPION MF66-PEG. Our data and results therefore 
add to the literature by describing the in vivo behaviour of one novel superparamagnetic iron 
oxide nanoparticle and comparing it to a commercially available sample already characterised 
by other authors. 
 
In most studies where novel SPIONs are tested in vivo, the authors report the 0" and 0"∗-
weighted images. However, we had the opportunity to also process our 0"∗-weighted gradient-
echo images with SGM in order to evaluate how the negative contrast we see in gradient-echo 
images compares to the positive contrast in SGM images. This was not only done for our novel 
SPION but also for a commercially available contrast agent (ferumoxytol) to allow comparison 
between the contrast behaviour of both SPIONs and be valuable data for other researchers 
looking to understand iron oxide contrast behaviour better in the future. 
 
10.5. Outlook 
The work for this thesis included novel iron oxide nanoparticles for use as MRI contrast agents 
and the technical development of MR imaging techniques i.e. positive contrast imaging. After 
gadolinium chelates, SPIONs are the second big group of MRI contrast agents. A lot of research 
has focused on the development of SPIONs to ensure homogenous size distribution, favourable 
magnetic characteristics for MR imaging and non-toxicological profiles to enable in vivo 
utilisation. SPIONs can be multifunctionalised as explained in detail in this thesis and the many 
parameter that can be changed during SPION synthesis opens up endless routes for research. 
Examples are testing different coating materials, linkers, doping SPIONs with transition metals 
to change their magnetic characteristics, attach biomolecules such as antibodies to the surface to 
increase specificity. Some examples of recent developments are polymer-iron oxide composite 
nanoparticles for EPR-independent drug delivery [502], VEGF-targeted magnetic nanoparticles 
for MRI visualisation of brain tumour [503], SPIONs for magnetically-guided and 
magnetically-responsive drug delivery [504] and the design of multifunctional 
SPIONs/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted 
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cancer therapy [505]. There have been a large number of papers on various new SPION aspects 
and many more will follow in the years to come. While those developments are important, it has 
become harder to keep up with the literature. However, it has become clear that knowledge is 
still missing on the fate of SPIONs in vivo and the exact processes by which they are taken up 
by cells. In particular the recent papers by Volatron et al. [506] and Kolosnjaj et al. [507] are 
valuable additions to the literature which describe how Ferritin protein regulates the degradation 
of iron oxide nanoparticles and the biotransformation of magnetic nanoparticles in the body, 
respectively. This knowledge is crucial in making the step from the lab to the clinic. 
 
Not much has been published recently on positive contrast imaging techniques for SPION 
detection. The most attention was given to these techniques during the establishment of several 
prominent methods such as GRASP, IRON, SGM and IDEAL. This work makes a small 
contribution by showing that Dixon is able to differentiate SPIONs without much customisation. 
The next step would be to further improve the implementation and customise it for its purpose 
as a positive contrast imaging technique. However, positive contrast techniques have decreased 
in popularity due to its limitations. It is still difficult to differentiate between SPION 
accumulations and other sources of inhomogeneity, even if the detection threshold can be 
lowered further. I believe the most promising technique will be post-processing techniques such 
as SGM and PGM. These can be acquired in addition to any negative contrast sequence and do 
not require any additional scan time. What is needed is a well optimised gradient echo sequence 
able of imaging SPION accumulations. In general, positive contrast techniques need to become 
more specific to the imaging of SPIONs and perhaps the next step is to make SPIONs more 
chemically and magnetically unique so that a second generation of positive contrast techniques 





In this work I have given an overview of the magnetic characteristics of SPIONs as well as their 
synthesis and stabilisation strategies. I have reviewed their applications as nanotheranostic 
particles with an emphasis on diagnostic methods for cancer and cardiovascular applications. 
The research that was presented in this work focuses on novel SPIONs that were synthesised 
with the aim of improved MR contrast characteristics while also allow for hyperthermia 
applications. This work focused on the assessment of the SPIONs for MRI. Some of the novel 
particles presented in chapter 8 exhibited very high transverse relaxivity values which translated 
to strong negative contrast characteristics on multi echo gradient-echo images. We showed that 
MRI can be used to differentiate between free SPIONs and bound SPIONs for these novel iron 
oxide-based nanoparticles. 
 
The MR imaging in this work was fosuced on positive contrast imaging which offers unique 
opportunities to imporve the visibility of areas of SPION uptake that would be difficult to see 
on 0"∗-weighted images. Positive contrast methods do not suffer from the problem to mistake 
areas of low signal intensity as negative contrast originating from field inhomogeneities 
introduced by SPIONs. Well established sequences in the literature are GRadient-echo 
Acqusition for Superparamagnetic particles with Positive contrast (GRASP), Inversion 
Recovery with ON-resonant water suppression (IRON) and Susceptbility Gradient Mapping 
(SGM). In this work I have described how GRASP, IRON and SGM generate positive contrast 
from signal voids introduced by SPIONs reviewed the literature with respect to their successful 
applications. 
 
The research in this work demonstrated the superior in vivo contrast behaviour on 0"∗-weighted 
images and susceptibility gradient maps acquired in a postprocessing step of a novel 
superparamagnetic iron oxide formulation compared to a commercial sample. I implemented the 
GRASP and IRON techniques and further developed these by devising a dynamic preparation 
phase to optimise the positive contrast imaging parameters such as the rephasing gardient 
strength for GRASP and the frequency offset for IRON. We have compared GRASP, IRON and 
SGM for two novel and two commercial SPIONs and found IRON to be the most reliable 
technique for all iron oxide formulations that also showed superior quantitative positive contrast 
behaviour. In Chapter 7 I describe a new positive contrast technique developed by us which is 
based on the Dixon multi echo sequence. We have demonstrated the capability of the Dixon 
positive contrast technique to successfully produce positive contrast in vitro and that the 
contrast produced is linearly dependent on the SPION concentration. Finally, we demonstrated 
that the Dixon method as a fat suppression technique is superior to SPIR in combination with 
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IRON positive contrast imaging. Overall, this work makes a contribution to the development of 
novel SPIONs for nanotheranostic applications. Specifically, new developments for positive 
contrast imaging with SPIONs are presented that could further improve the usability of these 
techniques in future diagnostic applications.  
 
MR imaging with iron oxide-based contrast agents offer great opportunities for the 
advancement of medical diagnostics but is also facing considerable challenges such as the 
efficient targeting and the bypassing of premature uptake by the cells of the monoculear 
phagocytic system. However, I believe these challenges can be overcome as more knowledge is 
acquired about the in vivo behaviour of SPIONs. It is therefore expected that superparamagnetic 
iron oxide nanoparticles and associated diagnostic and therapeutic technologies will remain a 
focus of biomedical research in the forseeable future and play a key role in benefiting patients in 
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Appendix I: Summary of types of steady-state sequences 
 
12.  rf-spoiled fast 












weighting 01 0"∗ 0" 01 and 0" 











PSIF, reversed FISP 
(Siemens) 
T2 FFE (Philips) 
CE-FAST (Picker) 





Description Residual transverse 
magnetisation is 
spoiled with a 
spoiler gradient to 
avoid interference 










gradients are not 
balanced. 
Based on a time 
reversal of the 
frequency-encoding 
and slice-select 
gradients (both are 
not balanced). The 
refocusing of the 
signal (echo 
formation) happens 
after the next rf 
excitations. 
Between two rf 
excitations, the sum 
of all positive 
gradients exactly 
matches the sum of 
all negative 
gradients for all 




The magnetisation at 
the beginning and at 
the end of a TR 
interval are the 
same. 
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